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1 Summary
Cancer is a condition associated with changes in the genome of the a↵ected cells. These genomic
changes can be somatic (present only in cancer cells) or inherited (present in all cells). The
landscape of these changes can vary from single base mutations to copy number alterations
(CNA) to changes of the genome structure. Besides changes in the genetic code, cancer cells
also acquire epigenetic changes. Analysis of cancer genomes can give detailed insights into the
mechanisms of cancer development and progression.
CNA are one type of genomic change reported in nearly all neoplasias. Most of the analyses
involving CNA data have been cancer type specific and dealt with identification of frequently
copy number altered regions. CNA profiles across samples have also been used to find heteroge-
neous groups in tumor sample data. The research community is in need of tools for the analysis
of CNA data from several systems biology aspects. In this thesis, I present various methods I
have used for analysis of CNA data.
The first tool developed by me involved finding co-occurring CNA across cancer samples.
The analysis resulted in the formulation of an algorithm, CDCOCA (complexity dependence
of co-occurring chromosomal aberrations) which accounts for genomic sample heterogeneity
during the determination of statistical relevance of co-occurring CNA. The major strength of
the method lies in the detection of relatively infrequent, but statistically highly correlated
CNA events. These CNA may be overlooked in conventional analyses, but potentially point
towards pathophysiological mechanisms relevant for cancer development. While looking for
gene associated signals in enriched genomic regions it was observed that multiple genes for
cancer associated pathways were present in these co-occurring CNA.
Signaling pathways are known to be altered by genomic events during neoplastic transfor-
mation. One of my projects explored how CNA target signaling pathways. Two new methods
for pathway enrichment analysis of CNA data, “G-path” and “S-path”, were developed. As a
unique feature of the method, S-path considers the issue of the genomic clustering of genes from
cellular pathways while deriving the statistical significance of pathway enrichment. Both new
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methods outperformed traditional techniques used for pathway enrichment. Pathway signatures
altered in a large heterogeneous dataset as well as across several cancer types were identified
using S-path.
Whole genome CNA patterns di↵er between distinct cancer entities. Some evidence points
towards recurring and possibly tissue type related CNA elements. As a sub-project of my work I
explored the relative specificity of CNA elements for di↵erent tumor entities. The methodology
is based on the hierarchical clustering of tumor type specific CNA frequency profiles with a
region specific signal randomization. Measuring region dependent perturbations of the initial
dendrogram statistics are used to identify “non-neutral” regions, whose propensity for copy
number alterations varied with the type of cancer at hand. In an analysis of data from 160
cancer entities, only a subset of these non-neutral loci overlapped with earlier implied, highly
recurrent (“hot-spot”) cytogenetic imbalance regions.
The work presented in this thesis gives important directions to a systemic analysis of CNA
data from di↵erent aspects, e.g. complexity dependence of co-occurring CNA, pathway al-
terations by CNA and the determination of CNA driving cancer to cancer divergence. The
statistical tools presented here should prove instrumental in the statistically sound analysis of
large scale cancer genome data, with implications for understanding the complexity of human
malignancies.
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2 Zusammenfassung
Krebserkrankungen gehen mit Vera¨nderungen im Genom der betro↵enen Zellen einher. Diese
Vera¨nderungen ko¨nnen entweder somatisch (d.h. nur in den Krebszellen vorhanden) oder aber
vererbt (d.h. in allen Zellen des ko¨rpers) sein. Die Landschaft dieser Vera¨nderungen variiert von
Mutationen einzelner DNS-Basen u¨ber regionale Vera¨nderungen der Anzahl der DNS-Kopien
(“copy number aberrations”, CNA) hin zu strukturellen Vera¨nderungen des Tumor zellgenoms.
Die Analyse von Krebsgenomen ermo¨glicht den Einblick in die Mechanismen von Krebsentste-
hung und -progression.
CNA sind eine Art von Vera¨nderungen der Tumorgenome, welche in der Mehrzahl der Neo-
plasien festgestellt werden konnte. Die Mehrzahl der bisher berichteten CNA-Analysen war
spezifisch fu¨r einzelne Entita¨ten und fokussiert auf die Bestimmung ha¨ufig betro↵ener Regio-
nen. Der Vergleich von CNA-Profilen multipler individueller Neoplasien wurde bereits zur Ein-
scha¨tzung der genomischen Heterogenita¨t innerhalb kliniko-pathologischer Entita¨ten verwendet.
Bisher fehlen allerdings Werkzeuge zur Analyse komplexer CNA-Daten aus einer systembiolo-
gischen Perspektive. In dieser Arbeit pra¨sentiere ich verschiedene Methoden die ich zur Analyse
von CNA Daten evaluiert oder selbst entwickelt habe.
Die erste von mir entwickelte Methode war auf die Bestimmung gemeinsam auftretender
CNA gerichtet. Dieses Teilprojekt resultierte in der Formulierung eines Algorithmus “CD-
COCA” (complexity dependence of co-occurring chromosomal aberrations; Komplexizita¨tsabha¨-
ngigkeit gemeinsam auftretender chromosomaler Aberrationen). Dieses biostatistische Ver-
fahren bezieht erstmalig die genomische Heterogenita¨t der einzelnen Tumoren als wichtigen
Parameter zur Bestimmung statistisch relevanter Kombinationen individueller CNA ein. Die
Sta¨rke dieses Verfahrens liegt in der Bestimmung relativ selten auftretender, aber statistisch
hochkorrelierter CNA-Ereignisse, welche auf fu¨r die Neoplasieentstehung relevante pathophysiol-
ogische Methanismen hinweisen ko¨nnen. In der Tat konnten in mittels CDCOCA identifizierten
CNA tumorassoziierte Gene gefunden werden.
Zellula¨re Signalkaskaden sind ein bekanntes Ziel onkogenomischer Mutationen. Ein weit-
5
eres Teilprojekt meiner Arbeit befasste sich mit der Entwicklung biostatistischer Methoden zur
Bestimmung von ha¨ufig von CNA betro↵enen Signalkaskaden, wobei bei der Methodenentwick-
lung die potentielle genomische Gruppierung funktionell verwandter Gene beru¨cksichtigt wurde.
In der Anwendung zeigten sich die beiden Methoden “G-Path” und “S-Path” gegenu¨ber tra-
ditionellen Verfahren zur Bestimmung relevanter Signalkaskaden u¨berlegen. Sowohl in einem
grossen, heterogenen Datensatz als auch in einzelnen Entita¨ten konnte S-Path Signaturen von
Signalkaskaden identifizieren.
Gesamtgenomische CNA-Muster di↵erieren zwischen unterschiedlichen Tumorentita¨ten, wobei
sich Hinweise auf wiederkehrende und gewebsassoziierte Elemente finden lassen. In einem weit-
eren Teilprojekt untersuchte ich die relative Spezifita¨t von CNA-Elementen fu¨r Tumorentita¨ten.
Das dazu entwickelte Verfahren basiert auf einer hierarchischen Clusteranalyse regionaler CNA-
Frequenzen in multiplen Tumorentita¨ten, gefolgt von einer systematischen Randomisierung der
regionalen Werte. Die Perturbationen der initialen Dendrogrammstatistik dienen hierbei als In-
dikator der Spezifita¨t der regionalen CNA fu¨r einzelne oder multiple Tumorentita¨ten (“nicht
neutral”). Die auf einer Sammlung der CNA-Profile von 160 Tumorentita¨ten basierenden
“nicht neutralen” CNA entsprachen dabei nur teilweise vorbeschriebenen hochrekurrenten CNA
Ereignissen und ko¨nnen auf tumortypspezifische Mechanismen hindeuten.
Die hier pra¨sentierte Arbeit bietet wichtige Beitra¨ge zur systematischer Analyse verschiedener
Aspekte von CNA-Daten, zum Beispiel der Feststellung gekoppelter CNA-Ereignisse, von durch
CNA pra¨ferentiell vera¨nderten Signalkaskaden als auch der Bestimmung von tumortypspezifis-
chen regionalen genomischen Ereignissen. Die neu entwinckelten statistischen Werkzeuge sollten
sich als relevant fu¨r die systematische Analyse grosser Tumordatensa¨tze erweisen, und Bedeu-
tung fu¨r das Versta¨ndnis der Komplexita¨t maligner Neoplasien erlangen.
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3 Introduction
3.1 Cancer as a disease
Neoplasias are a class of disease marked by uncontrolled and abnormal cell proliferation. Neo-
plasia may from localized masses of cells, termed “tumors”. A neoplasm with a confined growth
is typically referred to as “benign”. Some neoplastic cells can become invasive and start in-
filtrating the surrounding normal tissues. This condition is termed as malignancy. Neoplastic
cells can also invade the lymphatic and/or the blood system and migrate to organs such as
lymph nodes, liver, brain, lungs and bones, leading to formation of tumors in these organs. The
spreading tumors are termed “metastiatic”. Lymph nodes can either act as mode of distant
transmission or a secondary organ in which cancer cells can grow.
Cancer is the second most common cause of deaths following cardiovascular diseases [1],
causing one in eight deaths worldwide [2]. Cancer can develop in the majority of human cell
types and tissues (Figure 1). Cancer classification systems relate to the type of tissue type
in which a cancer originates (histology) or the primary site (body location in which cancer
first develops). For ease of understanding, cancer can be separated into a number of major
categories: [3]
1. Carcinoma - Carcinomas are the cancers of epithelial origin which consists of the inner
and outer lining of the human body( e.g. skin and lining of organs), accounting for
about 80-90% of human cancers. Examples include breast, prostrate and lung carcinomas.
Carcinomas can broadly be sub-divided as - a) squamous cell carcinoma - originating in
squamous epithelium and b) adenocarcinoma - developing in an organ or a gland.
2. Sarcoma - Sarcomas are the cancers of supportive and connective tissue originating from
the embryonic mesoderm. Examples of sarcomas are Osteosarcoma (bone tumors) and
Liposarcoma (tumors of the adipose tissue).
3. Leukemia, Lymphoma and Myeloma - This category consists of malignancies origi-
nating in the hematopoietic system. Leukemias develop in the bone marrow and is charac-
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Figure 1: Estimated US cancer cases 2011 [4]. Relative frequency of cancer occurrence among
di↵erent sites in human body between men and women.
terized by abnormal production of anomalous white blood cells. When leukemia develops
from an immature blood cell it is termed as “acute leukemia” (e.g. Acute lymphoblas-
tic leukemia (ALL) ) whereas leukemia developing from mature blood cells is termed as
“chronic leukemia” (e.g. Chronic myelogenous leukemia).
Lymphoma is a cancer of lymphocytes and develops in lymph nodes, causing them to
expand. Malignant lymphomas consist of a large number of di↵erent entities, which are
defined based on clinical, phenotypic, and molecular characteristics according to the World
Health Organization (Table 1). The major groups are Mature B cell neoplasms (e.g.
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Di↵use large B cell lymphoma), Mature T cell, and natural killer (NK) cell neoplasms (e.g.
Adult T cell leukemia/lymphoma) and Hodgkin lymphoma (e.g. Nodular lymphocyte-
predominant Hodgkin lymphoma).
Myeloma is a cancer of the plasma cells, a type of white blood cells producing antibodies
e.g. multiple myeloma.
4. Germ cell tumor - Germ cell tumors consist of cells matching one or more of the 3 germ
layers. Germ layer tumors also called as teratoma, can also consist of normal tissues found
in lung, liver and brain.
Table 1: Examples of malignant lymphomas
Mature B cell neoplasms Mature T cell and natural
killer (NK) cell neoplasms
Hodgkin lymphoma
Chronic lymphocytic
leukemia /small lympho-
cytic lymphoma
T-cell prolymphocytic leukemia Nodular lymphocyte-
predominant Hodgkin
lymphoma
Splenic marginal zone lym-
phoma
T-cell large granular lympho-
cytic leukemia
Classical Hodgkin lym-
phoma
Hairy cell leukemia Aggressive NK cell leukemia
Plasma cell myeloma Subcutaneous panniculitis-like
T-cell lymphoma
Splenic lym-
phoma/leukemia, un-
classifiable
Adult T-cell leukemia/ lym-
phoma
Extranodal marginal zone
B-cell lymphoma of mucosa-
associated lymphoid tissue
(MALT lymphoma)
Se´zary syndrome
Nodal marginal zone B-cell
lymphoma (MZL)
Primary cutaneous gamma-
delta T-cell lymphoma
Follicular lymphoma Anaplastic large cell lymphoma
(ALCL), ALK
Mantle cell lymphoma Systemic EBV+ T-cell lympho-
proliferative disease of child-
hood
Di↵use large B-cell lym-
phoma (DLBCL), not other-
wise specified
Hepatosplenic T-cell lymphoma
Burkitt lymphoma Mycosis fungoides
Cancer develops due to mutations in genome a↵ecting di↵erent kinds of genes. The rate
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of mutation in cells can be enhanced by the presence of various etiological factors. In the
following section the standard cancer etiology i.e. factors which are known to increase the rate
of carcinogenesis are discussed.
3.2 Cancer etiology
Cancer is a group of very complex and diverse diseases, di↵ering in their causes of occurrence.
During a regular cell cycle the DNA of any given cell may acquire errors (mutations) which are
corrected by error correction machinery of the cell. However this machinery is not 100% e cient
and still some errors are propagated to the daughter cells. The e ciency of error correction
machinery is reduced in several environments (such as exposure to carcinogens), resulting in a
higher mutation accumulation rate.
Major external factors associated with cancer development can be grouped in the following
categories.
1. Bacteria associated carcinogenesis - Bacterial infections are rarely associated with
cancer development. A notable exception is the infection with Helicobacter pylori. Studies
have shown that Helicobacter pylori infected individuals have an increased risk of devel-
oping gastric adenocarcinomas or mucosa associated B-NHL[5, 6, 7]. H.pylori produces
a protein CagA which helps the bacteria to attach with the stomach lining. Exposure
to CagA causes inflammation, increasing the risk of cancer. It is shown that individuals
infected with CagA+ bacteria have a higher risk of developing gastric cancers [5].
2. Virus associated carcinogenesis - Around 15% of human cancers are known to be
caused by viruses [8]. A virus can ideally induce cancer development either by carrying
an overactive oncogene called viral oncogene (“v-onc”) into the host cell or by activating
a cellular oncogene (proto-oncogene).
However the majority of virus related human malignancies are based on the inflammation
caused by chronic infections. Chronic infection by hepatitis C virus (RNA virus) and
hepatitis B virus (DNA virus) can result in cirrhosis, leading to primary hepatocellular
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carcinoma. Persistent HPV (Human papilloma virus) infection can cause cervical cancer
[9], resulting in deaths of one-third diagnosed cases [10]. HPV has also been associated
with oral and anal squamous cell carcinomas. An e↵ective vaccination has shown to
prevent infections against HPV [11]. Two vaccines Gardasil and Cervarix have been
approved by Food and Drug Administration (FDA) against HPV.
Other virus infections may predispose to cancer through a modulation of the host’s immune
system e.g. Epstein-Barr virus (EBV) is associated with many malignancies such as B and
T cell lymphomas and Hodgkin’s lymphoma [12]. HIV (Human immunodeficiency virus)
is associated with malignancies e.g. Kaposi’s sarcoma and non-Hodgkin’s lymphoma. HIV
infection compromises the immune system, which can further result in an increased risk
of other cancer associated infections e.g. HHV-8, EBV, HBV [13, 14].
3. Mutagenic agents - Mutagenic agents increase the genome mutation rate which can
lead to cancer development. DNA damaging agents can cause multiple kinds of genomic
errors (Table2). Tobacco smoke is associated with several cancers e.g. lung, larynx and
head and neck carcinoma. Tobacco contains several carcinogens such as nitrosamines,
polycyclic aromatic hydrocarbons and benzene. It has been observed that tobacco can
increase the risk of mutations in the human genome by causing DNA damage [15, 16].
Ionizing radiation (e.g X-rays) causes DNA damage either by generation of active radicals
(e.g. reactive oxygen specie) or by directly breaking the DNA molecules. Radiations such
as UV induce thymine dimerization which can increase the overall genome mutation rate
as not all dimers are e ciently corrected by DNA repair enzymes.
3.3 Cancer associated genes
Normal replication processes as well as exposure to mutagenic substances and microbial infec-
tions can lead to DNA damage which increases the genome mutation accumulation rate. These
mutations can a↵ect any gene in the genome. However, alterations in some cancer associated
genes can lead to cancer development (termed as “drivers”, contrary to those not causing can-
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Table 2: DNA damaging agents
Type of DNA damaging
agent
Examples Toxic lesion
Radiotherapy and ra-
diomimetics
Ionizing radiation, Biomycin Single strange break,
double strand break,
base damage
Antimetabolites 5-Fluorouracil, Thiopurines,
Folate analogues
Base damage, replication
lesions
Replication inhibitors Aphidicolin, Hydroxyures Double strand break,
replication lesions
Bifunctional alkylators Nitrogen mustard, Cisplatin Double strand breaks,
DNA cross links, Replica-
tion lesions
cer, “passengers”). Cancer development associated genes are broadly classified into two major
categories.
3.3.1 Oncogenes
Oncogenes are defined through their cancer promoting activity when activated in the wrong
context or without proper regulation. They are either over-expressed in cancer and/or mutations
make them constitutively active.
One of the first evidences of oncogene activation came through the study in Burkitt’s lym-
phoma (BL). In BL, the MYC oncogene on chromosome band 8q24 was found to be translocated
to immunoglobulin loci on chromosomes 14q, 22q and 2p, leading to an over-expression of MYC.
This lead to the conclusion that MYC translocation could be an initiating event [17]. Another
oncogene commonly activated by translocation is BCL2 in follicular and di↵use large cell lym-
phomas [18, 19]. In comparison to MYC and BCL2, oncogenic activity of KRAS oncogene was
identified using transfection experiments. Mouse fibroblasts were transfected with DNA from
human cancer cells, leading to development of cancer like properties in fibroblast cells. The
KRAS gene was found to be responsible for this transformation activity [20, 21]. A few more
examples of oncogenes are listed in Tables 3 and 4.
Oncogenes can be activated via several mechanisms such as point mutations, translocations,
copy number alterations (CNA) and epigenetic changes. All the mentioned changes lead to either
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an over-expression and/or constant activation of an oncogene. Point mutational activation is
observed in BRAF, where the mutation converts a valine present in kinase domain of BRAF to
glutamate and alters the phosphorylation of adjacent residues, rendering the gene constitutively
active [22, 23, 24]. BRAF also attains an over-expression by gain CNA in astrocytomas [25, 26].
Oncogenes can have a variety of functions in a cell. Some genes such as TMPR552 function
as a transcription factors. In prostrate cancer it often fuses with ETV1 making it constitutively
active, which further activates or represses genes involved in di↵erentiation and apoptosis [27].
Other examples of transcription factor genes include MYC, REL and ERBA1. Oncogenes such
as platelet derived growth factor (PDGF) function as growth factors and their over-expression
can induce transformation in cells over-expressing PDGFR receptors [28]. Oncogenes can also
function as growth factor receptors (e.g. Epidermal growth factor receptor (EGFR)) and signal
transducers e.g. (ABL, SRC, PI3K) [29].
Oncogene derived proteins can potentially act as drug targets for cancer treatment, as cancer
cells may depend on that protein’s production for their survival. For example, oncogenic proteins
can be targeted by molecular markers or antibodies (cell surface proteins) to hinder the growth
of cancer cells. Examples are Imanitib which a↵ects KIT and PDGFR receptor kinases [30],
gasatinib, an inhibitor of SRC tyrosine kinase family [31] and gefitinib which is an EGFR
inhibitor [32].
3.3.2 Tumor suppressor genes
Unlike oncogenes, alterations in tumor suppressor genes are aimed at reducing their activity.
This reduction can come either via a deactivating mutation or loss of gene copies a↵ecting the
protein amount. The idea about existence of tumor suppressor genes came from a somatic fusion
experiment. Fusion of cancer cells with normal cells reverted cancer cells to normal phenotype
[33]. Further studies on retinoblastoma tumors in children led to the “two hit hypothesis” model
of tumor suppression [34] (Figure 2) in which both the alleles of a gene should be mutated to
produce a cancer phenotype. In hereditary retinoblastoma one mutated allele of RB1 gene is
inherited and the other is somatically mutated leading to cancer development. The two hit model
13
Table 3: Germ line mutated cancer genes and associated syndromes
Gene Associated Syndrome Gene type Mutation type
ALK Familial neuroblastoma oncogene T, Mis, A
RET Multiple endocrine neopla-
sia 2A/2B
oncogene T, Mis, N, F
CDK4 Familial malignant
melanoma
oncogene Mis
KIT Familial gastrointestinal
stromal tumor
oncogene Mis, O
APC Adenomatous polyposis coli;
Turcot syndrome
tumor-suppressor D, Mis, N, F, S
BRCA1 Hereditary breast/ovarian
cancer
tumor-suppressor D, Mis, N, F, S
BRCA2 Hereditary breast/ovarian
cancer
tumor-suppressor D, Mis, N, F, S
BLM Bloom Syndrome tumor-suppressor Mis, N, F
EGFR Familial lung cancer oncogene A, O, Mis
FANCD2 Fanconi anaemia D2 tumor-suppressor D, Mis, N, F
MLH1 Hereditary non-polyposis
colorectal cancer, Turcot
syndrome
tumor-suppressor D, Mis, N, F, S
MSH2 Hereditary non-polyposis
colorectal cancer
tumor-suppressor D, Mis, N, F, S
RB1 Familial retinoblastoma tumor-suppressor D, Mis, N, F, S
TP53 Li-Fraumeni syndrome tumor-suppressor D,Mis, N, F
Examples of cancer associated genes a↵ected by hereditary mutations, the name of associated
syndromes and the mutation type they are often altered with.
was validated by identification of a deletion locus involving chromosome 13 in retinoblastoma.
The gene RB1 present in this locus was subsequently cloned [35, 36, 37]. Due to the two
hit model most of the early attempts were made to identify biallelically deactivated tumor
suppressor genes e.g. APC [38], BRCA1[39] and BRCA2 [40].
In recent years it has been also established that not all tumor suppressor genes follow a
two hit model and some show “haploinsu ency”, i.e. inactivation of a single copy of tumor
suppressor gene is enough to facilitate cancer development. Examples for genes with relevant
haploinsu ency are e.g. BRCA1, BRCA2 [41, 42, 43] and PTEN[44] (Figure 2).
Like oncogenes, tumor suppressor genes can also have a variety of functions inside a cell.
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Figure 2: Tumor suppression model. RB follows a two-hit paradigm where loss of both ales
induces cancer. This loss can be germ line or somatic. TP53 whereas shows haploinsu ency,
where loss of one allele is su cient to induce cancer formation [44].
Some tumor suppresor genes such as RB1 act as transcriptional corepressors. RB1 interacts
with transcription factors and regulates expression of genes required for replication and DNA
metabolism. A loss of RB1 leads to disassociation of external signal to cell cycle machinery,
leading to cell proliferation [45]. Others such as TP53 are considered as guardians of the genome.
It is a transcription factor, involved in processes e.g. DNA repair and apoptosis [46]. Others
e.g. APC and SMAD4 act as signal transduction molecules.
Recently another class of tumor suppressor genes, “stability/caretakers genes” has been de-
fined. Examples include genes involved in mismatch repair, base-excision repair, and nucleotide
repair pathways e.g. BRCA1 and ATM a↵ect processes involving chromosomal segregation
and recombination, hence a↵ecting overall genomic stability. When stability genes are a↵ected,
overall mutation accumulation rate of a cell increases, leading to mutations in oncogenes and
tumor suppressor genes eventually causing cancer. Germline mutations in stability genes e.g.
BLM (associated with Bloom syndrome) [47, 48] and BRCA1/2 [49, 50] predispose humans to
15
several cancers (Table 3).
Most of the mutations in cancer happen somatically i.e. only the cancer tissue shows their
presence. However germline mutations (mutations in germ cells and inherited) in cancer genes
predispose di↵erent human tissues to cancers. Some hereditary gene mutations increase the risk
of multiple cancers in di↵erent parts of human body (Table 3). People with hereditary mutations
in disease causing genes are categorized as “genetic susceptible” as they have a higher rise of
developing cancer than those with no hereditary mutations.
Table 4: Most common somatically altered cancer associated genes
Gene Tumour Type Gene type Mutation type
ABL1 CML, ALL, T-ALL oncogene T, Mis
AKT2 ovarian, pancreatic oncogene A
ALK ALCL, NSCLC, Neuroblastoma oncogene T, Mis, A
ERBB2 breast, ovarian, other tumor
types, NSCLC, gastric
oncogene A, Mis, O
LMO1 T-ALL, neuroblastoma oncogene A, T, A
MDM4 GBM, bladder, retinoblastoma oncogene A
MYC Burkitt lymphoma, amplified in
other cancers, B-CLL
oncogene A, T
MYCN neuroblastoma oncogene A
REL Hodgkin Lymphoma oncogene A
ATM T-PLL tumor-suppressor D, Mis, N, F, S
RB1 retinoblastoma, sarcoma,
breast, small cell lung
tumor-suppressor D, Mis, N, F, S
TP53 breast, colorectal, lung, sar-
coma, adrenocortical, glioma,
multiple other tumor types
tumor-suppressor D,Mis, N, F
BAP1 uveal melanoma, breast,
NSCLC
tumor-suppressor N, Mis, F, S, O
CDKN2C glioma, MM tumor-suppressor D
DNMT3A AML tumor-suppressor Mis, F, N, S
NF1 neurofibroma, glioma tumor-suppressor D, Mis, N, F, S, O
PIK3R1 gliobastoma, ovarian, colorectal tumor-suppressor Mis, F, O
IKZF1 ALL tumor-suppressor D
TNFAIP3 marginal zone B-cell lym-
phomas, Hodgkin’s lymphoma,
primary mediastinal B cell
lymphoma
tumor-suppressor D, N, F
Examples of cancer associated genes a↵ected by somatic mutations, the cancer type they are
commonly mutated in and the mutation type they are often altered with.
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Various types of genomic mutations can target multiple genes, resulting in development of
di↵erent cancer types. This association can either be gene-mutation and/or gene-cancer type
specific (Table 4). Cancer genes can be targeted by several genomic changes, altering their
expression/activity. The kind of genomic alterations observed in cancer are described in next
section.
3.4 Genomic alterations in cancer
Cancer develops due to changes at the genome level. All cells in human body originate from
a single fertilized egg through a series of mitotic divisions. Cell division involves replication of
cell DNA to form two daughter cells. However, this replication e ciency is not 100% accurate
and during the division process cells acquire mutations. Mutations can also happen during the
non-replicative phase of cell cycle due to DNA damage, which can happen because of exogenous
agents (e.g. tobacco smoke and radiation). Mutations in cancer cell can be “germline” i.e.
hereditary and present in all cells of an organism or “somatic”, present only in cancer cells
and their precursors. Alterations in cancer cells can vary from single base changes (e.g. point
mutations) to structural alterations (e.g. translocations) to chromosome arm level changes (e.g.
copy number alterations). All these changes can be associated with cancer development and
progression [2, 51, 52, 53, 54].
It has been well established that cancer follows an evolutionary dynamics [2] and muta-
tions accumulation in a stepwise manner (Figure 3). Mutation accumulate randomly in the
genome followed by selection to produce a phenotype. Cancer cells are selected for a prolif-
erative phenotype either by faster cell divisions, a reduction in cell death and apoptosis or
apoptotic/senescence escape. During the process of mutation accumulation (during cell divi-
sion or repair of damaged DNA) cells acquire changes. Most of these changes are neutral and
are removed from the system. However some of the changes can lead to cancer development.
The changes associated with cancer development are called “driver” changes and most of these
changes happen in oncogenes and/or tumor suppressor genes. Mutations not related to cancer
development are termed “passengers” (Figure 3). A very simple way to find drivers is by looking
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at their frequency of occurrence at any genomic locus across several samples. Another way is
by comparing di↵erent stages of cancer development and progression. Mutations which occur
more frequent than random could be important for cancer development and can be cancer type
specific. Through comparing di↵erent tumor stages for somatic alterations a classic tumor pro-
gression model has been derived [55, 56]. The cancer evolution paradigm was recently extended
by observing massive genomic rearrangements that can accumulate at once in cells [57] and
may result in the development of cancer. However, the exact cause of these high number of
rearrangements is still questionable.
An individual cancer cell can acquire all kinds of genomic changes [2, 51, 52, 53, 54, 58]. In
the following section we describe the mutational changes observed in cancer.
Figure 3: Pattern of mutation accumulation across cells. Some of them called drivers give
selective edge to cells and lead to development. Others termed passengers just accumulate
during normal cell divisions and has either no role in cancer development or give selective edge
to it [2].
18
3.4.1 Point mutations
Point mutations are a single base substitution, addition or deletion events. They have been
described in nearly all cancers studied. Their relative abundance is still a subject of discussion.
Consortiums such as TCGA and ICGC have recently sequenced some cancer patient’s genomes
(as well as cell lines) to access the total amount of point mutations in cancer. However, the stud-
ies still need a large amount of genomes to be sequenced to define a point mutation landscape.
A base substitution event at any particular exon position in a gene can be synonymous (no
change in coded amino acid) or non-synonymous (coded amino acid changes). Non-synonymous
mutations can alter the protein activity, increasing the activity in case of oncogenes or lower-
ing/extinguishing for tumor suppressor genes. Most point mutations in a cell are either neutral
or detrimental and only very few mutations are beneficial for the development and undergo
positive selection.
By a↵ecting a coding amino acid, point mutations can alter the protein folding, stability,
function and protein-protein interactions. Examples of oncogene activating point mutations
include mutations in KRAS, HRAS and BRAF [29], whereas tumor-suppressor gene deactivating
mutations have been observed in TP53, APC and RB1 [59]. Other examples of point mutational
activation/deactivation are listed in Table 3 and 4.
Research has been focussed on predicting the functional impact of point mutations to dif-
ferentiate between mutations a↵ecting protein activity with neutral ones. Several methods for
assessing the mutational e↵ect of a change have been developed. These methods compare the
properties e.g. size, polarity, structural information of protein and evolutionary conservation of
the original and substituted amino acids [60].
3.4.2 Chromosomal rearrangements
Chromosomal rearrangements are a type of genomic change observed in the majority of human
neoplasias. Chromosomal translocations involve an exchange of genetic material between two or
more chromosomes. Chromosomal inversion are another kind of genomic rearrangement here, a
genomic region within a chromosome is broken at two points and is rejoined in inverted position
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on the same chromosome. Chromosomal rearrangements can lead to an increase in the gene
expression of targeted genes by transferring them to an active promotor or vice versa. They can
also lead to formation of constantly active hybrid genes or the deactivation of genes through
disruption of coding regions. Chromosomal rearrangements can be identified using techniques
such as FISH and SKY. Recurrent translocations have mostly been studied in hematologic
malignancies.
One of the first consistent chromosomal abnormalities detected was the presence the of
Philadelphia (Ph) chromosome in around 90% of chronic myeloid leukemia patients [61]. Ini-
tially this was thought to be chromosome 22q deletion; however later on it was identified as a
reciprocal translocation involving chromosome 9 and 22 (t (9;22)(q34;q11)) [62]. The reciprocal
translocation involving the ABL gene on chromosome 9 and the BCR gene on chromosome 22
[63] leads to the formation of a constantly active tyrosine kinase. This fusion protein activates
other cell cycle proteins and enhances cell division.
Another example of a fusion protein is the dimerization between FOS transcription protein
and the JUN transcription factor to form AP1 transcription factor resulting in activation of
genes controlling cell division [64, 65]. At present more than 200 fusion proteins have already
been identified [66].
MYC was the one of the first oncogenes identified as translocated in BL. The MYC lo-
cus on 8q24 can translocate to three di↵erent loci on chromosome 14q, 22q and 2p, carrying
immunoglobulin genes (t(8;14,q24;q32), t(22;8,q11;q24), t(2;8,p12;q24)) [17, 23, 24, 67]. All
the translocations lead to an over-activation of MYC either by transferring MYC to an active
immunoglobulin locus (e.g. MYC translocated to IgH locus t(8;14)) or vice versa. Other translo-
cations such as t(14;18)(q32;q21), t(11;14)(q13;q32), t(3;14)(q27;q32) and t(11;18)(q21;q21)
are very common in B-cell lymphomas. The most common translocation observed in follic-
ular lymphomas and di↵use large B-cell lymphomas involves the anti-apoptotic gene BCL2
(t(14;18)(q32;q21) ) and the immunoglobulin heavy chain locus [18, 19].
Some chromosome translocations are highly specific to a single cancer type e.g. t(15;17)
observed only in acute promyelocytic leukemia (APL) [68] and t(1;19) found only in B-cell
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precursor acute lymphoblastic leukemia (ALL) [69]. Inherited syndromes can predispose in-
dividuals to hematologic malignancies e.g. ataxia-telangiectasia patients harboring ATM mu-
tations are prone to develop chromosomal translocations involving T-cell or immunoglobulin
antigen-receptor loci [70].
3.4.3 Copy Number Alterations/Aberrations
Copy number alterations/aberrations are one kind of genomic change reported in nearly all
cancer types. A copy number alteration is gain or loss of a genomic region and can range from
focal events to whole chromosome level changes (aneuploidy). Alterations involving addition or
deletion of a single base can have a possible impact due to a quantitative structural or functional
change. This is in contrast to a purely qualitative change e.g. frame shift and point mutations.
Arm level (or whole chromosome) changes are observed frequently in cancer however it becomes
di cult to identify cancer associated genes in these regions. With recent advances in detection
of focal CNA some cancer associated genes have been identified [71, 72, 73].
CNA are a key event in cancer development and progression. This thesis deals with the
statistical analysis of cancer CNA data from multiple aspects. In the following sections var-
ious mechanisms generating CNA, how they can be detected and their importance in cancer
development and progression are discussed.
3.5 Copy number alterations and cancer
The nearly omnivorous presence of CNA across cancer types have made them an ideal candidate
to identify and study. CNA can accumulate inside a cell due to several mechanisms, which are
described in next section.
3.5.1 Mechanisms generating CNA
CNA can have a variable size, ranging from few base additions/deletions to whole chromosome
arm level changes. Depending upon the size of copy number alteration various mechanisms can
be associated with their occurrence. The major responsible mechanisms are listed here.
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1. Homologous recombination (HR) - HR is a major pathway to repair double strand
breaks and requires homology search of the damaged DNA with undamaged DNA to
repair it. It is majorly involved in S and G2 phase of cell cycle [52, 74, 75]. HR is
further sub-divided into 4 categories a) non-allelic homologous recombination (NAHR),
b) gene conversion, c) break-induced replication (BIR), d) single-strand annealing (SSA).
These mechanisms can repair damaged DNA via slightly di↵erent mechanisms [52] creating
di↵erent kinds and size of genomic changes. Deletions can be produced by NAHR, BIR
and SSA (small scale deletions) where as duplications can be produced by NAHR, gene
conversion (small duplications) and BIR.
2. Non-homologous end joining (NHEJ) - NHEJ does not require (or very less) homol-
ogy search to repair the damaged DNA. NHEJ is a very important DNA repair mechanism
as it can work any time during the cell cycle [52, 74, 75]. NHEJ is associated with small
deletions and insertions.
3. Other mechanisms generating small changes - a) LINE-1 (Interspersed nuclear
elements-1) are retrotransposons which can give rise to copy number changes in embryonic
stages. Wnt signaling is associated with the activation of LINE-1 elements [76, 77]. b)
DNA repeats carrying regions can be extended/deleted due to DNA polymerase slippage
and less e cient mismatch repair pathways.
4. Chromosome level changes - CNA involving chromosome level changes can happen
mainly in the anaphase of cell cycle due to errors in chromosomal segregation and sepa-
ration. Mutations in “chromosome stability genes” playing a role in chromosome con-
densation, kinetochore functions, sister-chromatid cohesion and microtubule assembly
have shown to be associated with aneuploidy in cancer. Examples of such genes include
BRACA1, BRACA2 and MAD2 [78, 79, 80]. Recently a new phenomenon “chromothrip-
sis” involving shattering of a chromosome in to multiple pieces and than rejoining, has
been proposed as an initiating event for cancer development [57]. No direct causes for this
phenomenon have been identified yet. However its association to mutations in genes such
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as TP53 has been proposed [81].
3.5.2 Techniques for detection of CNA
3.5.2.1 Cancer karyotyping Human chromosomes were already being analyzed in nine-
teenth century by German scholars [82, 83, 84, 85]. However only in 1956 it was shown that
humans have 46 chromosomes [86]. Clinical cancer cytogenetics started in 1960 by identification
of the Philadelphia chromosome in the blood of chronic myeloid leukemia patients [61].
Cytogenetics was extended with the use of fluorochromes coupled with alkylating agents
in the late 1960s, leading to identification of the complete human karyotype [87]. Quinacrine
Mustard (QM) was used as a fluorescent agent to bind interphase nuclei. Chromosomes were
grouped into di↵erent types based on their fluorescence patterns which was determined pho-
toelectrically. Fluorophore labeling proved to be better than other chromosome identification
methods e.g. centromere index or autoradiography. Fluorochrome labeling was replaced by
Giemsa banding in 1970s [62] (Figure 4). Giemsa stains AT rich regions in the genome as dark
and others light, producing bands on chromosomes. Various parameters such as centromere
positioning, length of chromosomes, number of chromosomes and length of telomeres can be
easily visualized using this staining. These parameters were then used to compare cancer cells
with normal cells to determine cancer specific patterns. In the 1980s it became quite obvious
that chromosome abnormalities were an essential feature of cancer cells.
The quality of handling techniques improved with the development of promataphase analysis
involving synchronized cells. The most common method is to grow cells in presence of Thymidine
to block cell cycle in S phase which can be released either by removal of thymidine or addition of
deoxycytidine [88]. The blocked cells can than be analyzed using banding techniques to obtain
a better resolution of bands.
Development of karyotyping techniques lead to banding analysis of cancer samples. Over
the last decades this data has been deposited and collected by repositories such as Mitelman
database [89, 90].
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3.5.2.2 Fluorescent in situ hybridization (FISH) Advancement in molecular-cytogenetics
techniques led to an increase in the resolution at which chromosome could be analyzed. FISH
involved sequence specific probes for labeling of genomic DNA in contrast to unspecific chro-
mosome staining. FISH techniques enabled the localization and detection of specific genome
regions [91, 92] in interphase or metaphase of cells. They also laid the foundation of current
whole resolution array techniques. An increase in resolution became possible primarily due to
the development of polymerase chain reaction (PCR) [93]. Since human DNA is very large,
fragmented human DNA is often used in designing FISH probes. The fragments were cloned in
form of artificial chromosomes (Bacterial artificial chromosomes - BAC) which could then easily
be maintained in replicating bacteria. These fragments can be used to generate specific probes.
Figure 4: G-banding (A) and SKY (B) karyotype of follicular thyroid carcinoma showing
t(3;7)(p25;q34) and dic(15;22)(p11;p11) [94]
The further advancement in FISH techniques came from the increase in number of di↵er-
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entially labelled probes in the same experiment. SKY (spectral karyotyping, Figure 4)[95] and
M-FISH (Multiplex Fluorescence In Situ Hybridization) [96] allow for simultaneous visualiza-
tion of all di↵erentially labelled human chromosomes. Degenerate oligonucleotide-primer PCR
(DOP-PCR) is used to produce chromosomes specific painting libraries from flow sorted chromo-
somes [97, 98] or region specific probes following micro-dissection [99]. Both SKY and M-FISH
use same labeling approach, however use di↵erent detection technique. In SKY, only one im-
age is captured using epifluorescence microscopy charge-coupled device imaging and Fourier
spectroscopy [100], making it possible to measure the entire emission spectrum with a single
exposure at all image points. This is in contrast to standard fluorescent imaging where bandpass
microscope filters are used to capture separate images for each of the fluorochromes which are
than combined.
Genomic abnormalities such as chromosomal breakpoints, translocations and complex rear-
rangements can be obtained using SKY/M-FISH.
3.5.2.3 Genome wide array techniques In comparison to traditional techniques dis-
cussed above, comparative genomic hybridization (CGH [101, 102]) allows for whole genome
screening of imbalances. CGH is a molecular-cytogenetic technique for copy number change
analysis of a given DNA sample. CGH can detect unbalanced chromosomal changes. CGH is
based on the principle of reverse in situ hybridization in which probes are present on a matrix
or slide and labelled DNA from tumor and control tissue is hybridized to the probes. Only
copy number changes can readily be identified using CGH. In comparison to CGH, array CGH
(aCGH) [103, 104] can detect CNA at a higher resolution.
aCGH involves use of bacterial artificial chromosomes (BACs) [105, 106]. The basic principle
of aCGH is same as that of cCGH the only di↵erence is that in aCGH metaphase chromosomes
have been replaced with relatively high number of mapped clones spotted onto a glass slide.
BAC arrays cover entire genome at di↵erently spaced intervals e.g. BCCRC Lam SMRT array
32k 1.2 has nearly 32,000 probes spaced 30Kb apart on genome, CGH-SANGER 3K 3 has
around 3K probes 1mb apart each. Analysis using aCGH has led to a reduction in resolution
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from about 5-10Mb (for cCGH) to ⇠100kb. Instead of large BAC clones DNA sequences (cDNA
arrays) [103] can also be used for aCGH. cDNA arrays allow the analysis of both DNA and RNA
using same platform however they only covered regions representing exons.
The basic principle of array CGH (aCGH) analysis is illustrated in Figure 5a. Cancer tissue
samples and normal genomic DNA are labeled with two di↵erent tags (e.g biotin - tumor DNA
and digoxigenin - control DNA). Both labelled DNA are mixed with c0t-1 DNA to prevent
non-specific hybridization. c0t-1 is placental DNA enriched for repetitive sequences (e.g. Alu
and Kpn) of about 50-300bp in length. The mix of three di↵erent DNAs is then hybridized
to target metaphase chromosomes. The amount of tumor and control DNA bound at any
given chromosomal location depends on the the relative abundance of this sequence in both
DNA samples. The hybridized DNA is then detected for fluorescence signal using fluorophores
(e.g. green-fluorescing fluorescein isothiocynate (FITC) for tumor DNA and red-flourescing
rhodamine antidigoxigenin for control DNA), which is than compared to identify abnormal
regions. A gain/loss of any genomic region will result in an elevated/reduced green to red ratio
respectively. The copy number karyotype of tumor is than generated by comparing DNA from
tumor and normal cells.
The resolution of aCGH improved further with the development of oligonucleotide arrays
(60 100bp). The first of the arrays were synthesized by mechanically spotting oligonucleotides
on to a slide [108] giving a resolution of one probe per 50kb of genome. Recently techniques have
been improved and oligonucleotide arrays are directly synthesized on a glass slide. NimbleGen
has further improved the resolution of oligonucleotide arrays by spotting around 2.1 million
oligonucleotides on the arrays which can detect CNA in range of⇠5kb. The biggest disadvantage
of oligonucleotide arrays is poor signal-to-noise ratio. The log2 ratio has a standard deviation
of around 0.25 in comparison to BAC arrays which is around 0.05.
An advancement in the analysis of CNA came from development of genotyping arrays which
could screen for several million probes simultaneously with the help of single nucleotide polymor-
phisms [109, 110, 111, 112] arrays. The arrays were primarily designed for genotyping SNPs,
however they have proven to be very useful for copy number detection. Unlike aCGH, SNP
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Figure 5: aCGH analysis of copy number changes. Both tumor and normal DNA are labelled
with two di↵erent colored probes. The labelled DNA is than loaded on to a cDNA carrying
chip. The ration of the the two intensities (in case ration of green and red) carries gain and loss
information about the region on the array chip [107].
arrays only require one DNA type for the analysis.
The hybridization intensities which are obtained from spotted oligonucleotides are compared
with that of controls. Any deviation in this intensity reflects a CNA change. In addition to
copy number analysis SNP arrays can also give information about genotype such as loss of
heterozygosity [113, 114]. For every SNP allele, 25 bases long 20 matched and mismatched
probe pairs are designed. The test DNA is first restriction digested and amplified. CNA are
detected by comparing intensities of matched and mismatched probes to control individuals.
SNPs are placed at a median spacing of 2.5 kb in A↵ymetrix GeneChip 500k arrays. Because
SNP arrays were used for CNA detection A↵ymetrix has designed SNP 6 arrays carrying around
1.8 million markers, which includes around 906,600 SNP and more than 946,000 probes for CNA
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detection.
The genome wide array techniques have been very successful in determining the “CNA
landscape” of cancer. A huge amount of data has been been analyzed and made available to
the research community. For this thesis project all the analysis have been performed on cCGH
and aCGH data which was collected and made available through Progenetix [90].
3.5.3 Role of CNA in cancer
The importance of CNA in cancer development and progression is illustrated by their presence
in majority of cancer types [115, 116]. CNA do not occur in a random manner which is reflected
by their re-occurring nature and a unique behavior across cancers [117, 115].
The direct e↵ect of CNA on the expression of genes has been proven across multiple cancer
types [118, 119, 120, 121, 122, 123]. In some cases CNA in a genomic region has also been
associated with a global gene expression change [124]. CNA can abrogate the function of tumor
suppressor genes by deleting both the alleles of the gene [125] or by deleting one copy of the gene
when the other is either germline or somaticaly point mutated [35, 36, 37]. Haploinsu ciecy in
some genes (e.g. PTEN [126], PTCH1, PTCH2 [127] and other DNA repair associated genes
such as MSD-3 [128] ) can contributes to tumorigenesis. In some cancer types the presence of
CNA is an essential event in tumorigenesis [55].
CNA, particularly small amplicons, have also led to direct identification of candidate tumor
suppressor genes and oncogenes [129, 130, 131]. CNA have been used to classify an individual
cancer into its subtypes [132]. The presence of CNA has also been linked with treatment outcome
[133].
CNA are associated with disease progression and recurrence in several cancer entities. Exam-
ples are loss of 1p, 3p,11q and gain of 17q are associated with poor clinical outcome in pediatric
neuroblastoma [134, 135, 136]. Two di↵erent clinicogenetic subtypes of neuroblastoma can be
defined using these imbalances, one with loss of 11q, 3p and gain of 17q and other with loss
of 1q and gain of 17q. Frequently occurring gains involving 2p have been associated with ad-
vanced stages in chronic lymphocytic leukemia [133]. Gains of regions carrying genes MYC,
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ERBB2, MDM2, EGFR and CCND1 are significantly associated with high grade breast cancer
[137]. In breast cancer the amount of CNA is associated with tumor grade, metastasis and
histology [138]. Worse clinical outcomes has been associated with an increase in overall chro-
mosomal imbalances [139]. Analysis of CNA data has helped in defining genomic regions which
are altered in multiple cancer types (e.g. gains on 1q (MCL1), loss on 3q (FHIT), gains on 8q
(MYC), losses on 13q (RB1), gains on 11p (CCND1), gains on 12 (KRAS, CDK4 and MDM2)
[117, 115]). CNA accumulation can start in the early phases of tumorigenesis, supporting the
claim that they are required for tumor development [140, 141, 142]
CNA profiles have been used to classify cancer patients genetically. It has been shown
that CNA can be used for accurate diagnosis of di↵erent malignant lymphomas and their
subtypes[143]. Frequent genomic amplifications were also used to classify cancer types and
it was shown that amplifications are selected according to the anatomical locations of cancer
[144].
CNA are also associated with clinical phenotypes and are often used in clinics for diagnosis.
Breast cancer patients with amplified ERBB2 gene are treated with Herceptin [145]. CNA gains
are associated with resistance to therapies e.g. TYMS in response to 5-fluorouracil [146], DHFR
in response to methotrexate [147].
3.5.4 Systems biology and CNA
CNA can spread through several genomic locations across chromosomes. Majority of the tumor
cases acquire more than one CNA. These CNA can work in a cooperative manner to a↵ect
interacting gene modules. Previous work [148, 149] has illustrated some cooperative nature of
CNA. [148] showed that frequently co-occurring CNA often involve interacting gene modules.
However none of the work so far has accounted for the genomic complex behavior of tumor
samples. Tumor complexity can be defined by the number of changes present in a tumor.
Tumors samples can acquire multiple CNA. A complexity dependent behavior of these changes
will help in defining co-occurring CNA landscape which is independent of the tumor complexity
[150]. CNAs co-occurring in samples with overall few changes may point towards their significant
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involvement in cancer.
Genes in CNA a↵ect cellular pathways, and previous studies have tried to address the role
of CNA in pathway dependencies [54, 151]. Others have integrated somatic mutation data
with CNA data [152] to identify pathways altered in cancer. Some others ranked gene modules
significantly a↵ected by frequently altered genes across CNA [153]. But so far there is neither
any standard method for pathway enrichment nor any large scale analysis (i.e. across multiple
di↵erent entities) that has been performed on cancer CNA data. Although a single CNA can
a↵ect a multitude of genes from similar pathways the issue of genomic clustering of pathway
genes [154] in relation to CNA has not been addressed yet.
Clustering has been extensively used to visualize and detect structures in cancer CNA data.
Clustering of CNA patterns is being used to identify oncogenomic similarities [117, 115, 155,
156, 143] among cancer samples. Clustering of CNA data divides tumor samples into several
groups with similar CNA profiles. These samples might follow a similar way of cancer progres-
sion/development. Previous work has tried to simplify the clustering by looking at frequently
altered genomic regions [157, 158]. Several kinds of clustering algorithms are available to the
research community, however hierarchical clustering is used more often than others as one does
not need to specify the number of clusters and the results can be viewed with the help of a den-
drogram tree. Multiple hierarchical clustering algorithms using di↵erent clustering algorithms
are described in literature. The quality of various hierarchical clustering algorithms can be
validated with the help of clustering quality measures defining the compactness, separation and
connectedness among clusters. A systemic validation of hierarchical clustering can identify the
best algorithm fitting the data of interest.
The application of clustering algorithms has been restricted to sample based analysis of CNA
data. However until now no one has tried to address the heterogeneous and complex behavior
of CNA across cancer types and use this information to find CNA separating cancer types [159].
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4 Objectives and Content of the Thesis
The main objective of this thesis is “oncogenomic pattern detection in cancer copy number
alteration data for pathway description and disease classification”. It involves development of
new tools for the analysis of cancer CNA data and than compare them to existing methods.
The methods designed or available should be tested on CNA data from multiple cancer types
to measure their performance. The specific aims are
1. Development of methods for functional associations in CNA data. This involves
development of tools for various kinds of systems biology analysis on CNA data. The
questions that can be addressed are
(a) How to find co-occurring CNA in cancer samples?
(b) Which pathways are targeted more often by CNA?
(c) Which CNA play a role in cancer to cancer divergence, i.e. cancer classifying nature
of CNA?
2. Exploration of available methods for analysis of cancer CNA data. While devel-
oping new methods available tools are also tested for the analogous analysis. The results
obtained are compared with what has been observed before.
3. Application of explored and developed methods to data available on Pro-
genetix. All the tools either developed or available should be tested on cancer CNA
data available through Progenetix. The application can either involve analysis of a small
data set from few cancer types or performance on a large heterogeneous data comprising
of all cancer types in Progenetix.
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5 Methods
5.1 Co-occurring nature of CNA - Paper I
Most of the tumors samples acquire more than one CNA during the time of cancer development
and progression. Identification of co-occurring CNA can help in defining relationships among
individual genomic changes accumulated in cancer. The co-altered genomic regions can harbor
genes, either directly interacting with each other or playing role in co-operative pathways.
Previous work has tried to address the co-occurring nature of CNA and suggested ways of
identifying frequently co-altered genomic regions [148, 149]. Simultaneously altered genomic
regions were shown to harbor interacting genes.
However, the co-occurring analysis of CNA is less trivial than contemplated. Cancer is a ge-
netically heterogeneous disease and samples from one cancer type can acquire variable numbers
of CNA [150]. Cancer samples can be classified on the basis of their genome complexity; “CNA
complex” with a high number of CNA in contrast to samples with very few changes (“CNA
simple”). The complexity of samples has to be considered while evaluating co-occurring CNA.
We defined a statistical method “CDCOCA” for complexity dependence of co-occurring chro-
mosomal aberrations, which considers the sample heterogeneity while identifying co-occurring
CNA [150]. The detailed formation of the algorithm has been described in paper I.
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5.2 Pathway enrichment across CNA data
Gene and pathway data
Several resources of pathway-associated annotations are publicly available (e.g. Reactome[160],
Kegg[161] and Nature signaling pathways [162]). We use Nature Signaling Pathways as a source
for all algorithms; it only consists of signaling cascades and does not include processes like
metabolism (present in KEGG). Another reason for using Nature Signaling Pathways is its
non-hierarchal pattern of annotation, contrary to e.g. Reactome where big pathways are further
divided into hierarchies of pathways.
Genes were mapped to genomic locations according to Human genome version 18 (hg18/build36).
Genes on chromosomes X and Y were removed prior to analysis due to inherent gender biases
(e.g. prostate carcinoma) and inconsistent reporting in the CNA data sets. The remaining
pathway-specific data consisted of 176 pathways containing a total of 2239 genes.
For genomic positions, we obtained the Ensembl gene list from Biomart release 54. This gene
list was processed to obtain genes with unique combination of Ensembl gene identifier (Ensembl
id) and chromosome start and end position. Mitochondrial and sex chromosomal genes were
removed resulting in a total of 20209 genes for the input gene list.
For S-path we divided all chromosomes in to non-overlapping segments of 1Mb each dividing
entire genome in to 2872 bins (we call this “segmentation”). The gene list was than mapped to
the artificial segments of 1Mb and all genes for any pathway present in these bins are considered
as a single gene. We expected that dividing the genome in to small bins resolved the issue of
pathway genes clustering. 2239 pathway genes were mapped to 1203 unique genomic segments.
Data sets
Cancer CNA data available through Progenetix [90] is used as an input to pathway algorithms.
A total of 19819 tumor samples from 132 di↵erent cancer types were analyzed for pathway
enrichment. The analysis was then extended to individual cancer type for entity specific path-
way enrichment profile. The genome for copy number data across all samples was reduced to
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segments of 1Mb each as an input to S-path. Such an input data has been used to enrich for
CNA which are altered more often than chance [163].
Model and parameters
We here define models and parameters for G-path and S-path. The only di↵erence between
G-path and S-path is the pathway input file. Genes are an input for G-path which are replaced
with segments for S-path. Here we use the term genes for both; genes for G-path and segments
for S-path.
A unique permutation strategy is used to compute pathway scores using G-path/S-path.
Let S represents a list of samples {S1, ...Sn, ...Sm} of a given cancer type. A pathway P is
represented as a set of genes Gi , where i is any number of genes with known genomic locations
on autosomes. We consider that for pathway P more than one gene can simultaneously be af-
fected by CNA Figure 6 shows the boxplot of number of 1Mb pathway segments altered in some
pathways across 19379 tumor samples, showing on average 10% of segments are copy number
altered across pathways. For every sample a pathway index SPn = NP is obtained. NP repre-
sents number of genes for pathway P which are copy number altered in sample Sn, NP ✏ Gi. The
overall pathway score for pathway P across all samples is obtained as OPP =
Pm
n=1 SPn. The
list of overall pathway scores is represented as {OP1, ...OPp, ....OPs}for s pathways. The cor-
responding list obtained on permutations is represented as {OP ⇤1 , ...OPp⇤, ....OPs⇤}. OPp can
vary between 0 ( when no gene for pathway P is copy number altered) and max{i⇤m}(when all
genes i are copy number altered across all m samples). All the three algorithms (G-path, S-path
and H-path) identifies pathways disapproving the null hypothesis that “there is no association
between pathway genes and CNA”.
Pathways enrichment with G-path and S-path
In this section we describe the two algorithm G-path and S-path. Genes for G-path represent
same as segments for S-path.
1. Overall pathway scores for all pathways {OP1, ...OPp, ....OPs}are computed.
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Figure 6: Proportion of genes showing CNA across entire cancer CNA data; 10 randomly chosen
pathways are shown here. The vertical line represents the average number of genes being hit
(median of per-case fraction of window bins overlapping CNA). The overall fraction of window
bins being hit in a given pathway uctuates around the expected value.
2. A null vector C = NULL of length s is defined. C measures the index how many times
expected scores across pathways are greater than or equal to observed scores.
3. For permutation all Ensemble genes (2872 segments for S-path) are randomly distributed
on to new genomic locations. This permutation helps in keeping gene pathway membership
consistent while a↵ecting only pathways Vs genomic location membership.
4. Expected pathway score {OP ⇤1 , ...OP ⇤p , ....OP ⇤s }on permutation for all pathways is com-
puted.
5. If expected score for pathway P is greater than or equal to the observed score Cp is
incremented as
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Cp = { Cp + 1 if OP ⇤p >= OPp
Cr if OP ⇤p < OPp
}
6. Step 2 to 5 are repeated over Z number of times (Z = 10000 in current analysis) increasing
the counter C for pathways which are altered by chance.
7. After all permutations a p value vector {p1, ..pp, ..ps} ✏ P are caclulated from C as pp = CpZ
8. All the p values are corrected for false discovery rate using Benjamini Hochberg correction.
H-path Algorithm
In this section we describe the methodology used by [152]. The null hypothesis tested for is
that pathway gene membership is random. For pathway P with Gi genes where i is any number
of genes with known genomic locations on autosomes. An index Ph is computed as number of
samples having more of more gene altered for pathway P . For simulation Gi are sample from
all set of pathway genes without replacement and index P ⇤h is recomputed. The p value for the
pathway P with index Ph is computed as number of times P ⇤h >= Ph. All p values are then
FDR corrected using Benjamini-Hochberg correction.
Genomic clustering of pathways
Genes for cellular pathways are clustered on the genome [154]. For all the pathways a clustering
score is compute as described in [154]. Since for S-path genes from pathways are represented
as segments the pathway clustering score is computed using these segments and not genes. For
each gene pair on same chromosome from a pathway a pair wise score of clustering is computed
as
pair score = average length of chromosomes in genomedistance between genes
For genes on di↵erent chromosome distance is computed as
pair score = average length of chromosomes in genomeaverage length of chromosomes the genes are located on
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The pathway clustering score is the sum of all pair wise scores divided by the number of genes
in that pathway. The original clustering score is compared to the expected scores obtained by
randomly creating pathways with same number of genes and then recalculating the expected
pathway clustering score (10000 permutations). p-values are generated by comparing the origi-
nal and expected scores as
pvalue = number of times expected clustering score   observer clustering scorenumber of permutations .
The p values are corrected for false discovery rate using Benjamini Hochberg correction.
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5.3 Evaluation of hierarchical clustering on CNA data
Hierarchical clustering is very commonly used to find heterogeneous groups in data. The aim
was to find best hierarchical clustering methods to cluster CNA frequency profiles across 160
di↵erent cancer types.
Data
Cancer CNA data consisting of chromosomal and array CGH experiments across 160 cancer
types, and a total of 25579 cancer samples was used. All cancer samples were classified on the
basis of International Classification of Disease Code (ICD). For validation of clustering methods
CNA information was reduced to 80 genomic intervals covering the entire genome. Gain and
loss events on every locus were considered separately.
Clustering validation
Internal cluster validation methods provide a way to determine the quality of clustering. Three
di↵erent cluster validation methods were used; They are silhouette width, Dunn index and
connectivity to find the best hierarchical clustering method for this data.
Silhouette width computes the compactness and separation among clusters. Well clustered
observations have a value close to 1 and poorly clustered close to -1. For any observation i
S(i) = bi aimax(bi,ai)
where ai is the average distance between i and all possible observations in same cluster and
bi the average distance between i and observations in the nearest neighbor cluster
bi = minCk2K,Ci
P
j2Ck
dist(i,j)
n(ck)
where C(i) is the cluster with observation i, dist(i,j) is the distance between observations i
and j and n(C) is the cardinality of cluster C. K is is clustering partition of k clusters. Silhouette
width lies between -1 and 1.
The connectivity measures the compactness, separation and connectedness of a clustering
algorithm. It can be obtained as
Connectivity =
PN
i=1,
PL
j=1 xi,nni(j)
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Where N is the number of observations, nni(j) is the jth nearest neighbor of i and xi,nn(j) is
zero if i and j are part of same cluster otherwise 1/j. Connectivity can assume a value between
0 and infinity and should be minimized.
Dunn Index is the ration of the smallest distance between observations not in same cluster
to the largest intra-cluster distance.
D(K) =
minCk,Cl2K,Ck 6=Cl (mini2Ck,j2Cldist(i,j))
maxCm2Kdiam(Cm)
where diam(Cm) is the maximum distance
between observations in cluster Cm. Dunn index varies between zero and infinity, and it should
be maximized.
The known cluster validation methods were compared to a new method “Tree length statis-
tics (TLS)” to find the best validation method among them. The TLS uses the information
present in the dendrogram tree obtained on clustering to determine the quality of clustered data.
TLS is defined as the sum of all parent-child distances in the dendrogram tree (Figure 7). Tree
distance between two cancer types on a dendrogram tree, obtained using clustering of cancer
CNA frequency profiles reflects the discrepancy in between CNA profiles of these cancers. For
any node i, the tree height di↵erence between this node and its immediate parent j is measured
as THj   THi. The overall tree height of a tree with n nodes is than obtained as OTH =Pi=n,j=n
i=1,j=1 THj   THi (Figure 7).
A permutation strategy was used to identify the hierarchical clustering algorithm in combi-
nation with a cluster validation method fitting best to the data. The strategy was as follows
1. Cluster CNA frequency profiles across all genome intervals across all cancer types.
2. A counter C is set to zero.
3. Calculate the observed cluster validation index (OV I).
4. Randomize the frequency values among all cancer types to generate a new frequency
matrix with similar number of cancer types and genomic intervals.
5. Cluster the randomized CNA frequency profiles and compute the random cluster validation
index (RV I).
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A B
DC
HA-C HB-D
HAB
E
HE
Figure 7: Schematic representation of the summed branch-length tree height statistic. Overall
tree height is computed by summing up the distance between all parents and child nodes. Note
that the branch lengths of terminal branches (“leafs”) are not considered. Overall tree height
= HA C +HBD +HAB +HE .
6. If RV I >= CV I, C is incremented as, C = C + 1.
7. p-value for the given cluster statistic, at the end of N (1000) permutations is computed as
p = CN .
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5.4 Non-neutral CNA - Paper II
Clustering of CNA data has mostly been biased towards sample based analysis involving fre-
quently altered genomic regions. We aimed at identification of genomic regions playing a crucial
role in clustering of cancer types. It is observed that the CNA landscape is very heterogeneous
and with greatly varying average CNA frequencies per cancer type (Paper 2). When CNA
frequency profiles among cancer types are used for analysis using clustering, results may be
distorted depending on the entities analyzed. We focused on identification of genomic regions
playing a crucial role in clustering of caner frequency profiles. For this normalized CNA fre-
quency profiles of cancer types were clustered using hierarchical ward clustering. A simple
permutation based methodology was used to measure the contribution of individual genomic
region to clustering of cancer types (Paper 2). A new clustering quality index termed ”Tree
height statistics” was used as a determine the quality of clustering obtained by permeation of
genomic regions. All the methodology is defined in detail in Paper II.
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6 Results and Discussion
The fact that CNA are important for cancer has been well established by their presence in
all tumor types. Because of their importance, an advancement in technologies for their easy
identification has been made. Several data sources such as SKY-CGH [100], Progenetix [90] and
arrayMap [164] have collected and made this data available to the research community. Because
of large scale data availability there is in immediate need for detailed and systemic analysis of
CNA data.
6.1 Co-occurring nature of CNA - Paper 1
The overall genome involved in CNA across cancer types vary considerably (Figure 8) which is
a↵ected by the number of CNA present in samples. Samples can be classified on the basis of
their CNA complexity which can be defined through the number of CNA present in a sample
and/or the overall amount of genome involvement. Cancer samples can be “CNA complex” ( a
high number of CNA) or “CNA simple” (very few changes). This complexity of samples has to
be considered while evaluating co-occurring CNA. A statistical method “CDCOCA” (complex-
ity dependence of co-occurring chromosomal aberrations) considering the sample heterogeneity
while identification of co-occurring CNA was formulated([150]). CDCOCA was applied to two
cancer types; mantle cell lymphoma and bladder carcinoma. It was observed that most of the
co-occurring changes across these two cancers resulted from a background of multiple and ex-
tended CNA. While correcting for sample complexity most of the associations involving high
frequent changes were removed indicating that these high frequent changes may be related to
an overall high genomic instability.
One can either focus on frequently co-occurring CNA, which can be identified using modi-
fied version of CDCOCA- “CICOCA” ( complexity independence of co-occurring chromosomal
aberrations) or CNA from cancers samples with less complex behavior (CDCOCA). CICOCA
and previous work focussed on identification of frequently co-occurring CNA however, with the
help of CDCOCA one can test for the specificity of their association. Most of the associations
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obtained using CICOCA and previous work [149] were also observed to be enriched using CD-
COCA. An advantage of CDCOCA is that it requires only one p value cuto↵, unlike other
methods [148, 149] also requiring frequency based thresholding. This helps in identification of
both frequently and eminently associated events of CNA. Genes from cancer associated path-
ways could be located in the enriched co-occurring regions. This bestowed the motivation for
further analysis, if genes from analogous pathways are targeted by CNA i.e. some pathways
genes are preferentially enriched in cancer CNA.
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Figure 8: Box plot for the percent of genome involved in CNA across cancer entities represented
in Progenetix [90].
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6.2 Pathway enrichment across CNA data
CNA can target multitude of genome genes and cellular pathways. A pathway centric analysis
involving CNA data can help in defining cancer associated pathway modules targeted more
often than chance. This analysis can be more useful than a gene centric analysis firstly because
most of the CNA cover large genomic regions and targeting high number of genes at once and
secondly for a similar pathway alteration multiple genes can be selectively/di↵erentially targeted
in a cancer. Pathway analysis using CNA data is non-trivial as several issues such as genomic
clustering of pathway genes and multiple pathway genes are targeted by a single CNA. All these
issues have to be considered for a CNA specific pathway analysis.
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Figure 9: A) The distribution of scores obtained for the genomic clustering of pathway genes.
log10 of the scores are plotted here for simplicity. B) Comparison of pathway clustering score
before and after segmentation. Dividing the genome into small segments reduces the pathway
clustering scores.
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Clustering of pathway genes
The pathway clustering score followed nearly a normal distribution with data having a mean
score of 89424.79 (Figure 9). The clustering score was independent of the number of genes
in a pathway (Figure 10). Dividing the genome into artificial segments of 1Mb resulted in a
reduction of genomic clustering scores (Figure 9) and the mean clustering score was reduced to
114.465. Also genomic pathway clustering signal was lost after segmentation (Figure 10). Before
segmentation genes from 47 pathways were clustered on genome with an FDR of 0.15. However
with segmentation none of the pathways remained clustered (Figure 10). This analysis points
towards the key issues about considering genomic segments as a set of pathway components and
not genes.
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Figure 10: A) Plot showing that clustering of pathways is not a↵ected by the number of genes
in that pathway. B) Benjamini Hochberg corrected p values for pathway clustering score before
and after segmentation are plotted here. None of the pathways were clustering on genome after
segmentation.
45
Comparison H-path, G-path and S-path
All the three methods were used to obtain a list of pathways targeted more often than chance
by CNA. Cancer CNA alterations span through multiple pathway genes (Figure 6), indicating
the importance of the total score as a pathway score parameter. A maximum FDR cuto↵ of
0.15 was used as a selection criteria to find enriched pathways. H-path led to an enrichment
of only one pathway (Figure 11) whereas with G-path 4 pathways (one genomic unclustered
and three clustered) were enriched (Figure 11). Using S-path 17 pathways were found to be
significantly altered (Figure 11). Genes from five of these pathways were clustered in genome
however since segments were considered this genomic clustering was not significant and did not
a↵ect the results.
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Figure 11: Plot of p values of pathways enriched using A) H-path, B) G-path, C) S-path. Grey
lines indicated the maximum FDR of 0.15
All the pathways enriched using G-path were also enriched using S-path along with additional
pathways identified with similar FDR cut-o↵s. The issue of genomic clustering is also resolved
by S-path as all the genes present in a window bin of 1Mb are considered as a single event.
H-path e ciently identifies pathways which are hit more often with CNA than by chance.
However the analysis lacks the ideology that for a given pathway more than one gene can be
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simultaneously copy number altered. The permutation strategy used by G-path and S-path
is unique in itself as till now no one has considered to keep genes (segments for S-path) and
pathway membership constant on permutations. Another advantage of G-path/S-path is that
a larger range of background CNA are considered in analysis.
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Figure 12: Pathways enriched in more than 20 cancer types with S-path are represented here.
51 (51/59). cancer types showed an enriched of commonly altered pathways. The BH corrected
p values are color coded as shown in right.
Pathways enriched
We extended the analysis using S-path to CNA data from 132 di↵erent cancer types. 59 cancer
types showed an enrichment of at least one pathway with an FDR cut o↵ of 0.15. 22 pathways
were enriched in more than 20 individual cancer types (Figure 12). On further scrutiny we nailed
down to 8 signaling pathways (Figure 13), which were identified in integrative analysis as well
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as were present in more than 20 ICD types. Interesting candidates included mTOR signaling
pathway and Thromboxane A2 receptor signaling, both of these pathways were enriched in
more than 30 cancer types. Identification of these pathways predicts an increased proliferation
or antiapoptotic properties in cancer cell (Figure 13).
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Figure 13: Pathways enriched by a combinatorial analysis are shown in the red rectangle and the
ones enriched in multiple cancer types (20) are shown in the blue rectangle. In the intersection of
both rectangles (grey shaded region) are pathways which were looked at in details. B) Network
of pathways enriched in cancers. Di↵erent enriched pathways (shown in rectangle with round
corners) converge to a↵ect cancer-associated cellular responses (rectangle with smooth corners).
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6.3 Best hierarchical clustering
Hierarchical clustering is very commonly used to find heterogeneous groups in data. The aim
of current analysis was to find best hierarchical clustering algorithm fitting the data of interest
with the help of cluster validation methods. Simultaneously it was also tested which cluster
validation method gives the best cancer to cancer separation on a dendrogram tree.
Four cluster validation methods (3 known and one new; TLS) were used to find the best
hierarchical clustering algorithm fitting CNA data. All the internal cluster validation mea-
sures require the data to be divided into di↵erent clusters. This was obtained by cutting the
dendrogram tree at various heights to generate desired number of clusters.
Connectivity measures connectedness among clusters i.e. to which extent observations are
in the same clusters as their nearest neighbors and its value should be minimized. The best
clustering on the original data in comparison to random data sets was observed using hierarchical
ward clustering with 8 separate clusters (Figure 14d, p value 0.008). With hierarchical ward
clustering connectivity increased with an increase in number of individual clusters (Figure 14).
In comparison to connectivity, Dunn index and silhouette width measure the compactness
of clusters. Both these measures look for intra-cluster variance to assess cluster homogeneity.
The value for Dunn index should be maximized whereas silhouette width should be close to 1
for perfect clustering.
Dunn index classified hierarchical single, average and complete clustering with 2 separated
clusters as the best clustering algorithm (Figure 15, p value = 0.003). In general Dunn index
followed an inverse relation to the number of clusters. When focussed on silhouette width all
the clustering algorithms worked equally well (Figure 16) on the original data in comparison
to random datasets. However the best clustering was observed using hierarchical single and
average clustering with a maximum silhouette width of 0.6 for 2 separated clusters.
When focused on the new cluster quality method TLS, all clustering algorithms worked
better on original data than on random ones(Figure 17). However hierarchical ward clustering
on original data gave the a maximum separation of 87.13 SD (standard deviation) than the mean
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of random data. When compared to other internal cluster validation methods TLS outperformed
all of them hence it should be used as a cluster quality index. TLS doest not depend on the
number of final clusters so it does not require the tree to be cut at random heights to produce
desired number of clusters unlike in other internal cluster validation methods.
With this analysis it was observed that hierarchical ward clustering generates best separation
of cancer types on a dendrogram tree. TLS was the best clustering validation method. The
combination of ward clustering and TLS was used to find non-neutral CNA in accumulated
cancer CNA data.
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(b) Hierarchical single clustering
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(c) Hierarchical complete clustering
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Figure 14: Measure of connectivity using di↵erent hierarchical clustering algorithms. The con-
nectivity values obtained by randomizing the data are represented using histograms bars. The
observed connectivity on the original data is shown with the help of red line. The p values on
right represent the how good the original clustering was than on a randomized data.
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(c) Hierarchical complete clustering
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(d) Hierarchical ward clustering
Figure 15: Measure of Dunn index using di↵erent hierarchical clustering algorithms. The Dunn
index values obtained by randomizing the data are represented using histograms bars. The
observed Dunn index on the original data is shown with the help of red line. The p values on
right represent the how good the original clustering was than on a randomized data.
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Figure 16: Measure of silhouette width using di↵erent hierarchical clustering algorithms. The
silhouette width values obtained by randomizing the data are represented using histograms bars.
The observed silhouette width on the original data is shown with the help of red line. The p
values on right represent the how good the original clustering was than on a randomized data.
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Figure 17: The distribution of overall tree height obtained by randomizing the data is plotted
using histogram bars. The overall tree height on original data is represented with red line.
The mean overall tree height obtained using randomized data is shown with blue line. Ward
clustering (d) gave the maximum separation of original tree height than mean of randomized
data (88.13 SD)
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6.4 Non-neutral CNA - Paper II
CNA can also be used to identify oncogenomic similarities among cancer samples. Clustering
methods are used as a way to visualize such similarities and find groups in data [117, 144,
157, 156, 143]. However most of the clustering has been performed only on samples, with few
exceptions [117, ?]. With the availability of huge amount of CNA data we aimed at clustering
cancer types (not samples) and to identify genomic regions playing a crucial role in cancer
type specific divergence. For this a dataset of 25579 samples from 160 di↵erent cancer types,
classified on the basis of ICD-O-3 code was used.
It was observed that overall sample to sample heterogeneity results in a greatly varying aver-
age frequencies of CNAs per cancer type. The variation in overall CNA occurrence frequencies
among genomic intervals should be considered before clustering analyses. In our analysis the
aggregated frequency profiles across cancer types were normalized to the overall mean observed
across the entire data set. The clustering of cancer types using normalized frequencies pro-
duced a signal resulted in grouping of cancer types with similar “root” cell types together. This
clustering was better than expected by chance.
With the confirmation of a signal in the dendrogram tree we aimed on finding genomic
changes playing a role in cancer to cancer divergence, termed as “non-neutral”. We used the
dendrogram tree obtained using clustering of normalized frequencies to look for non-neutral
CNA. When several internal clustering measures were compared to a new method “TLS”, using
a randomization approach, it was observed the best separation among cancer types was observed
using hierarchical Ward clustering. TLS outperformed other internal cluster validation methods.
TLS was than used to identify changes playing a pilot role in cancer to cancer divergence. The
tree length statistic was ideal for measuring the quality of clustering as it does not require to
cut the tree at several heights to produce clusters of variable size, which is a prerequisite for
several external and internal cluster validation methods. 43 genomic regions (out of 160) were
identified to be enriched in the analysis (corrected p value  0.016). There was no preferential
bias towards losses or gains, and very few (14 out of 43) changes overlapped with the frequently
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altered regions pointing that analysis using only frequently altered regions may not always be
very useful in aiding data-driven evaluation of cancer (sub-) types.Changes such as 7q losses
(present in myeloid and germ cell tumors) and 8q losses (present in meduloblastomas) were
identified as targets not reported before to be selectively present in these cancer types. The
analysis was done only using CNA data reduced to band resolutions (80 genomic intervals) so no
claims could be made about the genes present in this region. Long regions have been reported
to be frequently altered in cancer types [115].
A detailed description of methodology and results can be obtained in Publication III, section
10.3.
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7 Conclusion
Cancer is the second dominating cause of death in the world. It is a group of diseases associated
with genomic changes. Genomic changes can occur during the normal phase of cell cycle or can
be induced by external factors such as radiation damage and inflammation. CNA are one type
of genome change observed in majority of neoplasias. Analysis involving CNA data can prove
to be very useful to determine the role CNA play in cancer development and progression. This
Ph.D. thesis is focusses on the systematic analysis of CNA data.
A new statistical method to find co-occurring CNA in cancer was formulated. CDCOCA
e ciently identifies changes with an overall less complex CNA background by considering the
number of CNA across tumor samples. When CDCOCA was applied to two di↵erent cancer
datasets it was observed that most of the frequent CNA were removed from the results reported,
indicating that the majority of highly frequent changes were related to a high genome instability.
While looking at co-occurring nature of CNA one can focus either on frequently co-occurring
or co-occurring CNA from a less complex background. When complexity is considered, CNA
associations may point towards preferred pathways modified during the events of carcinogenesis.
CDCOCA can prove to be very useful for defining associations at gene level. Thus, the results
obtained with the method can be further explored using known protein-protein interactions.
Systematic analysis of genomic CNA can provide information about genes involved in can-
cer initiation and progression. Recurring CNA have been used in identification of candidate
oncogenes. However, recently the complex contributions of multiple, cooperating genes and
pathways has come into focus. With the commonly observed involvement of large genomic re-
gions, CNA can a↵ect the expression of a multitude of genes far beyond canonical oncogenes
or tumor suppressors. CNA can be used to identify the functional cooperative gene modules
targeted by them. We used a new approach to identify pathways whose genomic loci are en-
riched among CNA. Our analysis was purely focussed on CNA data which is available for a
large number of tumor samples.
A detail analysis of some tools which can be used to find CNA targeted signaling pathways
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in cancer is presented here. According to the analysis, CNA harbor several genes and can in
turn a↵ect several pathways. When the genomic clustering of pathway genes is considered then
a gene based analysis to look for enriched pathways does not produce any significant results
(H-path). The segmentation approach (S-path) identifies pathways altered in CNA data and
considers the fact that these pathways can be clustered on the genome. However, it does not
solve the issue of identifying which genes could be important for a clustered set of genes for any
pathway. In our analysis of various unrelated cancer types, we were able to identify common
signaling pathways that likely have a pathogenetic relevance in these entities. The results of
our analyses identified a convergence of distant signaling pathways towards a restricted set of
interconnected cellular responses.
To test which clustering algorithm along with a cluster quality measure gives the best sepa-
ration of cancer CNA frequency profiles than of a random one, it was observed that TLS with
hierarchical ward clustering was the best fit to our data. When cancer types were clustered using
their normalized CNA frequency profiles, we identified a new category of CNA playing crucial
role in cancer to cancer divergence. This analysis disapproved the point that only frequent
CNA can be used in clustering cancer data. With our current study, involving 160 di↵erent
cancer types, we aimed to provide a generalized approach for identification of changes relevant
for genesis of individual cancer types. Our methodology might prove to be useful in separating
biological related entities.
Most of our analysis is based on low resolution data from chromosomal CGH experiments,
collected through publications. With the recent availability of high resolution (www.arrayMap.org
[164]) and sequencing data our tools can prove to be very useful in defining cancer to cancer
genome signature. Introduction of other kinds of genomic data such as somatic mutations,
methylations, and expression can help in validating (simultaneously extending) the results pro-
cured from CNA data to other kinds of alteration reported in cancer. This might further indicate
if CNA a↵ect cancer in similar way as other kinds of genomic changes and target same gene
modules.
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8 Outlook
Analysis of cancer genomes can prove to be crucial for finding genes and pathways responsible
for cancer development. Currently the largest amount of data available through cancer genome
mutation studies is CNA data. I have developed tools for the analysis and interpretation
of this data. With advancement in molecular screening technologies di↵erent kinds of whole
genome mutation data (such as somatic mutations, methylation) will be made available to
the research community. While consortiums such as TCGA (The cancer genome atlas) and
ICGC (International cancer genome consortium) are playing a pilot role in such an analysis, an
important aspect of these projects is the generation of rich datasets which can be included into
meta-analysis studies.
We believe that input from di↵erent kinds of genomic mutation data can increase the predic-
tion power of our algorithms. None of the research so far has been focussed on a combinatorial
analysis involving all kinds of mutation data across multiple cancer types. A combined analysis
of cancer genome data can be used to answer questions such as
1. Preferential bias of genes towards any kind of genomic alterations - Whole
genome somatic mutation data can be used to find, if there is a preferential bias of genes
towards di↵erent genomic mutations. This analysis can help in concluding if some genes
are preferred to be targeted by any specific genomic change or are in general targeted
more often by any type of change.
2. Co-occurring and mutually exclusive gene modules - Our in house developed al-
gorithm CDCOCA has proven to be useful to find co-altered genomic CNA regions. Our
algorithm can be used to find out genes which are either altered together (co-occurring)
or are mutually exclusive across entire mutational landscape of cancer. This analysis will
help in identifying key gene associations in cancer. Genes altered together more often than
chance can be essential for cancer development or progression whereas genes showing a
mutually exclusive behavior would define di↵erent genomic pathway by which a cancer
can develop.
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3. Integrative analysis using other data types - All of our analysis done till now is
being focussed only on cancer CNA data. Integration of RNA and protein expression can
help in identification of CNA regions altering either (or both) RNA expression or protein
expression. This can help in reducing the complexity of genes altered by CNA to identify
the probable candidates which show a standard pattern from CNA ! RNA expression !
protein expression.
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CDCOCA: A statistical method to define
complexity dependence of co-occuring
chromosomal aberrations
Nitin Kumar1, Hubert Rehrauer2, Haoyang Cai1, Michael Baudis1*
Abstract
Background: Copy number alterations (CNA) play a key role in cancer development and progression. Since more
than one CNA can be detected in most tumors, frequently co-occurring genetic CNA may point to cooperating
cancer related genes. Existing methods for co-occurrence evaluation so far have not considered the overall
heterogeneity of CNA per tumor, resulting in a preferential detection of frequent changes with limited specificity
for each association due to the high genetic instability of many samples.
Method: We hypothesize that in cancer some linkage-independent CNA may display a non-random co-occurrence,
and that these CNA could be of pathogenetic relevance for the respective cancer. We also hypothesize that the
statistical relevance of co-occurring CNA may depend on the sample specific CNA complexity. We verify our
hypotheses with a simulation based algorithm CDCOCA (complexity dependence of co-occurring chromosomal
aberrations).
Results: Application of CDCOCA to example data sets identified co-occurring CNA from low complex background
which otherwise went unnoticed. Identification of cancer associated genes in these co-occurring changes can
provide insights of cooperative genes involved in oncogenesis.
Conclusions: We have developed a method to detect associations of regional copy number abnormalities in
cancer data. Along with finding statistically relevant CNA co-occurrences, our algorithm points towards a generally
low specificity for co-occurrence of regional imbalances in CNA rich samples, which may have negative impact on
pathway modeling approaches relying on frequent CNA events.
Background
Genetic alterations are an absolute requirement for
malignant neoplasias in humans [1,2]. Both kind of
genetic alterations and order of occurrence are impor-
tant for cancer development and progression [3]. Addi-
tionally to sequential event models, large scale analysis
of genomes from patient’s tumors have shown that mul-
tiple genetic abnormalities can promote the develop-
ment of one cancer entity [4]. Alterations in cancer
genome can range from subtle sequence changes (e.g.
point mutations) over structural alterations with func-
tional impact on the coding sequence (e.g. generation of
fusion genes by chromosomal translocations) to regional
or whole-chromosome copy number abnormalities (see
e.g. [5-7]).
Through a gene dosage effect, genomic copy number
alterations (CNA) may lead to insufficient expression of
tumor suppressors or overexpression of proto-oncogenes,
respectively. Recurrent CNA have been identified in
nearly all cancer entities [8-10]). Comparative Genomic
Hybridization (CGH) [11,12] is a genome wide CNA
screening technology which has been widely applied
throughout the last two decades. Building on the reverse
in situ hybridization principle developed for chromoso-
mal CGH [13], genomic microarray technology (aCGH;
[14,15]) now utilizes intensity values from up to millions
of short DNA sequences to derive regional copy number
estimates.
Large data sets from copy number screening experiments
should provide a powerful resource for oncogenomic data
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mining studies. In contrast to expression data, copy num-
ber data arises from the projection of discrete values into
the experimental space. As such, a reduction of the (a)
CGH data can result in the minimal information of seg-
mental status (gain/loss/normal) and genomic position.
This facilitates efforts to integrate data across large num-
bers of experimental series and derived from diverse tumor
entities. So far, most of these efforts have been of descrip-
tive nature [10,16] or have been aimed at the definition of
disease-specific genomic patterns and useful pattern
descriptors ("markers”, e.g. [17]). Other publications have
attempted the reconstruction of relation and temporal
order of oncogenetic events [18-20].
For some cancers types such as subsets of colorectal
adenocarcinoma, presence of a limited number of
genetic events including several CNA is critical for can-
cer development [21]. Other neoplasias such as chronic
lymphocytic leukemia (CLL) display a paucity of CNA,
which however may be correlated to patient survival
[22]. These examples illustrate that the presence of cer-
tain CNA is not a chance phenomenon, but may either
be necessary for cancer development or give a selective
edge to affected clones. Previous publications have tried
to address the cooperative nature of co-occurring CNA
[23,24]. So far, these approaches have not considered
the high variability in the complexity of CNAs among
individual malignant tumors. Here, we develop an algo-
rithm CDCOCA for analysis of co-occurring oncoge-
nomic CNA events which considers the genomic
complexity of the individual samples. We use our
approach for detection of CNA events in real-world
example data sets. Furthermore, we compare the results
from CDCOCA to a previously published method [23]
(which we call “analysis 3” in this paper) and also to a
modified version of CDCOCA which does not include
the adjustment for genomic complexity.
Methods
Data
Annotated copy number and associated data was
selected from our Progenetix (a)CGH database ([25]:
http://www.progenetix.net; status as of 2010-03-01). For
model development and testing, we choose one hemato-
poietic (MCL) and one solid tumor entity (BLCA) due
to their overall intermediate genomic complexity, with-
out consideration of their previously established geno-
mic imbalance profiles or CNA subset analysis.
For analysis, copy number status data was determined
for 320 genomic intervals based on corresponding cyto-
genetic bands. Sex chromosomes were removed due to
possible bias in some of the published series (e.g. use as
normalization control in (a)CGH experiments), resulting
in 303 genomic intervals. For analysis by CDCOCA/
CICOCA, gain and loss status of all genomic intervals
were considered separately, leading to a data matrix
with 606 categories. Only genomic intervals showing
change in at least one sample were considered for analy-
sis resulting in a CDCOCA/CICOCA input matrix with
593 categories for BLCA and 571 for MCL. For analysis
3, the original data matrix containing 303 genomic
intervals was used. As a surrogate score for genomic
complexity, a case specific score was calculated by add-
ing each type of genomic imbalances (gain and/or loss)
occurring on a chromosomal arm [26].
From now onwards we will use the term “genomic
interval” for genomic interval status. A gain and loss
association on same chromosome (e.g. -1p and + 1q)
will be referred as “bidirectional” change. The modified
structure of the data matrices is exemplified in Table 1.
Any gain/loss status of a genomic interval is represented
by the value 1.
Model
Let D be the data matrix of dimension nxm, where n is
the number of samples and m is the number of genomic
intervals. Di,j = 1, if a CNA is present in genomic inter-
val j in sample i else Di,j = 0. Fj represents the number
of sample having CNA at genomic interval j, Fj is given
by Diji
n
=
∑ 1 . P P Pw w wn= ( ... )1 represents the vector of
probability weights given to samples. The prior probabil-
ity weight for any sample r is defined by the number of
CNAs in patient r over total number of CNA across all
samples
P
D
D
w
r
rjj
m
t jj
m
i
n=
=
==
∑
∑∑
1
00 ,
Simulation of any genomic interval j is achieved by
redistribution of the CNA status over all samples. For
genomic interval j, we define D D Di j
n* * *( ... )= 1
1 as the cor-
responding vector representing the CNA status of simu-
lated data. D j* is obtained in a way so that F Fj j
*
≈ .
Overlay between two genomic intervals is computed
using Jaccard’s index [27]. Jaccard’s index gives a value
Table 1 Binary matrix derived from CGH data
g-c1p11 g-c1p12 g-c1p13 l-c1p11 l-c1p12 l-c1p13
1 0 0 1 1 1 0
2 0 0 0 0 0 1
3 0 0 1 1 0 0
4 1 1 1 0 0 0
5 1 1 1 0 0 0
6 0 0 0 0 1 1
For each cytogentic band (e.g. c1p12) occurrence of gain (e.g. g-c1p12) and
loss (e.g. l-c1p12) is annotated as separate event for each case.
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between 0 and 1, where one represents a perfect overlap
and zero, no overlap. The Jaccard’s index between any
two genomic intervals j and k is computed as
J
N
N N N
jk
jk
jk jk jk
=
+ +
11
10 01 11
N jk
11 number of samples with CNA in genomic inter-
vals status, j and k.
N jk
10 number of samples with CNA in genomic inter-
val status j but not k.
N jk
01 number of samples with CNA in genomic inter-
val status k but not j.
The overlap obtained on permutation is represented
by J jk
∗ Frequency of a co-occurrence is computed as
F
N
njk
jk
=
11
Fjk frequency of an overlap between genomic intervals
status i and j.
N jk
11 number of samples having change in both geno-
mic interval status i and j. n total number of samples in
the data.
CDCOCA Algorithm
Let S be the number of simulations and C is the counter
measuring the number of times the expected (i.e. per-
muted) overlap is greater than or equal to the observed
overlap. We set the counter of C = 0.
1. Initialize C = 0.
2. Calculate Jaccard’s overlap Jjk between genomic
interval j and k.
3. For genomic interval j simulate the data to obtain
D j* as
a. Obtain a sample index r of size 1, from N =
(1,....,n) using Pw
i such that sample with maxi-
mum weight given has a higher probability of get-
ting a change on permutation, update D j
r* = 1.
b. Update N = N[-r].
c. Update P P P
P
P
P
P
P
w
i
w
i
w
i w
i
w
i
i
w
i w
i
w
i= − = =
=∑[ ,r],   1 .
d. Repeat step 3a and 3b Fj times to obtain simu-
lated vector D j* .
4. For genomic interval k simulate the data using
step 3 to obtain Dk
* .
5. Recompute Jaccard’s overlap J J jjk jk jk
* *,   if ≥
increase C = C + 1.
6. Repeat step 3, 4 and 5 for S times.
7. At the end of S (5000 in our case) permutations
calculate p value as, p CS= .
The p-value obtained after step 7 represent the prob-
ability of co-occurrence of two CNAs in absence of any
other CNA in sample. A low p-value cut off will help in
enriching for CNAs which occur together even in less
heterogenous samples.
Results and Discussion
We here propose a methodology named CDCOCA
(Complexity dependence of co-occurring chromosomal
aberrations) that defines highly correlated pairs of CNA
in cancer samples while correcting for the overall degree
of genomic instability.
We determine CNA complexity based on the number of
segmental CNA in a sample while accounting for variations
introduced through different resolutions and/or segmenta-
tion algorithms [10]. A sample is called “CNA complex” if
it has acquired a high number of CNA, and conversely
“CNA simple” if a low number of segmental imbalances
have been detected. In Figure 1 the distribution of copy
number complexities is presented for data from selected
tumor entities, extracted from the Progenetix database.
The performance of CDCOCA depends on the number
of tumor samples, number of genomic intervals and num-
ber of iterations. CDCOCA produces a matrix of p values
for all possible associations in the data matrix which are
then used to enrich for associations dependent on sample
complexity. The algorithm is implemented in the R statis-
tical framework and is available through R package
“CDCOCA” provided on the Progenetix website [25].
We applied the CDCOCA algorithm to bladder car-
cinoma (BLCA) and mantle cell lymphoma (MCL)
copy number data, considering gains and losses for
each interval as separate events. The readout of the
analyses consisted of the p values obtained after rando-
mization for all observed associations in both cancers
after 5000 permutations each. We used Jaccard’s index
to calculate the overlap between genomic intervals
[27]. Figure 2 and 3 show the log of p values plotted
against the log of Jaccard’s index. For simplicity, here
p values for only 4 chromosomal changes were plotted.
Using CDCOCA we observed that most of the genetic
associations have very low Jaccard’s overlap and arise
Kumar et al. BMC Medical Genomics 2011, 4:21
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from genetic changes which occur in CNA complex
samples (hence high p values). Associations presenting
with high Jaccard’s indices and low p-values represent
CNA with high probability of specific co-occurrence
(i.e. frequent co-occurrence independent of high sam-
ple CNA complexity).
Our results show that most of the CNA data for both
cancers are derived on a background of multiple and
extended CNA. The total number of genetic associations
in both cancer types remains beyond scope of the
         
        
     
           

BNHL: CLL
Ca.: prostate adenoca.
BNHL: MCL
Ca.: bladder ca.
Ca.: esophagus ca.
0 5 10 15 20 25 30
Imbalance complexity
Figure 1 Complexity boxplot of CNA in some selected cancers.
Box plot for the overall CNA complexity in selected cancer entities.
As a surrogate marker for genomic complexity, each cytogenetic
arm was scored independently for gains and losses (i.e., max. score
of 4 for a chromosome with both gains and losses on both arms),
and chromosome scores were summarized for each case.
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Figure 2 Log of p value plotted against log of Jaccard’s index
for BLCA. For simplicity reasons all the associations involving only 4
chromosomal changes are shown here. Each color dot reprent an
association of that particular chromosome with some other
chromosomal band. Most of the associations have a low Jaccard’s
index and very high p values (upper left side of plot) these
associations represent CNA in CNA complex samples. Few
associations have a high Jaccard’s index and low p values (lower
right side of plot); these associations are present in “CNA simple”
samples.
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Figure 3 Log of p value plotted against log of Jaccard’s index
for MCL. Most of the associations have a very high CNA complex
background (upper right side of plot) whereas a associations with
high Jaccard’s index and low p value (lower right side) are also
present for all chromosomes.
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Figure 4 Matrix plot showing results obtained for BLCA with
CDCOCA. The diagonal lower half of the image represents all the
possible associations in BLCA data where as diagonal upper half
represents associations obtained after p value cut off. Frequency of
genomic intervals is represented by histogram at the top. Color code
represents the value of Jaccard’s overlap between associations. The
high correlation throughout the diagonal confirms shows the strong
connection between CNA co-occurrence and close genetic linkage.
Kumar et al. BMC Medical Genomics 2011, 4:21
http://www.biomedcentral.com/1755-8794/4/21
Page 4 of 10
current analysis. However, with CDCOCA we are able
to focus on a defined set of statistically relevant, specific
changes.
For estimating the performance of our methodology in
relation to otherwise discussed models we compared
CDCOCA to a modified version “CICOCA” (see supple-
ment) and a previously published method [23]. Both the
later algorithms do not include an estimate of sample
complexity and primarily identify associations with a
high frequency. CICOCA and analysis 3 use different
methods to compute overlap resulting in slightly differ-
ent but overall concordant results.
With CICOCA, a high number of co-occurring
changes were obtained after p value cut off (Figure 1
and 2 in additional file 1). In contrast, introduction of
complexity estimation leads to a focus on changes aris-
ing on a low complexity background (Figure 4 and 5).
With analysis 3 (Figure 3 and 4 in additional file 1) a
very low number of associations was obtained in our
sample data set. As expected these only involved high
frequent changes. We could show that most of the CNA
obtained by analysis 3 (Figure 3 and 4 in additional file
1) were also detected using CDCOCA (Figure 4 and 5)
and CICOCA (Figure 1 and 2 in additional file 1).
CICOCA and analysis 3 can be used to describe fre-
quent associations, while CDCOCA additionally allows
to test the specificity of associations and to apply
thresholds accordingly. Compared to frequency based
thresholding, one advantage of CDCOCA is its indepen-
dence from arbitrary cut-off values. The algorithm
scores every association. The p value obtained assigns a
statistical significance to the associations which is inde-
pendent of the frequency of the association in the data
but takes the complexity of the sample into account.
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Figure 5 Matrix plot showing results obtained for MCL with
CDCOCA. The diagonal lower half of the image represents all the
possible associations in BLCA data where as diagonal upper half
represents associations obtained after p value cut off. Frequency of
genomic intervals is represented by histogram at the top. Color code
represents the value of Jaccard’s overlap between associations. The
high correlation throughout the diagonal confirms shows the strong
connection between CNA co-occurrence and close genetic linkage.
Table 2 Statistic of associations in BLCA
Analysis
method
Total
associations
No. intra-chromosomal
associations
p-value FDR Associations
obtained
No. intera-chromosomal
associations
1 CDCOCA 96436 4786 0.02 0.275 6991 3619
2 CICOCA 96436 4786 0.02 0.096 20089 3891
2 Analysis 3 40284 2577 0.02 0.7211 321 152
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Figure 6 Matrix plot showing frequency of associations in
BLCA. Associations are shown similar to figure 4 but here
displaying frequencies of associations in place of Jaccard’s overlap
values. Most frequent CNA associations involve genetically linked
CNA. Associations involving high frequent changes are lost after p
value cut off indicating their occurrence in a CNA complex
background.
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Bladder carcinoma
An overview of the most frequent genomic imbalances
in urinary BLCA can be found in e.g. [10]. Most fre-
quent gains in BLCA include regions on 1q, 5p, 8q,17,
19 and 21q, while the most frequent losses occur on 2q,
4, 5q, 6q, 8p, 9, and 13q (Figure 1 and 3 in additional
file 1 and Figure 4 barplot). Due to the high degree of
aneuploidy in BLCA, CNA data is highly complex
(Figure 4 matrix plot) resulting in a very high number
of total associations (Table 2).
A large proportion of associations combine a low fre-
quency with a high Jaccard’s index (Figure 4 and 6 matrix
plots). We applied a p-value cut off of 0.02 resulting in a
false discovery rate (FDR) of 27.5%. At this p-value cut
off, 75% of intra-chromosomal associations passed the
threshold, confirming the correlation between genetic
linkage and involvement in CNA events. Table 2 contains
the information about the comparison of results for all
three analysis. For simplicity reasons here we limit the
display to the 100 most frequent inter-chromosomal
changes obtained after p-value cut off.
According to CDCOCA, specific pairs of genomic
imbalances in bladder carcinoma include concurrent
“bidirectional” losses on 8p and gains on 8q (Figure 7).
In the comparative analysis, gains involving chromo-
some 8q were detected with all three methods (Figure
5 and 6 in additional file 1 and Figure 7). However,
with CDCOCA the frequent co-occurrence of these
CNA on the background of a low genomic complexity
became more apparent. This observation may point to
an early appearance of these CNA during tumorigen-
esis, with a possible role as cancer initiating event.
While gains on distal 8q are the most consistent copy
number change in epithelial neoplasias with MYC con-
sidered a predominant target, recently deletions on
8p23.3 have been associated with aggressive clinical
behavior in BLCA [28]. Another observation concerned
changes involving concurrent gains on 5p and losses
on 5q which were also associated with losses on chro-
mosome 4q and distal 6q (6q22). These co-occurrences
(Figure 5 and 6 in additional file 1 and Figure 7).
Although one may assume that “bidirectional” changes
involving both chromosomal arms are based on simple
cytogenetic events, e.g. isochromosome formation, the
limitation of this pattern to distinct chromosomes
points at an evolutionary advantage of both gain and
Figure 7 100 frequent associations obtained after p value cut off in BLCA with CDCOCA. Pathway associations for presumptive target
genes from the 100 most frequent associations in BLCA obtained after p value cut-off are shown. TGF-beta signaling genes (blue triangles) and
genes from cellular apoptotic pathways (red triangles) present in these genetic locations are displayed. Gains are represented with prefix “g” and
green color circles whereas losses with prefix “l” and orange circles. Associations were drawn using cytoscape [42].
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loss accumulation for the malignant clone. Other event
pairs obtained by CDCCOA include gains on 8q23
along with gains on 3q, as well as gain on 20q11 with
loss on 18q23.
The abundance of 8p losses, 8q gains, 5q losses, 5p
gains, 3q gains, 4q losses points towards the importance
of these CNA in tumors carrying them. Genes from
TGF-beta receptor signaling (blue triangles) and cellular
apoptotic pathways (red triangles) located to the co-
occurring changes are shown in Figure 7. The presence
of genes from the same pathways on co-occurring CNA
point towards a possible cooperative action of these
genes. CDC23 (5q31), CASP6 (4q25) and PMAIP1
(18q21) are among TGF-receptor cascade genes with
well established role in cancer [29,30] Other possible
targets for genetic cooperation include PMSD2, PAK2,
BCL2L1 and FNTA. Genes from apoptotic signaling
pathways mapped to these regions include CDC23
(5q31), SMAD2 (18q21), SMAD4 (18q21) and SMAD7
(18q21) which have been shown defective in several can-
cer entities [31]. As possible target on 5p, loss of SKP2
had been shown to cause cell senescence [32]. On 5q,
loss of function mutations including copy number losses
of both APC and MCC have been associated with a vari-
ety of epithelial neoplasias [33-36].
Mantle cell lymphoma
For MCL, an overall p value distribution similar to that
of BLCA was observed (Figure 3). Most common CNA
in MCL included gains on chromosomes 3q, 6p, 7p and
8q, while most common losses involved regions on 6q,
8p, 9, 11q and 13q (Figure 7 and 8 in additional file 1
and Figure 5).
A p value cut-off of 0.04 giving a FDR of 30% was
applied with CDCOCA (Table 3 and Figure 8). About
80% of intra-chromosomal associations passed this
threshold, representing approx. 50% of all post cut-off
associations. The 100 strongest associations obtained
with CDCOCA are shown in Figure 9. As in BLCA,
CDCOCA detected losses on 8p with gains on 8q, which
was not described as association in the other analyses.
Also, only CDCOCA selected groups of co-occurrences
involving low frequency CNA (e.g. associations involving
gains 7p, 6p, 12p and 18q). Other changes such as losses
on highly occurring 13q along with gains on not so fre-
quently occurring 7q were obtained using CDCOCA and
not with CICOCA and analysis 3 in the top 100 events
(Figure 7 and 8 in additional file 1).
As candidate targets, TNF-signaling genes (red trian-
gles) and T-cell receptor signaling genes (blue triangles)
are marked on their corresponding band locations in
Figure 9. The role of genes such as MDM2 (12p15),
TNFRSF1A (12p13), MALT1 (18q21) for neoplastic
transformation and/or progression has already been well
established [37-39]. Other examples for cancer relevant
genes mapping to those regions are STAT2 (12q13), and
STAT3 (17q) [40,41].
Conclusions
We have developed a method CDCOCA to define com-
plexity dependence of co-occurring CNA in cancer
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Figure 8 Matrix plot showing frequency of associations in MCL.
Associations are shown similar to figure 7 but here displaying
frequencies of associations in place of Jaccard’s overlap values. Most
frequent CNA associations involve genetically linked CNA.
Associations involving high frequent changes are lost after p value
cut off indicating their occurrence in a CNA complex background.
Table 3 Statistic of associations in MCL
Analysis
method
Total
associations
No. intra-chromosomal
associations
p-value FDR Associations
obtained
No. intera-chromosomal
associations
1 CDCOCA 57644 3918 0.04 0.30 7513 3175
2 CICOCA 57644 3918 0.04 0.197 11673 3918
2 Analysis 3 31136 2418 0.04 0.571 867 207
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samples. In contrast to methods published previously
[23] and a modified algorithm which does not include
the complexity adjustment step, CDCOCA does not
simply focus on the most frequent co-occurrences of
regional genomic copy number changes in cancer enti-
ties. Here, we determine statistically relevant co-occur-
ring CNA through accounting for the CNA
“background noise”, introduced e.g. through chromo-
some scale imbalances (e.g. isochromosomes, chromoso-
mal aneuploidy). In theory, this procedure should
highlight specific but comparatively rare CNA events.
As indicated by our analysis of BLCA and MCL, two
unrelated cancer entities with overall intermediate copy
number complexity, the relevant CNA associations in
many specimen are obscured due to the large number
and/or extension of regional CNA. When correcting for
genomic background heterogeneity most of the associa-
tions involving highly recurring CNA were removed.
This indicates that many high frequency changes may
be related to the overall genomic instability and there-
fore cannot unanimously be assigned a causative role in
oncogenesis. Especially regarding the large number of
genes affected by complex genomic imbalances, some of
the cancer type specific CNA patterns may represent an
epiphenomenon of disturbed genomic maintenance pro-
cesses rather than the expression of copy number
dependent target gene modifications.
However, when accounting for the overall complexity,
CNA associations may point towards connected events
and/or preferred pathways activated during carcinogenesis.
Based on our CNA associations, we found multiple genes
from single well defined cancer pathways to be a effected
in sample subsets. Alteration of more than one gene in a
pathway may potentiate the effect on pathway function
and be responsible for a specific clonal phenotype.
CDCOCA should prove to be a powerful tool for
defining mutual associations at gene level and to gain
insights into cellular mechanisms relevant for oncogen-
esis. Although we applied our method to CGH data at
band resolution, there is no practical obstacle against
use with segmented data from high resolution genomic
array experiments. In fact, this should facilitate a gene
centric analysis and automatic integration with func-
tional data sources.
Figure 9 100 frequent associations obtained after p value cut off in MCL with CDCOCA. Pathway associations for presumptive target
genes from the 100 most frequent associations in MCL. TNF-alpha signaling genes (red triangles) and T-cell receptor signaling pathway genes
(blue triangles) present in these genetic locations are shown. Gains are represented with prefix “g” and green color circles whereas losses with
prefix “l” and orange circles.
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Additional material
Additional file 1: CICOCA: A method to define complexity
independence of co-occurring chromosomal aberrations. The
additional file contains information about the statistical method CICOCA
which is compared with CDCOCA. This method (as described in text
above) aims in finding co-occurring chromosomal associations
independent of the sample complexity. In addition to CICOCA this file
also contains all the additional figures which are referred in the paper
along with a detail description of all the additional figures.
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Abstract
Regional genomic copy number aberrations (CNA) are a type of mutation observed in the vast majority of
cancer entities. Since many of the CNA in cancer may simply represent neutral somatic variants, and since they
typically cover several genes simultaneously, their causal contribution to tumorigenesis has been di cult to
quantify. The detection of systematically enriched functional pathways among CAN-a↵ected genes would be one
way to assess causality and such an observation would also be instrumental in better describing cancer pathways
with respect to their entire spectrum of mutations.
We here use three di↵erent strategies (H-path [1], G-path and S-path) to search for pathways a↵ected by CNA
more often than expected by chance. In addition to pathway enrichment S-path also considers the key issue of
genomic clustering of cellular pathways. The analysis is performed on CNA data from a total of 19819 tumor
samples. The new strategy S-path outperforms the other two methods, but still finds only a very restricted set
of pathways that might be somewhat enriched. The analysis is then extended to 132 individual cancer types
classified on the basis of international classification of disease code (ICD) to define a cancer specific pathway
signature. We here show that some pathways are altered by CNA more often than chance and are enriched
among multiple cancer types. A knowledge driven analysis of enriched pathways lead to the definition of specific
functions controlling cancer associated cellular responses.
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Background
Somatic mutations are an essential requirement for the development of a neoplastic cell clone. Regional
deviations of the DNA copy number from the normal diploid status (termed “copy number
alterations/aberrations”, CNA) can be observed in the majority of malignant neoplasias. Several regional
CNA hot-spots (i.e. local peaks of recurring gains / losses) have been linked to specific oncogenes and
tumor suppressor genes such as REL (2p13-12), p53 (17p13), MYCN (2p24). Some recurring CNA are
present across multiple cancer types [2, 3]. However, the extensive CNA heterogeneity observed in human
malignancies may obscure any underlying activation of common growth mechanisms, because di↵erent
components of tumor-related pathways will be a↵ected in each patient [4, 5].The determination of cellular
pathways systematically enriched in CNA regions would provide insights in the relative importance of
functional mechanisms for the development of specific neoplastic entities, and should lead to an extensive
delineation of specific CNA targets.
Previously, extensive pathway analyses have been performed using expression array data [6–11].
Additionally, some studies have reported integrative analyses of CNA and expression array data to predict
pathways altered in cancers [12, 13], or have combined CNA with somatic mutation data [1]. Methods have
also been developed to detect enriched pathways in cancer SNP data [14,15]. However, to the best of our
knowledge no analysis has been performed to search for enriched cellular pathways solely based on cancer
CNA data across multiple cancer types. Such an unbiased analysis should prove especially useful due to
the potential for analysis across very large CNA datasets available through public resources.
Here, we first propose two new permutation methodology, “G-path” (gene based pathway enrichment) and
“S-path” (for segment based pathway enrichment), to detect enriched cellular pathways among the
genomic regions a↵ected by copy number changes in cancer. S-path is a variant of G-path, which defines
pathways as a set of genomic segments and not genes (see Methods); this considers the key issue of
genomic clustering of cellular pathway genes which may otherwise lead to false-positive calls of pathway
enrichments [16]. The analysis is also compared to a know pathway enrichment methodology [1]
(supplement, referred to as “H-path” for pathway hit enrichment). Both G-path and S-path consider the
following two points about pathway-based analysis in CNA data:
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• A cellular pathway consists of multiple interacting proteins, modulators and e?ectors, and hence
multiple genes/segments may be simultaneously altered in any individual tumor, potentially
conferring a certain growth-advantage.
• Annotated pathways may often partially overlap, and also cover widely di↵erent levels of functional
specificity, so both gene-pathway and segment pathway (for S-path) membership are conserved while
performing a whole genome permutation strategy, in order to search for statistically enriched
pathways.
We first tested the three algorithms on a cancer dataset encompassing 19819 tumor samples available
through our website Progenetix [17] and chose the best performing algorithm on the basis of the number of
pathways reported as enriched below a given FDR threshold. The analysis was then extended to 132
individual cancer types classified with the help of international classification of disease (ICD) codes.
High-scoring pathways were than inspected to determine how they may interact and what kind of cellular
response they might generate.
Methods
Gene and pathway data
Several resources of pathway-associated annotations are publicly available (e.g. Reactome [18], Kegg [19],
Nature Signaling Pathways [20]). We use Nature Signaling Pathways as a pathways source for all analyses
reported here; it consists of signaling cascades only and does not include processes such as metabolism
(present in KEGG). Another reason for using Nature Signaling Pathways is its non-hierarchal pattern of
annotation, contrary to e.g. Reactome where large pathways are further divided into hierarchies of
pathways making analysis di cult. Genes were mapped to genomic locations according to Human genome
version 18 (hg18/build36). Genes on chromosomes X and Y were removed prior to analysis due to inherent
gender biases (e.g. prostate carcinoma) and inconsistent reporting in the CNA data sets. The remaining
pathway-specific data consisted of 176 pathways containing a total of 2239 genes.
For genomic positions, we obtained the Ensembl gene list from Biomart release 54. This gene list was
processed to obtain genes with unique combination of Ensembl gene identifier (Ensembl id) and
chromosome start and end position. Mitochondrial and sex chromosomal genes were removed resulting in a
total of 20209 genes for the input gene list.
For S-path we divided all chromosomes in to non-overlapping segments of 1Mb each, dividing the entire
genome into 2872 bins (we call this “segmentation”). The gene list was than mapped to the artifical
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segments of 1Mb, and each segment containing one or more genes of a given pathway was counted exactly
once for that pathway. We expected that dividing the genome into small bins resolved the issue of pathway
genes clustering. 2239 pathway genes were mapped to 1203 unique genomic segments.
Data sets
Cancer CNA data available through progenetix [17] is used as an input to pathway algorithms. A total of
19819 tumor samples from 132 di↵erent cancer types were analyzed for pathway enrichment. The analysis
was then extended to individual cancer type for entity specific pathway enrichment profile. The genome for
copy number data across all samples was reduced to segments of 1Mb each as an input to S-path. Such an
input data has been used to enrich for CNA which are altered more often than chance [21].
Model and parameters
We here define models and parameters for G-path and S-path. The only di↵erence between G-path and
S-path is the pathway input file. Genes are an input for G-path which are replaced with segments for
S-path. Here we use the term genes for both; genes for G-path and segments for S-path.
A unique permutation strategy is used to compute pathway scores using G-path/S-path. Let S represents
a list of samples {S1, ...Sn, ...Sm} of a given cancer type. A pathway P is represented as a set of genes Gi ,
where i is any number of genes with known genomic locations on autosomes. We consider that for pathway
P more than one gene can simultaneously be a↵ected by CNA Figure 1 shows the boxplot of number of
1Mb pathway segments altered in some pathways across 19379 tumor samples, showing on average 10% of
segments are copy number altered across pathways. For every sample a pathway index SPn = NP is
obtained. NP represents number of genes for pathway P which are copy number altered in sample Sn, NP
✏ Gi. The overall pathway score for pathway P across all samples is obtained as OPP =
Pm
n=1 SPn. The
list of overall pathway scores is represented as {OP1, ...OPp, ....OPs}for s pathways. The corresponding
list obtained on permutations is represented as {OP ⇤1 , ...OPp⇤, ....OPs⇤}. OPp can vary between 0 ( when
no gene for pathway P is copy number altered) and max{i ⇤m}(when all genes i are copy number altered
across all m samples). All the three algorithms (G-path, S-path and H-path) identify pathways rejecting
the null hypothesis that “there is no association between pathway genes and CNA”.
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Pathways enrichment with G-path and S-path
In this section we describe the two algorithm G-path and S-path. Genes for G-path represent same as
segments for S-path.
1. Overall pathway scores for all pathways {OP1, ...OPp, ....OPs}are computed.
2. A null vector C = NULL of length s is defined. C measures the index how many times expected
scores across pathways are greater than or equal to observed scores.
3. For permutation all Ensemble genes (2872 segments for S-path) are randomly distributed on to new
genomic locations. This permutation helps in keeping gene pathway membership consistent while
a↵ecting only pathways Vs genomic location membership.
4. Expected pathway score {OP ⇤1 , ...OP ⇤p , ....OP ⇤s }on permutation for all pathways is computed.
5. If expected score for pathway P is greater than or equal to the observed score Cp is incremented as
Cp = { Cp + 1 if OP ⇤p >= OPpCr if OP ⇤p < OPp }
6. Step 2 to 5 are repeated over Z number of times (Z = 10000 in current analysis) increasing the
counter C for pathways which are altered by chance.
7. After all permutations a p value vector {p1, ..pp, ..ps} ✏ P are calculated from C as pp = CpZ
8. All the p values are corrected for false discovery rate using Benjamini Hochberg correction.
Genomic clustering of pathways
Genes for cellular pathways are clustered on the genome [16]. For all the pathways a clustering score is
compute as described in [16]. Since for S-path genes from pathways are represented as segments the
pathway clustering score is computed using these segments and not genes. For each gene pair on same
chromosome from a pathway a pair wise score of clustering is computed as
pairscore = average length of chromosomes in genomedistance between genes
For genes on di↵erent chromosome distance is computed as
pairscore = average length of chromosomes in genomeaverage length of chromosomes the genes are located on
The pathway clustering score is the sum of all pair wise scores divided by the number of genes in that
pathway. The original clustering score is compared to the expected scores obtained by randomly creating
pathways with same number of genes and then recalculating the expected pathway clustering score (10000
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permutations). p-values are generated by comparing the original and expected scores as
pvalue = number of times expected clustering score   observer clustering scorenumber of permutations .
The p values are corrected for false discovery rate using Benjamini Hochberg correction.
Results and Discussion
Clustering of pathway genes
The pathway clustering score followed nearly a normal distribution with data having a mean score of
89424.79 (Figure 2). The clustering score was independent of the number of genes in pathways
(Supplement figure 1). Dividing the genome into artificial segments of 1Mb resulted in a suppression of
genomic clustering (Figure 2) and the mean clustering score was reduced to 114.465. Genomic pathway
clustering signal was lost after genome segmentation (supplement figure 1). Before segmentation 47
pathways were found to be genomic clustered at this FDR (Supplement table 1). However when segments
were considered none of the pathways remained clustered (supplement figure 1). This analysis points
towards a key issues about considering these genomic segments as a set of pathway components and not
genes. As considering genes produce a signal which is a↵ected by the genomic clustering of pathways.
Comparison H-path, G-path and S-path
We compared all the three methods to obtain a list of pathways targeted by can more often than expected
by chance. Cancer CNA alterations span through multiple pathway genes (Figure 1), indicating the
importance of the total score as a pathway score parameter. A maximum FDR cuto↵ of 0.15 was used as a
selection criteria to find enriched pathways. H-path led to an enrichment of only one pathway (Supplement
figure 2) whereas 4 pathways (one genomic unclustered and three clustered) were enriched with G-path
(Supplement figure 3). Using S-path 17 pathways were found to be significantly enriched (Figure 3). Genes
from five of these pathways were clustered in genome however since we considered segments this genomic
clustering was not significant and did not a↵ect our results.
All the pathways enriched in G-path were enriched using S-path however additional pathways were
identified using S-path with same FDR cut-o↵s. The issue of genomic clustering is also resolved by S-path
as all the genes present in a window bin of 1Mb are considered as a single event. H-path e ciently
identifies pathways which are hit more often with CNA than by chance. However the analysis lacks the
ideology that for a given pathway more than one gene can be simultaneously copy number altered. The
permutation strategy used by G-path and S-path is unique in itself as till now no one has considered to
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keep genes (segment) and pathway membership constant on permutations. Another advantage of
G-path/S-path is that a much large range of background CNA are considered in analysis.
Pathways enriched
We extended the analysis using S-path to CNA data from 132 di↵erent cancer types. 59 cancer types
showed an enrichment of at least one pathway with a FDR cut o↵ of 0.15. 22 pathways were enriched in
more than 20 individual cancer types (Supplement figure 4). On further scrutiny we nailed down to 8
signaling pathways (Figure 4), which were identified in integrative analysis as well as were present in more
than 20 ICD types. Interesting candidates included mTOR signaling pathway and Thromboxane A2
receptor signaling, both of these pathways were enriched in more than 30 cancer types.
Identification of these pathways predicts increased proliferation or antiapoptotic properties in cancer cell
(Figure 4). For instance, although a6b integrin are known for their function in cellular adhesion to the
extracellular matrix, recent studies have added a new oncogenic role of these integrins through
enhancement of erbB and MET signaling pathways [22,23]. In the samples we analyzed, a6b integrin gene
loci are gained concurrently with erbB receptors and MET (Supplement Table 1), suggesting a potentiation
of erbB/MET signaling through cooperation with these integrins. The PTP1b pathways that are negative
regulators of receptor tyrosine kinase (RTK) signaling also showed gain for genes encoding growth factor
receptors (Supplement Table 1) or their downstream positive regulators [24–26]. Other important
pathways that are found significantly modulated in terms of gene copy number include thromboxane
signaling pathway which is a GPCR signaling pathway also known to activate growth factor signaling by a
novel mechanism known as receptor transactivation.
The mechanism of cellular proliferation is dissected into cyclic entry of cells in mitosis regulated by set of
transcription factors. An important class of such transcription factors is E2F family. Several member of
this family were found increased in copy number. Interestingly, an important tumor suppressor called pRb
is lost in our samples, which strengthen the confidence in our algorithm in identifying important signaling
pathways, and their genes involved in tumor development. The mammalian target of rapamycin (mTOR)
is known as growth regulator of cells by its virtue of regulating protein synthesis, metabolism, and
autophagy in response to converging signals transduced from cell surface receptors. The EGFR or Met
receptor signaling positively regulates mTOR signaling thus a gain in mTOR pathway will also lead to
amplification of these oncogenic signals. We noticed gain and loss of bonafide genes of mTOR pathway
regulating autophagy, fatty acid metabolism and protein synthesis.
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Once tumor develops to a certain size, it evolves a set of molecular machinery, which helps tumor cells to
spread in the body and to identify new niche for growth. A very important molecular signaling network
involved in cellular chemotaxis and strongly associated with metastasis is CXCR4-SDF1 signaling pathway.
Our data set identify genes that are involved in chemotactic signaling in cancer cells transduced by
CXCR4. Another important pathway associated with malignancy and metastasis is IL6 signaling pathway.
Several known amplifiers and regulators annotated in this signaling pathway are significantly gained in
tumor samples including STAT family members as well as upstream activators such as IL6R and JAK2.
Collectively, we demonstrate that signaling pathway prediction by copy number analysis in cancer patient
samples not only identifies oncogenes but also identifies the crucial oncogenic signaling pathways. The
benefit of our approach lies in exhaustive analysis of cancer samples by integrating the information
generated by computational analysis with intuitive networking of identified pathways for a biological
output. Using this approach one can nail down putative drug targets as well biomarkers for cancer
management.
Conclusion
Systematic analysis of genomic CNA can provide information about genes involved in cancer initiation and
progression. While focusing on recurring CNA hot-spots has been useful in identifying candidate
oncogenes, increasingly the complex contributions of multiple, cooperating genes and pathways has come
into focus. With the commonly observed involvement of large genomic regions, CNA can a↵ect the
expression of a multitude of genes far beyond canonical oncogenes or tumor suppressors. This argument is
substantiated by the observation of recurring patterns of cancer type specific CNA which point towards
tumor-dependent distinct evolutionary pressure on large scale CNA selection.
In our view, CNA data can be used to identify relevant functional cooperations of multiple genes in a given
tumor type. We base our approach on the identification of pathways whose member’s genomic loci are
enriched among CNA. A↵ected pathways allow the identification of tumor type related molecular
mechanisms and, by conjecture, their probable functional relevance in those cancers. In contrast to other
attempts, our analysis is purely based on CNA data, which is increasingly becoming available for large
patient cohorts and does not su↵er from the experimental and platform-related normalization problems
inherent to e.g. expression data series. Our analysis also tests the hypothesis if and how CNA can be used
to detect pathway alterations in cancer.
We here give a detail analysis of the tools which can be used to find CNA targeted signaling pathways in
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cancer. According to our analysis CNA harbor several genes and can in turn a↵ect several pathways. When
the genomic clustering of pathways is considered then a gene based analysis to look for enriched pathways
does not produce any significant results. The segmentation approach (S-path) identifies pathways altered
in CNA data and considers the fact that pathways can be clustered on the genome. However it does not
solve the issue of identifying which genes could be important for a clustered set of genes for any pathway.
In our analysis of various unrelated cancer types, we were able to identify common signaling pathways that
likely have pathogenetic relevance in these entities. The results of our analyses point towards a convergence
of distinct signaling towards a restricts set of interconnected cellular responses. While considering a
multitude of CNA-a↵ected, potentially functionally relevant genes, the discrimination of a limited set of
e↵ector pathways specific to each entity may help to provide guidance for selecting appropriate therapeutic
targets.
In our opinion, a bioinformatics methodology based on large datasets, in combination with informed
biological analysis can help to define future modes of cancer management. We expect that the S-path
method will prove to be a powerful utility for large scale, comparative analyses of cancer genome datasets.
Conclusions
Author’s contributions
NK, HC, MB collected the data. NK and MB have designed the analysis. NK performed all the analysis.
NK,HC and MB wrote and corrected the manuscript.
Acknowledgements
NK is supported through a grant by Krebsliga Schweiz (Swiss Cancer League) and University Research
Priority Program (URPP) at University of Zurich. Haoyang Cai is supported through a grant from China
Scholarship Council.
References
1. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J,
Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VEH, Yuan W, Li
L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe
D, Sauvage FJD, Faham M, Seshagiri S: Diverse somatic mutation patterns and pathway alterations
in human cancers. Nature 2010, 466(7308):869–873.
2. Baudis M: Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis
of chromosomal CGH data. BMC Cancer 2007, 7:226.
3. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, Henry KTM, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W,
9
Trk receptor signaling mediated by PI3K and PLC−gamma
Paxillin−independent events mediated by a4b1 and a4b7
Angiopoietin receptor Tie2−mediated signaling
Calcium signaling in the CD4+ TCR pathway
Regulation of RhoA activity
IL8− and CXCR2−mediated signaling events
IL2 signaling events mediated by STAT5
Validated targets of C−MYC transcriptional repression
Regulation of p38−alpha and p38−beta
Internalization of ErbB1
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
60.0 0.2 0.3 0.4 0.5 0.6
Internaliz ti n of Er 1
Regulation of p38-alpha and p38-beta
Validated targets of C-  transcriptional repression
I t  iate  by STAT5
IL8- and CXCR2- i  i li  e ts
l ti  f  tivity
l i  signaling in the D4+ T  ath ay
Angiopoietin receptor Tie2-mediated signalin
illi -i i  y 1 a  a4 7
Trk receptor signaling mediated by PI3K and PLC-ga ma
0.1
Proportion of pathway genes copy number altered
Figure 1: Proportion of genes showing CNA across entire cancer CNA data; 10 randomly chosen pathways
are shown here. The vertical line represents the average number of genes being hit (median of per-case
fraction of window bins overlapping CNA). The overall fraction of window bins being hit in a given pathway
fluctuates around the expected value.
Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Ho↵man C, Prensner J, Liefeld T, Gao Q,
Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS,
Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK,
Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL,
Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M: The landscape of somatic
copy-number alteration across human cancers. Nature 2010, 463(7283):899–905.
4. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 2004, 10(8):789–799.
5. Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL,
Olivi A, Mclendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA,
Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R,
Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: An Integrated Genomic
Analysis of Human Glioblastoma Multiforme. Science 2008, 321(5897):1807–1812.
6. Subramaniana A, Tamayoa P, Moothaa VK, Mukherjeed S, Eberta BL, Gillettea MA, Paulovichg A, Pomeroyh
SL, Goluba TR, Landera ES, Mesirova JP, Gene set enrichment analysis: A knowledge-based
approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of
Sciences 2005, 102(43):6.
7. Edelman EJ, Guinney J, Chi JT, Febbo PG, Mukherjee S: Modeling Cancer Progression via Pathway
Dependencies. PLoS Comput Biol 2008, 4(2):e28.
8. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A,
Olson JA, Marks JR, Dressman HK, West M, Nevins JR: Oncogenic pathway signatures in human
cancers as a guide to targeted therapies. Nature 2006, 439(7074):353–357.
10
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
1
2
3
4
5
6
7
Pathway clustering score (after segmentation)
P
at
hw
ay
 c
lu
st
er
in
g 
sc
or
e 
(b
ef
or
e 
se
gm
en
ta
tio
n)
Pathway clustering score
F
re
qu
en
cy
0 1 2 3 4 5 6 7
0
10
20
30
40
50
F
re
q
ue
nc
y
P
at
hw
ay
 c
lu
st
er
in
g
 s
co
re
 (b
ef
o
re
 s
eg
m
en
ta
tio
n)
0.5 1 1.5 2 2.5 3 3.50 1 2 3 4 5 6 7
Pathway clustering score Pathway clustering score (after segmentation)
1
2
10
0
A B
Figure 2: A) The distribution of scores obtained for the genomic clustering of pathway genes. log10 of
the scores are plotted here for simplicity. B) Comparison of pathway clustering score before and after
segmentation. Dividing the genome into small segments reduces the pathway clustering scores.
9. Kim TM, Yim SH, Jeong YB, Jung YC, Chung YJ: PathCluster: a framework for gene set-based
hierarchical clustering. Bioinformatics 2008, 24(17):1957–1958.
10. Shen K, Tseng GC: Meta-analysis for pathway enrichment analysis when combining multiple
genomic studies. Bioinformatics 2010, 26(10):1316–1323.
11. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B,
Potti A, Nevins JR: A pathway-based classification of human breast cancer. Proceedings of the National
Academy of Sciences 2010, 107(15):6994–6999.
12. Mclendon R, Friedman A, Bigner D, Meir EGV, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman
N, Aldape K, Yung WKA, Bogler O, Vandenberg S, Berger M, Prados M, Muzny D, Morgan M, Scherer S,
Sabo A, Nazareth L, Lewis L, Hall O, Zhu Y, Ren Y, Alvi O, Yao J, Hawes A, Jhangiani S, Fowler G, Lucas
AS, Kovar C, Cree A, Dinh H, Santibanez J, Joshi V, Gonzalez-Garay ML, Miller CA, Milosavljevic A,
Donehower L, Wheeler DA, Gibbs RA, Cibulskis K, Sougnez C, Fennell T, Mahan S, Wilkinson J, Ziaugra L,
Onofrio R, Bloom T, Nicol R, Ardlie K, Baldwin J, Gabriel S, Lander ES, Ding L, Fulton RS, Mclellan MD,
Wallis J, Larson DE, Shi X, Abbott R, Fulton L, Chen K, Koboldt DC, Wendl MC, Meyer R, Tang Y, Lin L,
Osborne JR, Dunford-Shore BH, Miner TL, Delehaunty K, Markovic C, Swift G, Courtney W, Pohl C, Abbott
S, Hawkins A, Leong S, Haipek C, Schmidt H, Wiechert M, Vickery T, Scott S, Dooling DJ, Chinwalla A,
Weinstock GM, Mardis ER, Wilson RK, Getz G, Winckler W, Verhaak RGW, Lawrence MS, O’kelly M,
Robinson J, Alexe G, Beroukhim R, Carter S, Chiang D, Gould J, Gupta S, Korn J, Mermel C, Mesirov J,
Monti S, Nguyen H, Parkin M, Reich M, Stransky N, Weir BA, Garraway L, Golub T, Meyerson M, Chin L,
Protopopov A, Zhang J, Perna I, Aronson S, Sathiamoorthy N, Ren G, Yao J, Wiedemeyer WR, Kim H, Kong
SW, Xiao Y, Kohane IS, Seidman J, Park PJ, Kucherlapati R, Laird PW, Cope L, Herman JG, Weisenberger
DJ, Pan F, Berg DVD, Neste LV, Yi JM, Schuebel KE, Baylin SB, Absher DM, Li JZ, Southwick A, Brady S,
Aggarwal A, Chung T, Sherlock G, Brooks JD, Myers RM, Spellman PT, Purdom E, Jakkula LR, Lapuk AV,
11
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
FDR enrichment
0
0.2
0.4
0.6
0.8
1
Signaling events mediated by PTP1BArf6 signaling eventsamb2 Integrin signalingArf1 pathwayEPHA forwa d
TGF−beta receptor signalingThromboxane A2 receptor signalingAngiopoietin eceptor Tie2−m diated
CXCR4−mediated signaling eventsILE2F transcription factor n twork
PDGFR−beta signaling pathway
a6b1 and a6b4 Integrin signaling
Class I PI3K signaling events mediated by Akt
mTOR signaling pathway
IL6−mediated signaling eventsRegulation of p38−alpha and p38−betaIL6-mediated signaling events
Regulation of p38-alpha and p38-beta
mTOR signaling pathway
Class I PI3K signaling events mediated by Akt
a6b1 and a6b4 Integrin signaling
PDGFR-beta signaling pathway
 Signaling events mediated by PTP1B
EPHA forward signaling
Arf1 pathway 
amb2 Integrin signaling
TGF-beta receptor signaling
Thrombox  A2 receptor sig aling
Angiopoietin receptor Tie2-mediated signaling
CXCR4-mediated si li g events
IL4-mediated signaling events
.0
.
.
0.6
.0
p values (before segm
entation)
S-path p values
0.0 0.2 0.4 0.6 0.8 1.0
Arf6 signaling events
E2F transcription factor network
Figure 3: Bejamini-Hochberg(BH) corrected p-values of pathways enriched using S-path are plotted against
BH corrected p values for clustering of those pathways. The grey lines represent the p value cuto↵ of 0.15
for both S-path enriched pathways and genomic clustering score. Some pathways enriched using S-path are
clustered on the genome however this clustering can be ignored as none of these pathways are significantly
clustering when segmentation was done.
Marr H, Dorton S, Choi YG, Han J, Ray A, Wang V, Durinck S, Robinson M, Wang NJ, Vranizan K, Peng V,
Name EV, Fontenay GV, Ngai J, Conboy JG, Parvin B, Feiler HS, Speed TP, Gray JW, Brennan C, Socci ND,
Olshen A, Taylor BS, Lash A, Schultz N, Reva B, Antipin Y, Stukalov A, Gross B, Cerami E, Wang WQ, Qin
LX, Seshan VE, Villafania L, Cavatore M, Borsu L, Viale A, Gerald W, Sander C, Ladanyi M, Perou CM,
Hayes DN, Topal MD, Hoadley KA, Qi Y, Balu S, Shi Y, Wu J, Penny R, Bittner M, Shelton T, Lenkiewicz E,
Morris S, Beasley D, Sanders S, Kahn A, Sfeir R, Chen J, Nassau D, Feng L, Hickey E, Zhang J, Weinstein JN,
Barker A, Gerhard DS, Vockley J, Compton C, Vaught J, Fielding P, Ferguson ML, Schaefer C, Madhavan S,
Buetow KH, Collins F, Good P, Guyer M, Ozenberger B, Peterson J, Thomson E: Comprehensive genomic
characterization defines human glioblastoma genes and core pathways. Nature 2008,
455(7216):1061–1068.
13. Lucas JE, Kung HN, Chi JTA, Tucker-Kellogg G: Latent Factor Analysis to Discover
Pathway-Associated Putative Segmental Aneuploidies in Human Cancers. PLoS Comput Biol 2010,
6(9):e1000920.
14. Holden M, Deng S, Wojnowski L, Kulle B: GSEA-SNP: applying gene set enrichment analysis to SNP
data from genome-wide association studies. Bioinformatics 2008, 24(23):2784–2785.
15. O’dushlaine C, Kenny E, Heron EA, Segurado R, Gill M, Morris DW, Corvin A: The SNP ratio test:
pathway analysis of genome-wide association datasets. Bioinformatics 2009, 25(20):2762–2763.
16. Lee JM: Genomic Gene Clustering Analysis of Pathways in Eukaryotes. Genome Research 2003,
13(5):875–882.
12
Thromboxane A2 
receptor signaling
a6b1 and a6b4 
Integrin signaling
Signaling events 
mediated by 
PTP1B
Cellular growth 
and proliferation 
IL6-mediated 
signaling events
CXCR4-mediated 
signaling events
PDGFR-beta 
signaling pathway
Cellular migration 
and metastasis 
mTOR signaling 
pathway
A
B
Angiopoietin receptor Tie2-mediated signaling
Arf1 pathway
Arf6 signaling events
Class I PI3K signaling events mediated by Akt
EPHA forward signaling
IL4-mediated signaling events
Regulation of p38-alpha and p38-beta
TGF-beta receptor signalin
amb2 Integrin signalin
C-MYB transcription factor network
CXCR3-mediated signaling events
Direct p53 effectors
ErbB1 downstream signaling 
ErbB2/ErbB3 signaling events
Glucocorticoid receptor regulatory network
IL8- and CXCR2-mediated signaling events
Insulin-mediated glucose transport
LKB1 signaling events
Regulation of nuclear beta catenin signaling 
and target gene transcription
Signaling events mediated by Hepatocyte
 Growth Factor Receptor (c-Met)
Urokinase-type plasminogen activator 
(uPA) and uPAR-mediated signaling
Validated transcriptional targets of 
AP1 family members Fra1 and Fra2
p38 MAPK signaling pathway
CXCR4-mediated signaling events
E2F transcription factor network
IL6-mediated signaling events
PDGFR-beta signaling pathway
Signaling events mediated by PTP1B
Thromboxane A2 receptor signaling
a6b1 and a6b4 Integrin signaling
mTOR signaling pathway
Figure 4: A) Pathways enriched by a combinatorial analysis are shown in the red rectangle and the ones
enriched in multiple cancer types (20) are shown in the blue rectangle. In the intersection of both rectangles
(grey shaded region) are pathways which were looked at in details. B) Network of pathways enriched in
cancers. di↵erent enriched pathways (shown in rectangle with round corners) converge to a↵ect cancer-
associated cellular responses (rectangle with smooth corners).
17. Baudis M, Cleary ML: Progenetix.net: an online repository for molecular cytogenetic aberration
data. Bioinformatics 2001, 17(12):1228–9.
18. Joshi-Tope G: Reactome: a knowledgebase of biological pathways. Nucleic Acids Research 2004,
33(Database issue):D428–D432.
19. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M: KEGG for representation and analysis of
molecular networks involving diseases and drugs. Nucleic Acids Research 2010,
38(Database):D355–D360.
13
20. Schaefer CF, Anthony K, Krupa S, Bucho↵ J, Day M, Hannay T, Buetow KH: PID: the Pathway
Interaction Database. Nucleic Acids Research 2009, 37(Database):D674–D679.
21. Curtis RK, Oresˇicˇ M, Vidal-Puig A: Pathways to the analysis of microarray data. Trends in
Biotechnology 2005, 23(8):429–435.
22. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG: 4 Integrin Amplifies
ErbB2 Signaling to Promote Mammary Tumorigenesis. Cell 2006, 126(3):489–502.
23. Trusolino L, Bertotti A, Comoglio PM: A signaling adapter function for alpha6beta4 integrin in the
control of HGF-dependent invasive growth. Cell 2001, 107(5):643–54.
24. Dube´ N, Cheng A, Tremblay ML: The role of protein tyrosine phosphatase 1B in Ras signaling. Proc
Natl Acad Sci USA 2004, 101(7):1834–9.
25. Klingler-Ho↵mann M: The Protein Tyrosine Phosphatase TCPTP Suppresses the Tumorigenicity of
Glioblastoma Cells Expressing a Mutant Epidermal Growth Factor Receptor. Journal of Biological
Chemistry 2001, 276(49):46313–46318.
26. Mattila E, Pellinen T, Nevo J, Vuoriluoto K, Arjonen A, Ivaska J: Negative regulation of EGFR
signalling through integrin-11-mediated activation of protein tyrosine phosphatase TCPTP.
Nature 2005, 7:78–85.
14
9.3 Publication 3: Specific genomic regions are di↵erentially a↵ected
by copy number alterations across distinct cancer types, in aggre-
gated cytogenetic data (submitted)
89
1Specific genomic regions are di↵erentially a↵ected by copy
number alterations across distinct cancer types, in aggregated
cytogenetic data
Nitin Kumar1#, Haoyang Cai1#, Christian von Mering1,2,⇤ Michael Baudis1,⇤
1 Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland
2 Swiss Institute of Bioinformatics, Quartier Sorge, Lausanne, Switzerland
⇤ E-mail: mbaudis@imls.uzh.ch, mering@imls.uzh.ch
# equal contribution
Abstract
Background
Regional genomic copy number alterations (CNA) are observed in the vast majority of cancers. Besides
specifically targeting well-known, canonical oncogenes, CNAs may also play more subtle roles in terms of
modulating genetic potential and broad gene expression patterns of developing tumors. Any significant
di↵erences in the overall CNA patterns between di↵erent cancer types may thus point towards specific
biological mechanisms acting in those cancers. In addition, di↵erences among CNA profiles may prove
valuable for cancer classifications beyond existing annotation systems.
Principal Findings
We have analyzed molecular-cytogenetic data from 25579 tumors samples, which were classified into
160 cancer types according to the International Classification of Disease (ICD) coding system. When
correcting for di↵erences in the overall CNA frequencies between cancer types, related cancers were often
found to cluster together according to similarities in their CNA profiles. Based on a randomization
approach, distance measures from the cluster dendrograms were used to identify those specific genomic
regions that contributed significantly to this signal. This approach identified 43 non-neutral genomic
regions whose propensity for the occurrence of copy number alterations varied with the type of cancer
at hand. Only a subset of these identified loci overlapped with previously implied, highly recurrent
(hot-spot) cytogenetic imbalance regions.
Conclusions
Thus, for many genomic regions, a simple null-hypothesis of independence between cancer type and
relative copy number alteration frequency can be rejected. Since a subset of these regions display relatively
low overall CNA frequencies, they may point towards second-tier genomic targets that are adaptively
relevant but not necessarily essential for cancer development.
Introduction
Genetic changes such as point mutations, regional copy number alterations/aberrations (CNA) and struc-
tural changes (e.g. gene fusion events) are all hallmarks of cancer. CNAs arise as somatic changes in the
tumor cell genome through a variety of mechanisms and can be observed in virtually all types of cancer,
to a varying extent. So far, the most widely used methods for the detection of CNAs have been chromoso-
mal and array-based Comparative Genomic Hybridization (CGH) techniques [1–4]. Localized, recurring
CNAs (hot-spots) have been shown to target canonical oncogenes (e.g. duplications/amplifications of
the MYC, MYCN, REL loci) or tumor suppressor genes (e.g. deletions of the CDKN2A/B, TP53, ATM
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2loci). Some regional CNAs such as gains on 8q and losses on 3p are present across multiple cancer types,
whereas other imbalances may be largely restricted to a limited number of cancer entities [5].
Datasets integrated across multiple cancer types have previously been analyzed, to report regional
”hot-spots” of frequent CNAs [5, 6]. In a given set of individual tumor samples, the number and distri-
bution of CNAs varies considerably [5] and this genetic heterogeneity has been used to detect and report
co-occurring CNAs [7].
In principle, specific patterns and similarities in the individual and/or disease specific CNA profiles
might point to distinct oncogenomic mechanisms acting in di↵erent cancer types and specimens, given a
su ciently large number of data points. Indeed, clustering of CNA patterns has been used to identify
oncogenomic similarities [5,8–11]. The adaptation of clustering techniques to the analysis of CNA patterns
has been subject of previous studies [12–14]. With a few exceptions [5, 14], however, sample-based
clustering has been the main focus of such studies so far. In contrast, we here explore the clustering of
cancer types, not of individual cancer samples.
Both descriptive and clustering-based analyses of CNA across multiple cancer types su↵er from a
bias towards the more frequently occurring events. Due to the heterogeneity of the overall CNA signal,
with greatly varying average frequencies of CNAs per cancer type (Figure 1a), clustering results may be
distorted depending on the disease entities analyzed. This variation in overall CNA occurrence frequencies
across cancer types may simply be owed to di↵erences in the average time points of clinical detection or
in di↵erent progression characteristics, and should be corrected for prior to clustering analyses. To the
best of our knowledge, so far no implementation has been reported for a comprehensive, very large-scale
clustering analysis of frequency-normalized cancer CNA profiles.
Here, we focus on the identification of genomic regions that contribute meaningfully to the clustering
of cancer types. From hereon we will refer to those as ”non-neutral” regions. As the starting point of
our analysis, we use hierarchical clustering to arrange cancer types on the basis of their CNA frequency
profiles. We then employ a permutation approach to estimate the relative contribution of individual
genomic regions to the quality of the clustering and to the derived relationship tree. The clustering quality
is inferred from an intrinsic measure (summed branch lengths: tree height statistics), and genomic regions
that reject the null hypothesis are termed non-neutral. Identified regions are compared to canonical CNA
hot-spots (i.e. those that occur most frequently across the entire dataset).
Our current analysis is based on data from a total of 25579 samples, which are classified into 160
di↵erent cancer entities (supplement table) according to the International Classification of Disease in
Oncology (ICD-O 3). Our approach is unique in that it a) focuses less on the clustering as such but more
on the individual genomic regions that best support the clustering, b) uses an intrinsic quality measure
coupled to a permutation strategy for validation, c) performs CNA frequency normalization prior to
analysis, and d) is based on a very large data set, processed in a standardized setup. We aim for the
identification of potential cancer-specific driver/modulator regions, which may not have been detected in
earlier, largely hot-spot-focused approaches. All of the underlying cancer data is available through our
Progenetix repository (www.progenetix.org; [15]).
Results
The average overall frequency of CNAs across the entire genome varies among di↵erent cancer types
(Figure 1a). Since the relative weight of CNAs at individual genomic regions in a given cancer type
depends on the observed overall genome-wide frequency, we aggregated all patient samples by cancer
type and normalized the frequencies of CNAs for each cancer type to the overall mean observed across
the entire data set (Figure 1b, Figure S1). The normalized CNA frequency profiles were then clustered
using hierarchical clustering. To evaluate the quality and the biological signal in the clustering, we
labeled each cancer type with its “root” cell type (i.e., an undi↵erentiated cell type from which the
tumor likely originated). We expected cancers of the same root cell type to cluster together; this was
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3used as an external proxy for the expected biological relationships between cancer entities. The Random
Index [16] was used to compute this external cluster quality measure. Tumors of the same cell type indeed
often clustered together, usually in 2-3 small groups (Figure 2). The consistency of this grouping was
significantly higher than expected at random, pointing towards biologically meaningful di↵erences in CNA
profiles between tumors of distinct origins. Cutting the tree at several heights always led to an observed
quality of clustering that was better than the expected random value (Figure 2), except for the cut at
the highest level, which resulted in only three clusters. This strongly argues against a completely neutral
occurrence pattern of CNAs in the genome, and supports a correlation between biologically meaningful
groups of cancer entities and their CNA profiles. Randomizations of the entire frequency matrix lead
to a complete loss of the signal present in the clustering tree (Figure S2), and also strongly reduced the
summed branch lengths tree-height statistic.
Non-neutral CNAs
The normalized and clustered frequency matrix encompassing 160 large-scale genomic regions and 160
cancer types is shown in Figure 3. To determine how much each individual genomic region contributes to
the overall signal, we individually randomized its profile across cancer types, while keeping the rest of the
data unchanged. We then examined the concomitant reduction in the tree length statistics (TLS) of the
clustering dendrogram, upon 100000 independent randomizations, to determine the statistical significance
of that region’s contribution. The resulting cancer-diverging CNA regions are important as they cannot
be fully neutral and have the potential to define relationships among cancer types. Indeed, 43 out of the
160 genomic regions (supplemental table) were observed to have a non-neutral contribution (Bonferroni-
corrected p-value  0.016) in the aggregated cancer CNA data. Note that gain and loss events were
treated independently, and no preferential bias towards gains or losses was observed among the detected
non-neutral regions (22 gains and 21 losses). The CNA occurrence frequencies of the non-neutral genomic
regions spread thorough the entire frequency spectrum (Figure 4). Only 13 (8 gains and 5 losses) of the
non-neutral regions were found altered overall more often than average (Figure 5, intersection of black
and grey rectangle), indicating that subset of frequently altered hotspot regions carry a detectable signal
to distinguish cancer types (the number of frequently altered regions stands at 59; Bonferroni-corrected
p-value  0.016, supplementary table). This observation emphasizes our key point that not only the
frequent CNA regions should be used to cluster and annotate cancer types.
22 genomic intervals across 12 chromosomes were found to be informative when specifically consid-
ering duplications/gains only (Table 1 and Figure 5). All three genomic segments of chromosome 18
(18p1, 18p2, 18q2) exhibited a signal. For other chromosomes such as chromosome 1 (1q2,1q3,1q4,1p2),
chromosome 3 (3q1, 3q2, 3p1), chromosome 12 (12q1,12q2) and chromosome 21 (21p1, 21q1) more than
50% of genomic regions were informative as gains, suggesting simultaneous involvement of multiple loci
from these chromosomes. Changes on chromosome 1(1p2), chromosome 3 (3p1, 3q1), chromosome 5 (5q2,
5q3), chromosome 9 (9p1), chromosome 11 (11p1), chromosome 12 (12q1, 12q2), chromosome 18 (18p1,
18q1, 18q2) and chromosome 21 (21p1, 21q1) were selectively informative only as gains. In terms of dele-
tions/losses, 10 chromosomes encompassing 21 genomic regions were found to be non-neutral. Like for
chromosome 18 gains, the complete chromosome 7 (7p1, 7p2, 7q1, 7q2, 7q3) was found to be informative
when lost (Table 1). Informative regions on chromosome 1 (1p1,1q1, 1q2, 1q3, 1q4) and chromosome 9
(9q1, 9q3, 9p2) covered more than 50% of genomic segments present on these chromosomes. Selective
losses were observed on chromosome 1 (1p1, 1q1), chromosome 6 (6q2), 7 (7q1, 7q2, 7q3, 7p2) , 8 (8q1,
8q2), 9 (9p2, 9q1, 9q3), 12 (12p1), 16 (16q1). CNAs involving chromosome 1 (1q2, 1q3, 1q4), chromosome
3 (3q2), chromosome 7 (7p1), chromosome 19 (19p1) and chromosome 22 (22q1) were informative both
as gain and loss events. This represents a small proportion (16%) of non-neutral CNA. Involvement of
a region both as gain and loss may point towards multiple adaptively relevant loci, and/or towards a
generally unstable nature of these regions.
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4Cancer diverging nature of non-neutral CNA
To provide few examples of cancer classifying behavior of non-neutral changes, we selected a few of
the enriched changes and analyzed them for their specific occurrence in di↵erent cancers. An example
include cancer entities showing predominant losses versus gains on 7q. Preferential losses involving 7q were
observed in germ cell, myeloid and myeloproliferative tumors (Figure 3) whereas neuroepithelial brain
tumors (among other entities) preferentially displayed gains on 7q. Losses involving 7q are common in
myeloid and myeloproliferative tumors [17–20] and are associated with advanced age and resistance to
therapies [21, 22]. However here we show that 7q losses are quite specific to myeloid tumors and give
them a selective divergence from rest of the cancer types. 7q losses in germ cell tumors are not being
looked at in details [23, 24]. Our analysis provides a strong link between myeloid and germ cell tumors,
linking them with respect to their 7q profiles and di↵erentiating them from other cancer types such as
neuroepithelial brain tumors showing a preferential gains of 7q.
Chromosome 8q gains are very common in most of the cancers [5, 6]. However 8q losses were en-
riched as non-neutral in our analysis. Preferential losses involving 8q were present in some brain tumors
(medulloblastoma, Figure 3), diverging them from other epithelial tumors. Di↵erences in preferential
losses involving 8q separated neuroepithelial tumors in two categories both having gains on 7q but only
one (mainly meduloblastomas) having preferential losses on 8q (Figure S3). Losses involving chromo-
some 8q across medulloblastomas have been reported by a few [25] studies but have not been looked at
in details. Our analysis shows that 8q losses are selective for medulloblastomas and can be important
for cancer development/progression. Preferential losses of 8q were also observed in germ cell tumors
separating them from epithelial tumors (Figure S4).
To give another examples we also looked for cancers showing gains involving chromosome 18. Follic-
ular lymphomas exhibited specific gains on chromosome 18 where as epithelial tumors prefered to loose
chromosome 18 (Figure S4). Chromosome 18 gains are very common in follicular lymphomas [26, 27]
however their role in separating them from other cancer types is shown here.
Discussion
Our current study represents the largest analysis performed to date on cancer CNA data, with the aim
of detecting oncogenomic features that may be specifically associated or enriched in certain subsets of
cancer entities. In contrast to gene-centric approaches, our analysis assesses the complete information
space of genomic copy number imbalances from whole genome profiling experiments.
Overall, the frequency of CNAs across genomic intervals varied between between 0.01% to 23% (Figure
4). Clustering of cancer types on the basis of their frequency profiles helped to identify a class of
underlying molecular signals that is orthogonal to histological classifications or clinical categories (the
latter are predominantly driven by the a↵ected organ/tissue). Cancer types vary from each other in
their CNA abundance, CNA size spectrum and degree of genomic instability. With respect to genomic
coverage, large CNAs are generally frequent in cancer [6] and should not be excluded from statistical
analyses of cancer genome patterns. While comparing CNA profiles of cancer types, their complexity
and variation in frequencies have to be considered. When correcting for these parameters, regional CNAs
defining the divergence of the overall profiles can be delineated.
We performed an analysis of a global cancer CNA dataset, identifying 43 genomic regions on 15
chromosomes as significant for CNA profile divergence in cancer types. Obviously, these changes do not
cover the entire spectrum of CNA events in cancer, but define a subset of genomic regions that may have a
possibly adaptive link to the distinct biology of various cancer types. These regions overlap rather poorly
with hotspot regions observed in many cancers. This suggests that hot-spot regions, though frequently
associated with canonical oncogenes, may not always be very useful in aiding data-driven evaluation of
cancer (sub-)types.
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5With our current study, we aim to provide a new, generalized approach at identifying genomic elements
relevant in the genesis of individual cancer entities. Though here showcasing a ”global” approach with-
out entity pre-selection, our methodology may prove valuable when targeting relevant genomic separators
in limited, biologically related entity sets. Since the current analysis is based primarily on molecular-
cytogenetic data from chromosomal CGH experiments with a spatial resolution of several megabases,
only inferred information about the causal genes present in the non-neutral regions could be obtained.
With upcoming high-resolution genomic array and/or sequencing data, similar analyses will more specif-
ically define the non-neutral CNAs and can be valuable starting points for an integration of the results
with functional pathway frameworks. Also, although we have focused our current analysis solely on a
CNA dataset, our approach should prove particularly valuable when combined with other sets of related
diagnostics (for example point mutation data), whereby the assignment of possible driver genes in the
non-neutral regions might become feasible.
Materials and Methods
Data
Cancer CNA data from chromosomal and array CGH experiments across 160 cancer types (a total of
25579 samples), as classified on the basis of International Classification of Disease codes (ICD), have been
collected over the last decade [5]. For our analysis, regional CNA information across all cancer types was
reduced to 80 genomic intervals covering the entire genome with the exception of the sex chromosomes.
Gain and loss events were considered separately for the analysis, resulting in a matrix of dimensions
nXm, where n is the number of samples and m is the number of genomic intervals (i.e. 160).
Cancer clustering
The frequency of CNA changes across all genomic intervals was computed for each ICD type, and the
entire frequency matrix was then normalized (Figure S1). The frequency matrix was ordered using
hierarchical Ward clustering. The aggregated separation distance between cancer entities obtained using
hierarchical clustering can be analyzed by parsing the clustering tree (dendrogram). The tree represents
the relatedness among groups present in the same clade (similar to phylogenetic trees). Randomized data
disrupts the tree completely (Figure S2), and the overall tree height statistic is reduced 3-fold, reflecting
the complete loss of ordering information present in the original tree.
Method to compare tree height
We used the tree height as an intrinsic measure to compare cancer associations obtained using clustering
and to gauge the information present in the tree; this was used to define non-neutral CNAs. This has ad-
vantages over traditional clustering evaluation techniques, as it a) does not require external gold standard
information, and b) does not require cutting the tree at an arbitrary distance. The overall tree height
is defined as the sum of all direct parent-child relation path lengths in the tree. Tree distances (branch
lengths) generally reflect the CNA profile discrepancies between two cancers (or groups of cancers). For
any node i, the tree height between this node and its immediate parent j can be measured as THj THi.
The overall tree height of a tree with n nodes is than obtained as OTH =
Pi=n,j=n
i=1,j=1 THj   THi (sup-
plement figure 3).
Tree length statistics (TLS)
To identify genomic regions that are non-neutrally a↵ected by CNA we have developed the following
permutation strategy:
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61. Normalized frequencies of CNA across all genomic intervals are computed across all cancer types.
2. The cancer classification tree is obtained using hierarchical Ward clustering.
3. The observed over all tree height (OTHo) is calculated as mentioned above (Figure S5).
4. A counter C is set to zero for every genomic interval in consideration.
5. For any genomic interval i, its status values are shu✏ed among all samples keeping its over all
frequency the same (ni).
6. The frequency of CNA at genomic interval i is re-calculated after randomization across all cancer
types. The shu✏ing in the previous step changes the frequency of interval i across all cancer types
keeping the normalized frequency distribution of all other genomic intervals.
7. The frequencies for interval i in the normalized frequency matrix from step one are replaced with
permuted frequencies for this interval and the permuted overall tree heigh (OTHi,p) is computed.
8. If OTHi,p   OTHo, C is incremented as C = C + 1.
9. p-value for genomic location i, at the end of N (100’000) permutations is computed as pi = C/N .
10. p-values across all bands are corrected for false discovery rate using Bonferroni correction.
Frequency based enrichment (FBE)
Frequently observed CNA regions (“hot-spots”) are genomic changes that occur more often than expected
under a fully random null model. Such hot-spot CNAs can be identified using the binomial probability
function [28]. Let’s suppose genomic interval i shows a CNA across ni samples out of N samples. The
background CNA frequency (nb) can be represented as the mean frequency change across all intervals.
The p value that the frequency of CNA ni, is more than any frequency x (ni   x) is obtained using the
binomial probability function.
p(ni|N,nb) =
 N
ni
 
nnib (1  nb)N ni
pi =
PN
n=x p(ni|N,nb)
Genomic intervals showing a large deviation from the mean will be assigned low p-values. All p-values
are corrected for false discovery rate using Bonferroni correction
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9Figure Legends
Figure 1: The overall frequency of genomic copy number alterations (CNA)
di↵ers among cancer types.
Boxplots show the CNA frequency distributions among tumor samples in 10 randomly selected cancer
types. The boxplot delineations mark the percentiles 5%, 25%, 75% and 95%. The red lines indicate
the mean frequency for each cancer type, whereas the blue line represents the overall mean frequency
across all 160 cancer types analyzed here. Frequency values are defined as the ratio of number of samples
showing a CNA for a genomic region (i.e., cytogenetic bands) over total number of samples in that cancer
type. a) Before normalization b) After normalization. In b) the nominal frequency distribution for each
cancer type is re-scaled so that its mean matches the overall mean across all cancer types. (NOS - “not
otherwise specified”: high-level classifications, not further assigned to lower, more detailed levels).
Figure 2: The tissue type of a cancer has a strong influence on its CNA
likelihood pattern.
a) examples of individual chromosome segments, showing their observed CNA frequencies stratified by
cell type. Each dot summarizes all samples classified under one particular ICD type, color-coded by root
cell type. In the left panel, three chromosome segments are shown that exhibit strong di↵erences between
cell types; on the right, three negative examples without such a signal. All p-values were corrected for
multiple testing according to Benjamini-Hochberg. b) the dendrogram (tree) has been obtained using
hierarchical Ward clustering on the global frequency-normalized CNA profiles across all 160 genomic
regions. Cancer types are again color-coded according to the cell type of origin, with the same legend as
in a). Partitioning the tree by cutting at di↵erent heights produces multiple clusters; validation of those
clusters based on the cancer origin (metric: Random Index) shows that the clustering works significantly
better than expected at random.
Figure 3: Examples for non-neutral CNA regions
a) Heatmap of CNA profiles on genomic regions (same clustering as in Figure 2). Genomic locations
are represented with orange color when considering duplications/gains, and in blue when considering
deletions/losses. Color intensity shows relative CNA frequencies; the most-a↵ected region in each row
is arbitrarily set the to brightest color (1.0) for display purposes. b) Small regions (black rectangles on
the heatmap) are zoomed in to show how non-neutral CNAs can di↵erentiate between cancer types. The
example shows that 7q is preferentially gained in brain tumors (red labels) whereas it is preferentially lost
in germ cell (black labels), myeloid and myeloproliferative cancer types (blue labels). c) Small regions
(red rectangles on the heatmap) are zoomed in to show how 8q is preferentially lost in medullublastomas
(green labels) and is preferentially gained in epithelial tumors (pink labels). Some chromosomes consist
entirely of non-neutral regions (such as chromosomes 18 and 7). Note that the spatial resolution of the
CNA data on the chromosome is limited (roughly corresponding to cytogenetic band resolution).
Figure 4: Not only CNA “hotspots” are informative in cancer classification.
Genomic regions (bands) are sorted according to their overall frequency of CNAs observed. Those regions
that are informative with respect to cancer type clustering are marked with arrows. a) Considering
duplications (gains) b) Considering deletions (losses).
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10
Figure 5: Comparison of non-neutral vs. hot-spot CNA.
Genomic regions a↵ected by CNAs, either more frequently than average (black rectangle), or non-neutrally
with respect to cancer-type classifications (grey rectangle). The intersection defines regions that are
a↵ected both frequently and non-neutrally. Changes are color-coded (gains in orange and losses in blue).
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Tables
Table 1. Number of non-neutral regions per chromosome
Chromosome No. No. genomic
locations
Non-neutral
gains
Non-neutral
losses
1 7 4 5
2 5 - -
3 4 3 1
4 4 - -
5 4 2 -
6 4 - 1
7 5 1 5
8 4 - 2
9 5 1 3
10 3 - -
11 3 1 -
12 3 2 1
13 4 1 -
14 4 - -
15 3 - -
16 3 - 1
17 3 - -
18 3 3 -
19 2 1 -
20 2 - -
21 3 2 -
22 2 1 -
Some chromosomes consist entirely of non-neutral regions (such as choromosomes 18 and 7). Note that
the spatial resolution of the CNA data on the chromosome is limited (it roughly corresponds to the
cytogenetic banding patterns).
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Additional Files
Supplement figure 1: Method for CNA frequency normalization across cancer
types.
All the frequencies among cancer types were normalized to the mean frequency of CAN changes across
across the 160 cancer types. This normalization was achieved by multiplying the cancer-type-specific
frequencies with an index An, whose value was calculated as shown.
Supplement figure 2: Dendrogram of a permuted frequency matrix
For this clustering, the frequencies among cancer types were permuted and then normalized. Hierarchial
Ward clustering was then performed and the dendrogram tree shown was obtained. The tree height
is severely a↵ected by the permutation. In this randomized clustering, similar cancer types no longer
clustered together.
Supplement figure 3: Small regions from heatmap in main Figure 3 are shown
here
These regions represent gains and losses on 7q and 8q. 8q changes di↵erentiate between two categories
of brain tumors, with a subset showing preferential losses on 8q (green labels) and other rarely showing
involvement of 8q locus (red label). Thus depending on 8q involvement neuroepithelial tumors can be
divided in to two di↵erent categories. Both of them show 7q gains.
Supplement figure 4: Examples for non-neutral CNA regions
a) Heatmap of CNA profiles on genomic regions (same as in Figure 3). b) Small regions (red rectangles on
the heatmap) are zoomed in to show how 8q is preferentially lost in in germ cell (black labels) tumors and
is preferentially gained in epithelial cancer types (pink labels). c) Small regions (black rectangles on the
heatmap) are zoomed in to show how 18q is preferentially gained in medullublastomas (brown labels) and
is preferentially lost in epithelial tumors (pink labels). The examples here show that how two di↵erent
non-neutral changes di↵erential epithelial tumors from germ cell tumors and follicular lymphomas.
Supplement figure 5: Calculation of over all tree height.
Schematic representation of the summed branch-length tree height statistic. Overall tree height is com-
puted by summing up the distance between all parents and child nodes. Note that the branch lengths of
terminal branches (“leafs”) are not considered. Overall tree height = HA C +HBD +HAB +HE .
SupplementTable.ods: Table with information about cancer types used in the
analysis, non-neutral and hot-spot p values
The table giving details about all cancer types used in this analysis with the corresponding numbers
of samples in them and the root cell type of each cancer. The table also has information about the
non-neutral and hot-spot p-values obtained for all genomic bands in analysis.
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11 Abbreviations
A Amplification
aCGH Array comparative genomic hybridization
ALCL Anaplastic large-cell lymphoma
ALL Acute lymphocytic leukemia
BAC Bacterial artificial chromosome
B-CLL B-cell Lymphocytic leukemia
B-NHL B-non hodgkin’s lymphoma
BL Burkitt’s lymphoma
CDCOCA Complexity dependence of co-occurring chromosomal aberrations
CGH Comparative genomic hybridization
CML Chronic myeloid leukemia
CNA Copy number alterations/aberrations
D Large deletion
EBV Ebstein-Barr virus
F Frameshift
FISH Fluorescent in situ hybridization
G-path Gene based pathway enrichment
HIV Human immunodeficiency virus
HPV Human papilloma virus
ICGC International Cancer Genome Consortium
M-FISH Multiplex Fluorescence In Situ Hybridization
Mis Mis-sense mutation
N Nonsense
NSCLC Non small cell lung cancer
O Other
PCR Polymerase chain reaction
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ROMA Representational oligonucleotide microarray analysis
S Splice site
S-path Segment based pathway enrichment
SKY Spectral karyotyping
SNP Single nucleotide polymorphism
T Translocation
T-ALL T-cell acute lymphoblastic leukemia
T-PLL T cell prolymphocytic leukaemia
TCGA The Cancer Genome Atlas
TLS Tree length statistics
UV Ultra violet
WHO World health organization
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Abstract
Background: The delineation of genomic copy number abnormalities (CNAs) from cancer samples has been instrumental
for identification of tumor suppressor genes and oncogenes and proven useful for clinical marker detection. An increasing
number of projects have mapped CNAs using high-resolution microarray based techniques. So far, no single resource does
provide a global collection of readily accessible oncogenomic array data.
Methodology/Principal Findings: We here present arrayMap, a curated reference database and bioinformatics resource
targeting copy number profiling data in human cancer. The arrayMap database provides a platform for meta-analysis and
systems level data integration of high-resolution oncogenomic CNA data. To date, the resource incorporates more than
40,000 arrays in 224 cancer types extracted from several resources, including the NCBI’s Gene Expression Omnibus (GEO),
EBI’s ArrayExpress (AE), The Cancer Genome Atlas (TCGA), publication supplements and direct submissions. For the majority
of the included datasets, probe level and integrated visualization facilitate gene level and genome wide data review. Results
from multi-case selections can be connected to downstream data analysis and visualization tools.
Conclusions/Significance: To our knowledge, currently no data source provides an extensive collection of high resolution
oncogenomic CNA data which readily could be used for genomic feature mining, across a representative range of cancer
entities. arrayMap represents our effort for providing a long term platform for oncogenomic CNA data independent of
specific platform considerations or specific project dependence. The online database can be accessed at http//www.
arraymap.org.
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Introduction
Genomic copy number abnormalities (CNAs) are a relevant
feature in the development of basically all forms of human
malignancies [1]. Many genomic imbalances are recurrent and
display tumor-specific patterns [2,3]. It is believed that these
genomic instabilities reveal mutations in tumor suppressor genes
and oncogenes which eventually result in a clone of fully malignant
cells. Investigation of CNA hot spots (chromosomal loci frequently
involved in CNA) has proven to be an effective methodology to
identify novel cancer-causing genes [4,5]. On a systems level, CNA
data along with expression or somatic mutation data is used to
detect pathways altered in cancers and to deduce functional
relevance of pathway members [6,7]. Since many CNAs have
been attributed to specific tumor types or clinical risk profiles, in
some entities copy number profiling is employed to characterize
different biological as well as clinical subtypes with implications for
treatment and individual prognosis. Subtype-associated CNA
regions are used to predict causative genes, furthering under-
standing of biological differences and leading to discovery of new
therapeutic targets [8,9].
Throughout the last two decades, molecular-cytogenetic tech-
niques have been applied to scan genomic copy number profiles in
virtually all types of human neoplasias. For whole genome analysis,
these techniques predominantly consist of chromosomal and array
comparative genomic hybridization (CGH), including CNA
detection by cDNA and single nucleotide polymorphism (SNP)
arrays [10–12]. While chromosomal CGH has a limited spatial
resolution of several megabases, the resolution of recent array
based technologies (aCGH) is mainly limited due to cost/benefit
evaluations instead of technical obstacles. In this article, we use the
terms ‘‘array CGH’’ and ‘‘aCGH’’ for all technical variants of
whole genome copy number arrays. This includes e.g. single color
arrays for which regional copy number normalization is performed
through bioinformatics procedures applied to external references
and internal data distribution.
The flood of new insights into structural genomic changes in
health and disease has led to an increased interest in genomic data
sets in genetic and cancer research. Several systematic studies of
CNAs across many cancer types have been performed [13,14].
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These efforts attempt a more complete understanding of
functional effect of CNAs in the context of cancer.
The exponential increase of high resolution CNA datasets offers
new challenges and opportunities for large-scale genomic data
mining, data modeling and functional data integration. Several
online resources have been developed, focusing on different
aspects of data content as well as representation [6,15–19]. An
overview of some of the prominent examples is given in Table 1.
In principle, these databases facilitate access and utilization of
CNA data. However, they are limited to specific aCGH platforms
and/or single institutions as well as limited disease categories, or,
as in the cases of GEO [15] and Ensembl ArrayExpress [16],
mainly serve as raw data repositories. To the best of our
knowledge, no single data source does yet provide an extensive
collection of high resolution oncogenomic CNA data which readily
could be used for genomic feature mining, across a representative
range of cancer entities.
Here we present ‘‘arrayMap’’, a web-based reference database
for genomic copy number data sets in cancer. We have generated
a pipeline to accumulate and process oncogenomic array data into
a unified and structured format. The resource incorporates
associated histopathological and clinical information where
accessible.
So far, arrayMap contains more than 40,000 arrays on 224
cancer types from five main data sources: NCBI GEO, EBI
ArrayExpress, The Cancer Genome Atlas, publication supple-
ments and user submitted data. Samples of interest can be
browsed, visualized and analyzed via an intuitive interface.
Computational tools are provided for biostatistical data analysis
such as CNA clustering for case specific or for subset data and
basic clinical correlations. arrayMap is publicly available at www.
arraymap.org.
Results
Data Content
Our combination of both ‘‘top-down’’ (publication driven) as
well as ‘‘bottom-up’’ (array data driven) approaches allowed us to
identify a comprehensive set of accessible aCGH based cancer
CNA data sets and to estimate the ratio of accessible data of the
overall published/deposited data.
As main result of the array data driven approach, we extracted
495 series comprising of 32002 arrays, generated on 237 platforms
from NCBI’s GEO. Among those, raw data files of approximately
29000 whole genome arrays were suitable for inclusion into our
data processing pipeline. When reviewing the content of AE, we
found that the majority of AE cancer genome data sets were also
submitted to GEO. At the time of writing, 11 datasets including
712 arrays not present in GEO had been processed based on AE
specific series. Detailed information on the GEO/AE data sets is
provided in Table S1.
The top-down procedure was based on our group’s continuous
monitoring of cancer related articles utilizing genome copy
number screening approaches, as established for our ‘‘Progenetix’’
project (www.progenetix.org; [19]). The census date for the
literature based data collection was August 15 2011. At this point,
we had identified 931 articles discussing a total of 53213 genomic
cancer CNA profiles based on aCGH techniques. Of these, 8728
cases out of 199 articles so far had been extracted from publication
related sources (e.g. supplementary data tables) and annotated and
made been accessible through Progenetix. This data included
cases for which only supervised information but no probe data was
available (e.g. author annotated Golden Path or cytogenetic CNA
regions). Literature based data sets containing probe specific data
or with the respective data presented to us by the authors (640
samples) were included into our arrayMap data processing
pipeline.
The data content of arrayMap is summarized in Table 2.
Current numbers on the website will include changes based on
ongoing annotation efforts (i.e. addition of data sets, removal of
low quality arrays).
As a by-product of our data collection and annotation efforts,
we are able to provide estimates of content and trends for the
platform usage and cancer entity coverage for the majority of
published data. According to the assigned ICD-O 3 (International
Classification of Diseases for Oncology, 3rd Edition) code and
descriptive diagnostic text, breast carcinoma predominates as
single largest clinical entity with 6459 arrays. Table S2 presents
sample sets in arrayMap classified by ICD-O code.
The most widely available array CGH platforms are either
based on large insert clones (BAC/P1 arrays) or based on shorter
single-stranded DNA molecules (oligonucleotide arrays), which
may or may not include single-nucleotide polymorphism specific
probe sequences (SNP arrays). Also, although designed for gene
expression profiling, cDNA arrays were used by several labora-
tories for measuring genomic copy number changes. Although all
these platforms are considered suitable for whole genome CNA
analysis, their probe densities and other parameters can affect
specific features of the analysis results [20–23]. Table S3 lists the
general platform types and corresponding overall numbers of the
data registered in arrayMap.
Table 1. Prominent online resources of genomic data.
Name Address Platform(s) Data format Comment
GEO [15] www.ncbi.nlm.nih.gov/geo 263 raw & normalized probe signal intensity largest microarray data repository
ArrayExpress* [16] www.ebi.ac.uk/arrayexpress 16 raw & normalized probe signal intensity many duplicate data in GEO
TCGA [6] cancergenome.nih.gov 1 segmentation data raw probe data is limited to download
CanGEM** [17] www.cangem.org 38 normalized probe signal intensity including many types of microarray data
CaSNP [18] cistrome.dfci.harvard.edu/CaSNP 8 average copy number & graphic focus on SNP array data
Progenetix [19] www.progenetix.org 235 ISCN*** & golden path data from publications
Data up to 29 April, 2011.
*excluding data both in GEO and ArrayExpress.
**statistical information only including CGH, SNP and cDNA data.
***International system for human cytogenetic nomenclature.
doi:10.1371/journal.pone.0036944.t001
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In reviewing the technical platform composition, two related
trends become apparent (Figure 1). Originally developed in groups
with expertise in molecular cytogenetics and cancer genome
analysis, printed large insert clone arrays (BAC/P1) were the first
whole genome CNA screening tools with a spatial resolution
surpassing that of chromosomal CGH. Other groups re-employed
cDNA arrays, developed for expression screening, for genomic
hybridizations. However, over the last years one can observe the
overwhelming use of various industrially produced oligonucleotide
array platforms, which compensate their low single probe fidelity
through a probe density at 1–3 orders of magnitude higher than
common for BAC/P1 arrays. Another reason for the success of
oligonucleotide arrays is the integration of SNP specific probes,
which in principle allows to use of the same experiments for
genetic association studies and the evaluation of copy number
neutral loss of heterozygosity regions [12,24,25].
Data Access and Usage Scenarios
Based on our experience from the Progenetix project, a strong
emphasis was put on a user friendly data interface. Here, we
followed a ‘‘dual user type’’ scenario: Users without bioinformatics
background should be able to intuitively visualize core data
features as well as to perform standard analysis procedures, while
for bioinformaticians the formatted database content should be
accessible to use with their analysis tools of choice.
Query interface. Data browsing in arrayMap is based on
two types of query methods: search by experimental series
metadata and search by sample features.
In the series query form, users can perform various search
options by specifying (i) descriptive diagnosis text; (ii) disease
classification (ICD-O 3 code(s)); (iii) disease locus (ICD topography
code(s)); (iv) PubMed ID; (v) technique(s); (vi) series ID. For sample
specific queries, additional features are available: sample ID;
platform ID or description; and single or combined regional
CNAs. Users can input gene name(s) in ‘‘regional CAN’’ search
field. When at least two characters are entered into the field,
suggestions based on a HUGO gene list are displayed for selection.
Gene selections will be converted to genomic locations.
In the results table, associated array information is displayed. A
number of links to additional and/or outside data is provided,
according to the information available: the corresponding
PubMed entries; the original GEO/AE accession display page
for more complete information; the case and publication entries on
the Progenetix website for further analysis; and importantly the
array specific data visualization page.
Data download options. On pages resulting from sample
queries or sample data processing, users are presented with options
to download sample data based on the current queryO˜s return.
Currently, three different file types are offered: JSON files, tab
separated feature files and segments list files. These files enable
bioinformaticians to perform further analyses based on their tools
of choice. Particularly, the JSON format can be used for direct
database import (e.g. MongoDB) or can be deparsed by common
libraries (e.g. JSON.pm), or being read into web applications.
Array probe data visualization. In the array plot interface,
original plots of genomic array data sets can be searched and
visualized (Figure S1). Default threshold parameters which were
either provided with the data or assigned during the initial
visualization will be loaded. In single array visualization, the
general view of probe distribution and post-thresholding segmen-
tation results are displayed for the whole genome as well as for
each individual chromosome. If multiple arrays are retrieved, users
can select sample data for downstream analysis procedures. Figure
S2 shows the screenshot of single array visualization.
Users can segment the raw data values and re-plot the results
after revising the following parameters:
N Golden path edition, default HG18/NCBI Build 36. This is
still the commonly used version of the human reference
genome assembly. At the moment, coordinates of probes from
all platforms were remapped to HG18. For the near future, we
intend to allow for a selection of updated genome editions.
N Chromosomes to plot, default 1 to 22. Single or all
chromosomes can be selected for re-plotting. To avoid gender
bias, most platforms do not contain probes in chromosome X
and Y during the design.
N Loss/gain thresholds. Cut-offs from which a segment is
considered a genomic loss or gain. The optimum thresholds
may vary between platforms.
N Region size in kb. Sets a filter to remove CNA below (e.g.
probable noise) or above (e.g. exclude non-focal CNA) a
certain size range.
N Minimal probe numbers for segments. This parameter can be
used to limit the minimal number of probes required for a
segment to be considered (e.g. to remove aberrant segmenta-
tion due to probe level noise). Empirical examples would be
values of 2–3 for high quality BAC arrays and 6–10 for
Affymetrix SNP 6 arrays.
N Plot region. Single genomic region to be plotted, overriding the
chromosome selection above. When selected, plots with this
region will be generated for all current arrays. This is valuable
to e.g. display the CNA status and copy number transition
points for specific genes of interest (Figure S3).
Zoom-in visualization of focal CNA. Figure 2 shows the
visualization of focal genomic imbalances, e.g. to identify genes of
interest targeted by focal CNA. The whole genome view of
GSM535547 (human high grade glioma sample analyzed by
Agilent Human Genome CGH Microarray 244A) shows a small
regional deletion in chromosome 9p21. When plotting the
approximate locus of the deletion (specified as chr9:21600000-
22400000), genes, probes and chromosome bands in this zoomed
in region are shown. Two genes, MTAP and CDKN2A can be
seen as being localized in a potential homozygously deleted region.
The focal deletion of these known tumor suppressor genes [26,27]
points to their specific involvement in the glioblastoma sample
analyzed here.
Querying compound CNA. The concept of focal CNA
detection can be integrated with a global search for arrays
Table 2. aCGH data integrated in arrayMap.
Data Source Arrays Cases Series Platforms Publications
GEO 32002 25728 495 237 490
ArrayExpress 712 11 16 11
TCGA 7249 3594 19 1 *
Publication
Supplements
.4578** 4578 137
Author Submission 556 539 8 7
Data up to 29 April, 2011.
*Due to lack of publication information, there may be a small amount of
duplicate data in GEO.
**Array number may be higher than case number since reported results per
case occasionally may be based on more than one array. The number does not
include data presented both in publication supplements as well as GEO.
doi:10.1371/journal.pone.0036944.t002
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containing gene specific regional imbalances. As an example, we
demonstrate the search for arrays displaying imbalances in 4 gene
loci associated with glioblastoma: EGFR, a transmembrane
receptor and proto-oncogene [28]; PTEN, a tumor suppressor
gene [29]; ASPM, frequently overexpressed in glioblastoma
relative to normal brain tissue [30]; and CDKN2A (see above).
In the ‘‘Search Samples’’ form, the ‘‘Match (Multiptle) Regions &
Types’’ can be used to specify the genomic regions of those four
genes including the expected CNA type: for EGFR
(chr7:55054219-55242524:1), PTEN (chr10:89613175-
89718511:-1), ASPM (chr1:195319885-195382287:1) and
CDKN2A (chr9:21957751-21984490:-1), respectively. When ex-
ecuting the query, these regions were matched with the whole
database and returned cases which have imbalances overlapping
all these regions. When excluding controls and ‘‘worst quality’’
datasets, 303 out of 42421 arrays could be identified matching all
four CNA regions. In addition to glioblastoma, several other types
of cancer cases were among the results, including e.g. neuroblas-
tomas, breast carcinomas, melanomas and lung carcinomas, which
is in accordance with some previous observations [31–34]. CNA
and associated data of those cases can be processed by online tools
for further analysis and visualization (Figure S4) or downloaded for
offline processing.
Copy number profiling of selected cancer entities. One
aim of arrayMap is to allow researchers to conveniently perform
aCGH meta-analysis across different platforms. By selecting a
single or several cancer entities e.g. based on their ICD entity
codes or diagnostic keywords, users are able to generate disease
specific CNA frequency profiles or to compare profiles of different
cancer types.
As an example, we used ICD-O code 9440/3 (glioblastoma,
NOS) to query the database. 1478 arrays from 25 publications
were returned and passed to our suite of online analysis tools.
Chromosomal ideograms and histograms were generated repre-
senting the frequency of copy number aberrations identified over
the whole dataset (Figure 3A). In the overall aberration profile, the
most common genomic imbalances included whole chromosome 7
gain and chromosome 10 loss, as well as focal gains e.g. on bands
1q21 and 17q21. In our example dataset, a prominent focal
deletion hot-spot was centered around 9p21.3 (921 of 1478 arrays,
62.31%) which had been discussed previously [35]. The distribu-
tion of CNAs over the individual arrays was visualized through a
matrix plot (Figure 3B). As additional information to the frequency
histograms, this form of visualization facilitates e.g. the detection of
CNA patterns among individual arrays as well as the concordance
of individual CNAs (e.g. here the arm-level changes in chromo-
some 7 and 10).
In the matrix plot, clicking on a certain segment would open
the related view in the UCSC genome browser [36], for
detailed information related to this genomic region (SVG plot
only). The plot order of arrays can be re-sorted according to
ICD morphology, ICD topography, clinical group or PubMed
ID, which can be helpful in associating CNA patterns to
external classification categories. For the selected classification
criterium (default: ICD morphology), regional CNA frequencies
for cases matching the different values will be visualized through
a heatmap (Figure 3C); this feature is especially useful when
comparing a number of different primary classification criteria.
An Overall Genomic Copy Number Profile of Cancer
Our high quality core dataset in arrayMap was used to generate
an overall cancer copy number aberration profile based on 29,137
arrays (Figure 4). This data represented 177 cancer types
according to ICD-O 3 code, with 59 types among them contained
Figure 1. Distribution of resolutions and techniques of GEO platforms. Each point represents a genomic array. The Y axis is labeled with
probe number in log scale. The X axis denotes the time sequence of array data generation. From left to right are years from 2001 to 2011.
doi:10.1371/journal.pone.0036944.g001
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more than 50 arrays. Overall, one of the most common genomic
alteration is copy-number gain of chromosome band 8q24, which
is found in 30% of total samples. According to the COSMIC [37]
database, the most significant cancer gene in this region is MYC. It
is a well-documented oncogene codes for a transcription factor
that is believed to regulate the expression of 15% of all genes,
including genes involved in cell division, growth, and apoptosis
[38,39]. Other common imbalances observed in at least 25% of
oncogenomic arrays included gains of regions on e.g. 17q21 (29%),
1q21 (33%) and loss of regions on e.g. 8p23 (32%) and 9p21
(25%), including focal deletions of the CDKN2A/B locus
(Figure 2).
While the overall CNA frequency distribution points towards
DNA features targeted in multiple entities, this information is
insufficient for deriving molecular mechanisms associated with
specific cancer types. The genomic heterogeneity of different
neoplasias is reflected in the varying patterns of regional CNA
frequencies. Based on our core dataset, we have generated a
heatmap-style visualization of frequency profiles for all ICD-O
entities containing more than 50 arrays (Figure S5). The striking
Figure 2. Zoom-in visualization of focal CNA. (A) GSM535547 (human high grade glioma, Agilent CGH 244A) shows high quality of probe
hybridization signal. CNAs are easy to distinguish. (B) When zoom-in the whole chromosome 9, an approximately 80 MB deletion is displayed, with
two breakpoints located in p and q arm respectively. In addition, a small regional deletion in 9p21 is quite clear. Color bars in lower region of the
panel represent 848 genes located in chromosome 9. (C) Zoom in the potential homozygously deleted region in 9p21 by specifying the exact region:
chr9:21600000-22400000. The zoomed-in plot shows probes, chromosome band and two tumor suppressor genes, MTAP and CDKN2A. Gene name
and location will be given while mouse hover. They link to UCSC genome browser with additional information.
doi:10.1371/journal.pone.0036944.g002
Figure 3. Copy number profiling of glioblastoma. (A) Chromosomal ideogram and histogram showing frequency of copy number aberrations.
Percentage values corresponding to gains (yellow) and losses (blue) identified over the whole dataset. The most frequent imbalances include gain of
chromosome 7 and loss of chromosome 10, 9p21.3. (B) Matrix plot of 1478 glioblastoma cases. The Y axis represents individual samples. The
distribution of genomic copy number imbalances reveals the individual aberration patterns of glioblastoma. (C) Heatmap of regional CNA frequencies
for 1478 arrays. The intensity of green and red color components correlates to the relative gain and loss frequencies, respectively. If dataset contains
cancer subtypes, cancers with similar CNA frequency profiles will be clustered together, such that differences between subtypes will be revealed (e.g.
see Figure S4H).
doi:10.1371/journal.pone.0036944.g003
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patterning of the CNA profiles indicates the non-random
occurrence of CNAs, and should be seen as an invitation to
explore e.g. CNA similarities shared by separate histopathological
entities, as a way to transpose knowledge about pathophysiological
mechanisms.
Discussion
arrayMap was developed to facilitate the progress of oncoge-
nomic research. Our aim is to provide high-quality genomic copy
number profiles of human tumors, along with a set of tools for
accessing and analyzing CNA data. The service has been
implemented with a straightforward web interface, including
search options for CNA features and clinical annotation data. All
assembled datasets are processed into platform independent
segmentation and, for the vast majority of arrays, probe level
data files, and are presented in consistent formats. Importantly, the
direct access to precomputed probe level data plots supports a
rapid evaluation of experiments for features of interest. As a
curated database using standardized annotation schemes (e.g. ICD
classification), arrayMap facilitates the exploration of cancer type
specific CNA data, as well as the statistical association of genomic
features to clinical parameters.
arrayMap is a dynamic database that is being continuously
expanded and improved. We will review the existing and newly
published articles to update the database periodically. Over the
past decade, we have witnessed a rapidly increasing number of
aCGH publications, which gives us sufficient evidences to
anticipate that cases in our database will continue to be deposited
at a high rate. Although arrayMap is not a user driven repository,
we welcome and support users interested in using the site for yet
undisclosed data, if they agree on data sharing upon publication.
Although, in contrast to the continuous data from expression
analysis, copy number analysis explores discrete value spaces
(countable number of DNA copies, for segments defined by
genomic base positions), interpretation of the data can vary due to
different low level (e.g. signal/background correction) and higher
level (e.g. segmentation algorithms, regional or size based filtering)
procedures. In that respect, we have to emphasize that the results
of our data processing and annotation procedures are open to
scrutiny. We encourage a critical review of individual results, and
are open for suggestions regarding improved processing proce-
dures for specific platforms.
In this paper, we have provided example scenarios of using
arrayMapondifferent levels, i.e. locus centric and for entityprofiling.
We believe that systematic analyses will help researchers to discover
features which are indiscernible in individual studies, and thus bring
new insights for understanding of disease pathology and the
development of new therapeutic approaches [40–43]. We expect
that researchers will integrate arrayMap datawith their own analysis
efforts, e.g. to increase sample size or for result verification purposes.
We hope that this database will promote further evolution of
microarray data meta-analysis. ArrayMap provides access to more
than 200 tumor types, which makes it suitable for research across
cancer entities. Furthermore, normal sample controls are of vital
importance for genomic imbalances studies. ArrayMap includes
more than 3000 normal samples from healthy individuals or from
normal tissues of cancer patients. These data could be integrated as
reference dataset e.g. to account for copy number variation data
superimposed on the tumor profiling results.
In the near future, with the continuous accumulation of very
high resolution CNA data from genomic arrays and next-
generation sequencing experiments, it will become possible to
integrate these data into systems biology methods to elucidate
effects of genomic instability, and describe the results from more
perspectives. Envisioned examples would be e.g. the identification
of genes that are involved in metastasis and treatment response;
identification of chromosomal breakpoints distribution in cancer;
and modeling functional networks in cancer by systems biology
approaches.
Methods
Dataset Collection
Raw experimental data from a variety of platforms and
repositories were extracted. They were converted to an uniform
format which is suited to our reanalysis and visualization system.
After a series of parsing procedures, the called copy number data is
stored in arrayMap. The flowchart of arrayMap data collection
and analysis is as shown in Figure 5. Five main data sources are
integrated into arrayMap:
GEO/AE. For extracting appropriate data Series from GEO/
AE, two basic criteria have to be fulfilled. First, the raw data has to
be from human malignancies analyzed by BAC, cDNA, aCGH or
oligonucleotide arrays. Second, the array platform must be
genome wide, with the optional omission of the sex chromosomes.
Figure 4. The overall cancer copy number aberration profile consisted of 29137 arrays. This plot represents 177 cancer types according to
ICD-O 3 code. Percentage values in Y axis corresponding to numbers of gains (green) and losses (red) account for the whole dataset.
doi:10.1371/journal.pone.0036944.g004
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Chromosome or region specific arrays were excluded because they
were not able to reveal the whole genomic profile of the respective
cancer. Associated clinical data was extracted if available.
TCGA. Segmentation data with available clinical information
was extracted and incorporated into the database. Due to data
sharing restrictions, TCGA data is an exception in that, so far no
probe level data is incorporated into arrayMap. This exception
Figure 5. The flowchart of arrayMap data collection and analysis procedures. Publicly available raw data or segmented data was collected
from the respective data sources. Files were re-processed by distinct procedures, according to the different data types. Probe coordinates were
remapped to the most commonly encountered human reference genome assembly (NCBI Build 36/hg18). All probe specific ratios were converted to
log2 values. Thresholds for genomic gain and loss were obtained from the original publications or series annotations; if not available, empirical
thresholds were assigned. A minimum of 2 probes was required for calling a CNA segment, with higher values used on high-density arrays and/or in
cases of excessive probe level noise. Processed probe and segment information was converted to uniform formats and stored in per-sample text files,
which are accessed through the arrayMap web applications.
doi:10.1371/journal.pone.0036944.g005
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was accepted since users will be able to access individual TCGA
datasets through the projects web portal at http://tcga-data.nci.
nih.gov/tcga/.
Publications. Many aCGH datasets can be found in the text
or supplementary files of publications. In order to collect data from
publications, we relied on our Progenetix projectO˜s setup. Data in
Progenetix is manually curated. The collection strategies are:
N literature mining using complex search parameters through
PubMed
N identification of called aCGH data, in GP annotation or
tabular format (article, supplementary tables)
N evaluation of supplementary files for probe specific data tables
N follow-up on article links outs, to repository entries or
referenced datasets
User submission. User submitted data was provided in a
number of formats which were converted to the standard format as
described. Although we accept and support private datasets, we
insist on integration of at least the genomic and core clinical data
(e.g. disease classifiers) upon publication of the datasets analysis
results.
Dataset Analysis
Probe remapping. A pipeline has been generated for
determining the genomic positions for the tens to hundreds of
thousands array probes with reference to a common genome
Golden Path edition. For each array platform, the genome
positions of probes were remapped to the current commonly used
version of the human reference genome assembly (NCBI Build
36.1/hg18). Specific mapping procedures were employed for
different types of probes. BAC clones were firstly remapped
according to the clone sets information of Sanger/DECIPHER
database [44]. If the probe position was not available, the UCSC
Genome annotation database [36] (release hg18) was used for
compensation. After these two steps, a mean of 98% of the BAC
clones were remapped. For IMAGE clone sets, only the UCSC
Genome annotation database was used. The average remapping
rate of IMAGE clones was 91%. Affymetrix raw CEL data files
were analyzed based on hg18 library files, namely the output
segments have hg18 coordinates. The summary of the percentage
of mapped probes is given in Table 3. The mapping details for
each platform can be found in the (Table S4).
Probe signal normalization. The array data available was
given in a variety of formats, most frequently as log2 ratio of probe
hybridization intensity. In order to make data from different
platforms directly comparable, all other types of normalized values
were converted to log2. For dye swap experiments, reference/
tumor intensity ratios data was ‘‘reversed’’ representing a tumor/
reference value. For some two-color arrays for which only raw
signal intensity were provided, the normalized log2 ratio for each
probe was calculated by.
r~ log 2 Ts{Tbð Þ=Rs{Rbð Þ:
where Ts and Tb represent tumor sample intensity and tumor
channel background intensity respectively, and Rs and Rb
represent reference sample intensity and reference channel
background intensity respectively. If multiple instances of the
same clone exist, the average signal intensity of the certain clone
was considered.
To call gains and losses according to normalized log2 ratio is an
important step to identify copy number imbalances. For each re-
analyzable dataset, related publications were explored to obtain
original threshold descriptions. If this information was not
available, empirical thresholds were assigned and resulting CNA
calls were visually compared with probe value plots. Processing
method and threshold information for each array are provided in
the Table S5.
Affymetrix genotyping arrays. For the widely used Affy-
metrix GenomeWide SNP arrays, raw CEL files were downloaded
and underwent a massive re-analysis using the R package
aroma.affymetrix [45] with the CRMAv.2 method [46]. During
the processing step, approximately 50 normal sample arrays were
employed as a reference set for each array type to reduce the noise
level. Normal tissue arrays from different labs were extracted and
used to build the reference dataset. In order to obtain high quality
arrays, we excluded arrays which contain segments greater than 3
mega-bases, since copy number variations are always smaller than
3 mega-bases. The list of normal tissue reference arrays is giving in
Table S6.
Quality control. In our review of array data deposited in
GEO or collected from publication supplements we encountered a
large number of individual data sets with insufficient or limited
probe quality. Also, for samples of unprocessed raw data (e.g.
Affymetrix CEL files), we found that QC measures reported
previously (e.g. call rate [47], NUSE [48], RLE [48]) only had a
limited accuracy for detection of arrays with inadequate probe
level data. Currently, the most viable strategy for quality
assessment of processed, heterogeneous copy number arrays is
the visual inspection of probe plotting and segmentation results
through an experienced researcher. For the first arrayMap edition
we generated a quality classification system, which contains a total
of 4 categories based on inspections of genome-wide array plots:
N Excellent. Probe signal distribution is significantly different
between normal regions and imbalance regions. Signal
baseline is distinct and unique, making segmentation threshold
realistic appearing. Chromosomal changes are pretty clear.
N Good. In general good quality. Probe signal may contain some
noise, but tolerable. Chromosomal changes are distinguish-
able.
Table 3. Percentage of remapped probes according to platform types.
Platform type Average mapping rate Number of arrays Number of GPLs
Original HG18 (Build 36) NA 1583 40
in situ oligonucleotide 99% 21678 55
BAC/P1 98% 5464 55
spotted DNA/cDNA 91% 2365 82
doi:10.1371/journal.pone.0036944.t003
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N Hypersegmented. Serrated distribution of probe signal inten-
sities, causing dozens of separate peaks and discontinuous
segments. Chromosomal changes are always up to several
hundreds and smaller than 5 mega-bases.
N Noisy. Probe signal intensities are highly scattered, but well-
distributed, with high standard deviation, resulting in the
inability to differentiate copy number changes.
Depending on the intended research purpose this basic
classification system can be used for a pre-analysis triage of copy
number data. Applying stringent review criteria we identified a
core dataset with ‘‘excellent’’ quality arrays accounting for
approximately 60 percent of total arrays. We are currently
working on a platform independent quality assessment system for
genomic arrays, which will be implemented in future versions of
the arrayMap resource.
Associated data. For arrayMap, data is stored with separate
datasets for each array. This is in contrast to the Progenetix
database, for which technical replicates where available are
combined into case specific CNA profiles. In arrayMap, technical
replicates are assigned an identical case identifier to facilitate
downstream statistical procedures including e.g. clinical data
correlations. The assignment of the correct diagnostic entity to
each sample is an essential step in generating a binding between
genomic and associated data points. At the same time, to ensure
annotation consistency and make the retrieval process more
efficient, for all CNA profiles the following data points were
manually collected from GEO/ArrayExpress and published
papers if available.
N Descriptive diagnostic text, as available through the original
source
N Diagnostic classification according to the International Clas-
sification of Diseases in Oncology (ICDO 3, morphology with
code)
N Tumor locus according to ICD (ICD topography with code)
N Source of material (e.g. primary tumor, cell line, metastasis)
N Clinical parameters where available, including age, gender,
grade, clinical stage (TNM coded), recurrence/progression,
time to recurrence/progression, death and followup
Web Server. An online interface of arrayMap database was
created using Perl common gateway interface (CGI) and R scripts
running on Mac OS X Server. Sample and series data is stored
using a MongoDB database eingine (http://www.mongodb.org).
Precomputed array plots are stored as flat files, mostly in both
SVG and PNG versions. The online release of the service has been
optimized to be compatible with major browsers supporting
current web standards (CSS2, HTML5, XML with inline SVG;
e.g. Safari .=3.0, Firefox .=3.0, InternetExplorer .=9,
Google Chrome) with limited fallback support. Dynamic graphics
provided in the array plot module were implemented as server side
services by technologies including XML/XHTML, JavaScript,
SVG and HTML5 Canvas.
For the future, we intend a quarterly database content revision
to ensure inclusion of newly published articles and GEO/AE
entries. Archived versions of the sample annotations will be made
available upon special request. Additional feature and small data
updates will be performed as seen necessary. The ‘‘News’’ page of
Progenetix/arrayMap will be used for feature and content
announcements.
Supporting Information
Figure S1 Array data sets visualization. Original plots and
optimized parameters for GSE21530 which contains 8 intimal
sarcoma samples hybridized on Agilent CGH Microarray 244A
platform. The normalized probe signal log2 ratios and post-
thresholding segmentation results for each array are intuitively
displayed. Genomic alterations are represented by horizontal
green (gain) and red (loss) lines. Alterations defined here as regions
with log2 ratio .0.15 or ,20.15. Simplified schemas of CNAs
link to UCSC genome browser for further review.
(PDF)
Figure S2 Screenshot of single array visualization.
ArrayMap plots for GSM630977 (acute myelogenous leukemia).
Besides the whole genome view, subviews of each chromosome are
displayed as well. From these plots, different kinds of genetic
variation events are clearly revealed, e.g. massive genomic
rearrangement in chromosome 6; arm-level gain of chromosome
8q and 3MB focal change around 1p31.3. Through the ‘‘Plot
Array Data’’ interface, users can segment the raw data values and
re-plot the results with customized parameters.
(PDF)
Figure S3 Plot single genomic region. In the ‘‘Plot Array
Data’’ interface, input the precise location (chr5:1100000-
1400000) in ‘‘Plot Region’’ field. Plots with this region were
generated for all 8 arrays in the current series (GSE21530). In this
region, there are 5 genes which are shown schematically as colored
boxes. CNA status and copy number transition points for these
genes are displayed.
(PDF)
Figure S4 Compound CNA query. (A) Four gene loci
associated with glioblastoma (EGFR, PTEN, ASPM and
CDKN2A) were inserted into ‘‘Match (Multiple) Regions &
Types’’ field. 303 out of 42421 arrays were returned. (B)
Classification information of these 303 arrays were displayed
and can be selected for the following analysis. (C) Statistical and
plot parameters can be customized. Associated data was processed
by online tools, and returned results included: (D) Chromosomal
ideogram and (E) histogram, show frequency of copy number
aberrations; (F) Matrix plot reveals the aberration pattern of
selected arrays; (G) Array classification tree generated by
hierarchical Ward clustering, arrays with similar frequency of
CNA are part of the tree branch. (H) Heatmap of CNA
frequencies clustered by clinical group.
(PDF)
Figure S5 Heatmap of frequency profiles for 59 cancer
types. Heatmap visualization of frequency profiles for all ICD-O
entities containing more than 50 arrays in our core dataset. Region
specific gain/loss frequencies were mapped to 1MB intervals. The
intensity of colors (green: gains; losses: red) corresponds to the
relative frequency of CNAs for each interval.
(PDF)
Table S1 Entities extracted from NCBI GEO and EBI
ArrayExpress.
(XLS)
Table S2 Cancer entities grouped by ICD-O code.
(XLS)
Table S3 Platform type distribution in arrayMap.
(XLS)
Table S4 Probe remapping rate for platforms.
(XLS)
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Table S5 Processing method and threshold for calling
genomic gains and losses.
(XLS)
Table S6 Normal tissue reference arrays for Affymetrix
platforms.
(XLS)
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Abstract
The DNA damage response has been mainly studied by investigating the effect of genotoxic 
agents such as ionizing radiation on the structure and function of chromatin. In the global 
approach described here, reverse phase protein arrays coupled with kinetic analyses were 
employed to decipher the cytoplasmic signaling network that is induced upon genotoxic stress by 
ionizing radiation (IR).
Proteome changes that have not been implicated in cellular IR-induced response before included 
the de-phosphorylation of Akt and c-Myc, a decrease of Rb, the activation of PAK4/5/6 as well as 
the early up-regulation of CREB, Bcl-2 and the delayed activation of PKC-zeta/lambda, Bad and 
Bcl-xl. Importantly, PKC signaling acted upstream of ATM, the transcription factor CREB, ERK, 
Bad and Bcl-2 and thereby regulated pro-survival and apoptotic pathways. In agreement with this 
finding, inhibition of PKC enzymatic activity hypersensitized MRC-5 cells to IR treatment by 
inducing CREB and Bad dephosphorylation, by increasing p53 stabilization, Bad up-regulation 
and Bcl-2 down-regulation. Together, our analysis strengthens the importance of cytoplasmic 
signaling induced by IR and suggests a key role of PKC signaling in the conditioning of stressed 
cells to allow efficient DNA repair and to prevent cell death and apoptosis.
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Introduction
Genotoxic stress such as ionizing radiation (IR) alters the organization and function of the genetic 
material and thereby induces diverse cellular responses that culminate in the activation of cell-
cycle checkpoints or DNA damage response (DDR) pathways (1-3). A hallmark of DDR 
signaling is the slowdown or arrest of the cell-cycle progression by inhibiting entry into S-phase 
and mitosis through the activation of cell-cycle checkpoint signaling cascade (at the G1/S or 
G2/M phase checkpoints) (4, 5), which is regulated by a complex signaling network including the 
established DDR pathways ATM and ATR (6). Depending on the type of DNA lesion, different 
repair mechanisms are activated and a defect in any of these can cause severe syndromes such as 
tissue degeneration, sensitivity to DNA-damaging agents and predisposition to cancer (7, 8). 
Recent large-scale mass spectrometry based analyses have significantly extended the 
understanding of DDR signaling and identified hundreds of new phosphorylation sites and target 
proteins (9-11). Zeptosens reverse phase protein arrays (RPPA) represent a new and powerful 
technology that relies on planar waveguide nanostructured chips for high sensitivity detection and 
the high-throughput quantification of protein changes at the single cell level in a multiplex setting 
(12). This approach allows performing quantitative kinetic analyses of hundreds of proteins in the 
same cell or tissue extract and thus generates data equivalent of thousands of western blots within 
a week (13). Protein arrays have already been applied to study changes of expression level or 
posttranslational modification status of proteins in cellular stress conditions or in normal and 
cancerous prostate and ovarian tissue in smaller scale (14-16).
Here, we applied the RPPA technology to study IR induced stress pathways in primary cells on a 
“signalosome level” by analyzing cellular candidate markers. In contrast to earlier studies, this 
work was performed with primary MRC-5 human fibroblasts and 165 different antibodies were 
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included in order to quantify and study all major components and post-translational modifications 
of nuclear and cytoplasmic stress signaling events. These results implicated significantly changed 
kinetics of pro-survival and anti-apoptotic key determinants in cell cycle arrest and the ability to 
withstand severe DNA damage.
Besides known components of the DNA damage response, such as changes in p21, p38 and p53 
well as activation of the MEK1/2, ERK1/2 and LKB-AMPK pathways, the RPPA analysis 
described here also identified novel components of the cellular IR response. Among these 
changes were the de-phosphorylation of Akt and c-Myc, a decrease of Rb, the activation of 
PAK4/5/6 as well as the up-regulation of CREB, Bad, Bcl-2, Bcl-xl and PKC-zeta/lambda. The 
PKC signaling pathway is known to integrate extracellular signals, calcium and secondary lipid 
messengers to regulate diverse cellular responses including apoptosis during genotoxic stress (17, 
18). The physiological importance of PKC enzymatic activity was highlighted by the 
hypersensitive phenotype of PKC inhibitor treated MRC-5 cells, which has been reported earlier 
(19). However, the mechanism by which PKC signaling leads to an IR-hyperresistant phenotype 
in primary human fibroblasts was so far unknown. Here, we elucidated the PKC-dependent pro-
survival and anti-apoptotic signals that confer the high IR-resistance to MRC-5 fibroblasts. PKC 
acted upstream of ATM, the cAMP response element-binding protein (CREB) transcription 
factor, ERK and Bad and Bcl-2 and thereby, regulated pro-survival and apoptotic pathways. 
Consequently, PKC inhibition hypersensitzed MRC-5 cells to IR and led to the induction of pro-
apoptotic factors (Bad) and the down-regulation of anti-apoptotic markers (Bcl-2 and p53 
stabilization). This multiplex analysis of the IR-induced signaling network thus identified PKC as 
a new key denominator of the IR response that conditions stressed cells for efficient DNA repair 
and thereby prevents cell death and apoptosis. 
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Results
Ionizing radiation induces significant proteome changes in MRC-5 fibroblasts 
Kinetic quantitative proteome changes were analyzed with reverse phase protein arrays (RPPA) 
after ionizing radiation (IR, 10 and 40 Gy) exposure of MRC-5 fibroblasts (Figs. 1A, S1). 
Irradiation of MRC-5 cells with IR doses between 4 - 10 Gy induced a dose-dependent increase 
and time-dependent decrease of H2A.X phosphorylation at Ser139 (γH2A.X) (Figs. S2A-C). 
However, DNA strand breaks were efficiently repaired within 8 h post-irradiation and continued 
24-48 h following IR treatment, as indicated by the strong reduction in γH2AX and 53BP1 foci 
(Fig. S2C). Even after 40 Gy irradiation, cells did not exhibit elevated apoptosis as indicated by 
the stable fraction of Annexin V positive cells and undetectable expression of NOXA and PUMA 
(relative to a significant increase after staurosporine or cycloheximide treatment; Figs. S3A-D). 
These results documented the efficient DDR of human MRC-5 lung fibroblasts (20) and 
confirmed the suitability of 10 Gy and 40 Gy IR to induce a DDR in MRC-5 cells. Based on 
these data it was concluded that 10 Gy and 40 Gy IR induce specific, significant and reproducible 
non-lethal changes in the proteome of MRC-5 fibroblasts. 
The arrays were probed with 165 validated antibodies that specifically recognize proteins of 
canonical signaling pathways. All quantitative RPPA data were subjected to statistical analysis 
(ANOVA: p < 0.05, n = 3 and fold change cut off: fold change ≥ 1.5xSD) (Figs. S4A-B). 
Altogether, 78 protein changes were either significant based on ANOVA and/or passed the 
1.5xSD cut off (Figs. S5-S8).
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Ionizing radiation of MRC-5 cells activates classical DNA damage response pathways
To validate the RPPA analysis of IR-treated MRC-5 fibroblasts, known components of the DDR 
pathway were assessed. Upon 10 Gy IR, levels of phosphorylated p38 MAPK (pT180, pY182), 
the effector Hsp27 (pS78), p53 (pS15) and Chk1 (pS345), as well as total p53 and p21 amounts, 
showed similar profiles (clusters 1-3, Figs. 1B, S9A). Activation of the cytoplasmic stress kinase 
p38 MAPK and its downstream effector, the small heat shock protein Hsp27, were both ATM-
dependent as confirmed by Western blotting (Fig. S9B). Changes in p53, which is the main target 
for ATM in response to IR (21), correlated with delayed up-regulation of p21. 
Upon 40 Gy IR, early proteome changes comprised the phosphorylation of MEK1/2 (pS217/222, 
pS221/226), ERK1/2 (pT202/185, pY204/187), LKB (pS428) and cyclin D1 (pT286), which 
were sharply induced at 0.5 h after irradiation and relaxed to much lower and constant levels 
thereafter (cluster 1, Figs. 1C, S9C). Both, the MEK-ERK and the LKB-AMPK pathways signal 
from the cell membrane and the cytoplasm to the nucleus and have already been linked to DDR 
(22, 23). 
The classical DDR protein changes comprising increased phosphorylation of Chk1 (pS345) and 
p53 (pS15), as well as higher protein levels of p53 and its downstream target p21 (CIP/WAF1), 
were only observed at later time-points after 40 Gy IR (clusters 2-4). Phosphorylation of p38 
MAPK (pT180, pY182) and its phosphorylation target MAPKAP2 (pT334) showed even an early 
decline, followed by a transient increase after 40 Gy IR (cluster 5). Similarly, HSP27 and Chk1 
were phosphorylated, while Chk2 phosphorylation upon 40Gy IR could only be shown by 
Western Blotting due to poor antibody performance in the RPPA (Fig. S9D). These results 
indicated that the activation of classical DDR components is preceded and likely regulated by 
cytoplasmic signaling cascades.
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The essential role of the p53 pathway in DDR and its function as a “guardian of the genome” (24, 
25) is emphasized by the fact that it was the only pathway significantly overrepresented among 
the proteins responding to both, 10 Gy and 40 Gy IR (Fig. 2A) and its many interactions (more 
than 14 interactions) in the predicted protein network (Figs. 2B, S9E). Protein network analysis 
also predicted a highly cross-linked network of IR-induced protein changes (e. g. Bad, SRC, ERK 
(MAPK1, MAPK3) that function in cytoplasmic signaling pathways. 
In conclusion, these findings supported the validity of the protein array approach described here 
and implicated cytoplasmic pro-survival signaling in the DDR upon IR treatment.
10 Gy and 40 Gy IR activate novel nuclear regulators in MRC-5 cells
DDR can either slow-down cell cycle progression to allow efficient DNA repair or induce 
apoptosis. However, IR treatment (10 and 40 Gy) of MRC-5 cells neither induced apoptosis (Fig. 
S2A-C) nor a G1/S cell cycle arrest (Fig. S9F), even though p53 and p21 up-regulation and 
Cyclin D1 phosphorylation (pT286) and degradation (Figs. 1B-C) hinted at such a possibility. 
Therefore, novel IR-induced protein changes functioning in the cell cycle were evaluated. 
Novel IR-dependent changes in the nucleus included a significant down-regulation of pRb (Rb) 
protein levels (cluster 5, Figs. 1B, S9A), which may explain the absence of a G1/S cell cycle 
arrest (26). Reduction in Rb could be confirmed by Western blotting and quantitative RT-PCR 
analysis (Figs. 3A, S9D, S9G), which supports in vivo Rb down-regulation upon IR in MRC-5 
fibroblasts. The relative phosphorylation of Rb at S780 increased significantly increased upon 10 
Gy after 8 h and already after 2 h following irradiation with 40 Gy, which could explained why a 
G1/S cell cycle arrest was not observed (Fig. S9F). Other novel nuclear and IR-dependent 
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changes included the increased expression of Cyclin C and the translation initiation factor elF4E, 
which are both involved in cell cycle regulation. 
Instead of a G1/S cell cycle arrest, 10 Gy and 40 Gy IR led to a visible G2/M cell cycle arrest 
after already 24 h post-IR. Interestingly, a strong reduction in colony formation was observed 
even after low doses of IR (1-6 Gy), indicating cell cycle exit (most probably from the G2/M cell 
cycle phase) and cell senescence after extended periods of time (Fig. S9H). Despite the efficient 
repair of DNA double strand breaks induced by IR within 8h (Fig. S2B), residual breaks that can 
potentially cause a permanent cell cycle arrest or replicative senescence cannot be excluded. For 
instance, residual γH2AX foci were detected even after irradiation with 1 Gy (Fig. S2A), which 
explains the observed reduction in colony formation under the tested conditions. 
These findings hint at a mechanism, which allows primary cells to survive severe DNA damage, 
while senescence prevents transmission of mutations into the next generation by partly escaping 
from the cell cycle. 
 
Novel IR-induced protein changes are involved cytoplasmic pro-survival signaling
The RPPA data for known DDR components indicated that cytoplasmic factors responded more 
quickly than nuclear signaling proteins to IR treatment (Figs. 1B-C, S9A-C). In addition, 
cytoplasmic signaling has already been described to regulate the DDR and DNA repair in a break 
independent manner (27, 28). Therefore, the novel IR-dependent cytoplasmic signaling routes 
were analyzed in more detail. 
Several novel components of cytoplasmic stress signaling involved in the regulation of cell 
survival were up-regulated at both 10 Gy and 40 Gy IR. These changes included early 
phosphorylation of CREB (pS133), Bad (pS112 and pS136), Bcl-2 (pS70 for 10Gy only) and a 
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cluster comprising protein kinase C (PKC) family members with phosphorylation of the novel 
PKC-δ (pT505) and of the atypical PKC-ζ/λ (pT410/403) in the activation loop, which marks the 
activated state of these two protein kinase C isoforms (Figs. 1B, 1C, 3B) (29). Among the late-
responding protein changes upon 40 Gy was the phosphorylation of PAK4/5/6 (p21-activated 
kinases of the group II) (cluster 4, Figs. 1C, S9C), which are kinases playing a role in 
cytoskeletal reorganization and survival that were not linked to DDR previously (30). Western 
blotting also showed a late increase in STAT3 (pS727) phosphorylation, which is an anti-
apoptotic modification described to be downstream of growth factor signaling and so far not 
implicated in the DDR (31). 
Together, these analyses suggested that IR and the consecutive DNA damage broadly affect 
cytoplasmic pro-survival signaling network. The majority of the identified signaling pathways 
mediated by MEK-ERK, p38-MK2-Hsp27 and PKCs function as cytoplasmic pro-survival 
pathways, indicating that IR treatment of MRC-5 cells induces cell protective regulatory 
networks.
PKC inhibition sensitizes MRC-5 cells to IR
Based on our initial findings and to elucidate the mechanism leading to elevated IR resistance of 
primary human fibroblasts, we performed a radiosensitivity screen using inhibitors specific for 
key components of the p38, ERK, JNK, AMPK and PKC pathways (Figs. S10A-B). Inhibition of 
p38 and MEK did not reveal a significant reduction in cell viability upon IR, while JNK and 
AMPK inhibitors strongly reduced MRC5 survival, but independent of IR. In contrast, MRC-5 
cells that were pretreated with PKC inhibitors (GF109203X or RO-318220) showed a stronger 
reduction in cell viability than cells pretreated with DMSO (the solvent) alone or without IR 
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exposure (Figs. 4A, S10C-D, S11A). These results suggested that inhibition of PKC signaling in 
MRC-5 cells leads to radiosensitivity. To elucidate whether PKC signaling acts upstream of the 
DDR in IR-treated MRC-5 cells, ATM phosphorylation as well as p53, p21 and γH2A.X were 
assessed (Figs. 4B, S11B-C). PKC pan inhibition by GF109203X resulted in reduced ATM 
phosphorylation, reduced p53 and p21 levels and slight reduction in γH2A.X phosphorylation 
after 2-4 h recovery from IR. A similar effect could be observed using Ro-318220, an alternative 
PKC-pan inhibitor, which also sensitized MRC-5 cells to 10 and 40 Gy (Figs. S10C-D). These 
results placed PKC signaling upstream of the ATM pathway following IR treatment, indicating 
induction of the DDR by signals from the cytoplasm. 
In order to decipher the signaling cascade leading to MRC-5 hypersensitization upon PKC 
inhibitor treatment, phosphorylation of the pro-apoptotic factor Bad and the transcription factor 
CREB was analyzed (Fig. S10C). PKC inhibition caused reduced phosphorylation of CREB 
(pS133) and Bad (pS136), which directs cells towards apoptosis.
To confirm apoptosis as the mechanism of radiosensitization by PKC inhibition, changes in pro- 
and anti-apoptotic markers were assessed by immunoblotting upon combination treatment (Fig. 
4C). 40 Gy IR treatment in the presence of PKC inhibitors led to markedly up-regulated p53 
levels, which was not observed in response to 10 Gy IR (Fig. 4C). The pro-apoptotic marker Bad 
was significantly induced in the presence of PKC inhibitors and IR treatment, while the anti-
apoptotic marker Bcl-2 was drastically reduced. Strikingly, 40 Gy induced elevated expression of 
the anti-apoptotic factor Bcl-xl following 20 h recovery, confirming RPPA data which revealed 
late Bcl-xl up-regulation only upon 40 Gy (Figs. S6, S8, S11D). Even more interesting, PKC 
inhibition led to a significant reduction in Bcl-xl, indicating PKC-dependent survival signaling 
especially upon severe DNA damage (Fig. 11D). Activation of an apoptotic program was also 
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confirmed by increased ARTD1 (PARP-1) cleavage as indicated by a reduction in ARTD1 levels 
and accumulation of the 89 kDa cleavage fragment specifically upon IR in combination with 
PKC inhibitor treatment (Fig. 4C-D, S11D).
In summary, these results suggest that DDR upon IR treatment involves activation of cytoplasmic 
PKC signaling, which acts upstream of the ATM pathway and the consecutive activation of pro-
survival signaling events (MEK/ERK, CREB, Bcl-2 and Bcl-xl) as well as inactivation of pro-
apoptotic factors (Bad) (Fig. 5). Activation of cytoplasmic PKC signaling upon IR is thus a novel 
mechanism that orchestrates the different IR-induced responses to ensure cell survival of primary 
human fibroblasts.
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Discussion 
To understand the dynamics of in vivo signaling events in response to IR, we performed a kinetic 
RPPA analysis, which is an antibody-based, targeted, proteomic approach allowing quantification 
of proteome changes at the cellular level in a multiplex setting (32). In contrast to earlier similar 
approaches, this study included many cytoplasmic signaling components and was thus not limited 
to nuclear proteins. The antibodies used here were specific for nuclear and cytoplasmic proteins, 
whole protein levels as well as different protein modifications and thereby elucidated the 
extended signaling network that is activated upon irradiation. We used MRC-5 primary human 
lung fibroblasts as a model cell line, because these cells have been previously employed for 
studying DNA repair after the induction of double strand breaks by IR and are known to be less 
sensitive to IR than transformed cells (20). Although primary MRC-5 fibroblasts can efficiently 
repair DNA damage induced by IR doses up to 80 Gy (20), it was so far not clear how these cells 
prevent apoptosis, which is induced at much lower IR doses in other cell types (33). 
One important advantage of reverse phase protein arrays over other proteomic approaches is the 
study of many treatment conditions in parallel. We were able to describe a dynamic picture of IR-
dependent proteome changes upon 10 Gy and 40 Gy in a multiplex setting. Strikingly, IR induced 
an early response, which was governed predominantly by growth factor and cytokine dependent 
signaling pathways including members of the MAPK family (MEK/ERK), protein kinase C 
(PKC) family (PKCδ, PKC-ζ/λ, PKCβII) as well as anti- and pro-apoptotic Bcl-2 family members 
(Bcl-2, Bad). Except for early Chk1 and Cyclin D1 phosphorylation, major ATM-dependent 
signaling events (H2AX, p53, p21, MKK3/6, p38, MK2, Hsp27, Chk2) followed delayed kinetics 
peaking 2-8 h upon IR, thus indicating cytoplasmic signaling events upstream of the canonical 
DDR. Indeed, an increasing body of evidence points at a cytoplasmic signaling network induced 
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upon IR in regulating DNA break repair (34).
The most important finding of this systematic RPPA analysis was the identification of PKC as a 
key regulator that orchestrates the downstream signaling pathways regulating cell cycle arrest and 
DNA repair, apoptosis and cellular survival (Fig. 5). IR-dependent PKC activation regulated 
ATM, Bad and CREB to induce DNA repair, prevent apoptosis and induce pro-survival signaling. 
Most proteome changes, in particular upon 40 Gy IR, indicated changes in mitogenic signaling 
events, which control cell-survival (MKK3/6-p38-MK2 pathway, MEK-ERK pathway, LKB-
AMPK pathway, PKC-Bad pathway). The PKC signaling pathway thus acted as an upstream 
regulator of the DDR and as a key determinant for a cells ability to withstand and recover from 
IR. PKC inhibitor application prior to IR treatment stabilized p53, which is a hallmark of cell 
cycle arrest or apoptosis (24), induced pro-apoptotic components (ARTD1 cleavage, Bad) and 
down-regulated anti-apoptotic factors (Bcl-2 and Bcl-xl). Our findings thus suggest that 
hypersensitization of primary fibroblasts by PKC inhibitors induces an apoptotic program that is 
mediated by effects on ATM, CREB, Bad and pro-apoptotic genes, particularly upon 40Gy. This 
is in line with cell viability data showing a stronger decline in cell viability upon 40Gy in 
combination with PKC inhibition compared to the lower dose. PKC-dependent regulation of 
DNA repair through the ATM pathway is thus proposed as a part of the mechanism by which 
primary fibroblasts resist high IR doses and circumvent apoptosis, which is in agreement with the 
high DNA repair efficiency and the PKC-dependent regulation of p53 function (20, 35).
This result has important implications for our understanding of DDR and the regulation of 
nuclear events in general and supports the concept of the cellular, in contrast to the nuclear, 
radiation response (36). Cellular stress such as IR is perceived at the plasma membrane and in the 
cytoplasm and initiates cytoplasmic signaling pathways that consecutively control nuclear events 
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such as the cell cycle and DNA repair. This is also suggested by the induction of IR-induced 
signaling in cells exposed to IR conditioned medium, which is termed the “bystander effect” (37). 
The classical DDR, comprised of nuclear events regulating cell cycle progression and DNA 
repair, is thus preeceded and controled by the cytoplasmic radiation response, which is mediated 
at least in part by the PKC signaling pathway.
This RPPA analysis of the IR-induced signaling network identified a new, cytoplasmic regulation 
of the DDR response that conditions stressed cells for efficient DNA repair and thereby prevents 
cell death and apoptosis. These findings may explain how tumorigenesis is initiated in response 
to severe irradiation stress; namely by the induction of pro-survival signaling and the evasion of 
apoptosis, which gives cells time to accumulate the mutations eventually leading to cancer. The 
results presented here thus shed new light on the cellular machinery that enables cells to 
withstand IR and may thus help optimize and improve radiotherapy.
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Materials and Methods
Cell culture, treatment, lysis and viability assays
MRC-5 and WI-38 human lung fibroblast cell lines (38, 39) were obtained from the American 
Type Culture Collection (ATCC) and cultured in supplemented MEM (Invitrogen). Cells were 
exposed to ionizing radiation (IR) using an X-ray generator (Pantak Seifert X-ray System; 120 
kV; 19 mA; aluminium filter, 3.11 Gy/min) and recovered for different time-periods. Whole cell 
extracts were prepared with Zeptosens Cell Lysis Buffer CLB1 (Bayer Technology Services 
GmbH) or RIPA lysis buffer. Cell viability was determined by seeding 2x103 cells in 96 well 
plates over night before irradiation or drug treatment. Cell viability was quantified using the 
WST-1 proliferation reagent (Roche) and a plate reader (Tecan). The clonogenic assay was 
performed as described elsewhere (40).
Reverse Phase Protein Arrays
RPPA were prepared as described (13) (32) (see supplementary material). The eight data points 
(100, 75, 50, 25% lysate amount in duplicates) were fitted using a weighted linear least squares 
fit (41) and the relative fluorescence intensity determined by interpolating at the median protein 
concentration or modification. To correct for small variations in protein content, relative 
intensities were normalized to the signals of β-Catenin, which did not show any significant 
variation in response to IR over indicated time points. Significance and clustering analysis was 
performed as described in detail in the supplementary material.
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Immunoblotting
For Western Blot analysis, bands were visualized by either using horseradish peroxidase-
conjugated antibodies (1:5000, GE Healthcare) and ECL detection (GE Healthcare) or by using 
IR-Dye-conjugated antibodies (1:15000, LI-COR) and detection by the Odyssey infrared imaging 
system (LI-COR). Antibodies used for Western blotting are listed in the supplementary material.
Immunofluorescence microscopy 
MRC-5 cells grown on cover slips over night (≈ 1x 104 cells) were irradiated and 
immunohistochemically stained with primary (1:500 mouse anti-Histone H2A.X Phospho 
(Ser139) IgG1, Millipore or 1:500 rabbit anti-53BP1 IgG1, Santa Cruz) and secondary antibodies 
(1:250 FITC conjugated donkey anti-mouse IgG, Jackson ImmunoResearch). 
Flow cytometry 
FACS analysis of IR-treated or untreated MRC-5 cells was performed using a Dako CyAn ADP 
flow cytometer (Dako). Annexin V staining was performed using the FITC Annexin V apoptosis 
detection kit (BD Pharmingen). 
RNA extraction and real-time PCR analysis
Total RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems). Real-time PCR was performed using SYBR green premixed buffer and 
analysed by the Rotor-Gene Q cycler (QIAGEN). 
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Figure Legends
Fig. 1. Identification of significant proteome changes in response to IR. 
A. Workflow for the characterization of IR-induced proteome changes by reverse phase protein 
arrays (RPPA). Early passage of 80-90% confluent MRC-5 cells were left untreated (U) or 
irradiated in biological triplicates with 10 Gy or 40 Gy. At different time-points, cell lysates were 
prepared and spotted in equal amounts on hydrophobic glass slides. Each lysate was spotted in a 
serial dilution at 1, 0.75, 0.5 and 0.25 relative to the total protein concentration in duplicates. 
Each array was incubated with a different primary antibody, directed against a protein of interest, 
and a secondary fluorophore-labeled antibody. Relative fluorescence intensities were quantified 
and used for statistical data analysis to identify significant proteome changes in response to 
irradiation. B-C. Time profile clustering of IR-dependent changes (ANOVA p < 0.05 , 1.5 S.D. 
cut off) using Self-Organizing Tree Algorithm (SOTA) showing protein expression and 
modification (e.g. phosphorylation) in green or downregulation and de-modification (e.g. 
dephosphorylation) in red. B. Clustering of proteome changes upon irradiation with 10 Gy. C. 
Clustering analysis of IR-dependent proteome changes upon 40 Gy treatment.
Fig. 2. Pathway and protein-protein interaction analysis of significant IR-induced proteome 
changes. 
A. Enrichment of pathways from the pathway interaction database (PID) with significant 
proteome changes (ANOVA, p < 0.05 / 1.5 S.D.) induced by 10 Gy only (red), 40 Gy only (blue) 
and overlapping changes (green) using Fisher’s exact test. (FDR corrected p-value cut off = 0.1). 
B. Protein-protein interaction analysis of significant proteome changes induced by 40 Gy using 
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STRING with a STRING score cut off > 0.7. Colors indicate phosphorylation (light blue), total 
protein changes (violet), phosphorylation and total protein changes (orange). Circles represent 
unique changes and squares overlapping changes. Large symbols indicate proteins that interact 
with more than 14 members.
Fig. 3. RPPA analysis identifies novel components of the DDR in IR-treated MRC-5 cells. 
A. RPPA (black bars) and western blot (white bars) analysis of IR-dependent total and 
phosphorylated Rb in response to 10 Gy (n=3, ANOVA with Dunnett’s post-hoc test, U 
(untreated) as reference group, * = p < 0.05, ** = p < 0.01, *** = p = 0.001). Western blot see 
Fig. S9G. B. Validation of novel IR-dependent proteome changes in response to 2 Gy, 10 Gy and 
40 Gy X-rays. MRC-5 were treated with 100 nM Insulin (Ins), 50 µM Anisomycin (Anis), 100 
nM PMA for 1 h, left untreated or irradiated and recovered for the indicated time points before 
cell lysis and immunoblotting. C. Positive regulation of the ATM pathway by IR-induced PKC 
signaling. MRC-5 were preincubated with 5 µM GF109203X (PKCi) for 2 h following 
irradiation, irradiated or left untreated as control and recovered for the indicated time points 
before cell lysis and immunoblotting. α-ERK was used as loading control.
Fig. 4. Inhibition of IR-dependent PKC signaling reduces proliferation and survival in 
primary human fibroblasts in response to X-rays. 
A. Radiosensitization of MRC-5 cells by a combination treatment with PKC inhibition and IR. 
MRC-5 were pretreated with PKCi (GF109203X, 10 µM, for 2 h) or DMSO as control before 
irradiation with 10 Gy or 40 Gy and recovery for the indicated time points, followed by cell 
viability analysis using the WST-1 assay. B. IR-dependent ATM pathway and pro-survival 
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signaling is negatively regulated by PKC inhibition. WB analysis of irradiated MRC-5 cells using 
ATM- and PKC-specific inhibitors (KU55933, 5 µM and Ro-318220, 5 µM with 2 h 
preincubation before irradiation). β-Tubulin was used as loading control. C. PKC inhibition and 
IR leads to ARTD1 cleavage, Bcl-2 down-regulation and Bad upregulation. WB analysis as in B. 
D. Quantification of ARD1 cleavage shown in C.
Figur 5. Model of PKC-dependent cellular pro-survival signaling in response to IR. 
IR-induced PKC signaling orchestrates cell cycle arrest and DNA repair, apoptosis and cellular 
survival via ATM phosphorylation, p53 stabilization and p21 and γH2AX induction as well as via 
up-regulation of Bad, ARTD1 cleavage and activation of Bcl-2 and CREB. Hypersensitization 
with PKC inhibitors (GF109203X, RO-318220) leads to an IR-induced activation of apoptosis.
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